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Abstract 
The transcription factor Nrf2 protects against cellular stress by inducing 
cytoprotective proteins. Activation of Nrf2 protects against inflammation and 
oxidative damage in disease models in vitro and in vivo. Nrf2 activation may be a 
good therapeutic strategy in these diseases.  
Some dietary components activate Nrf2, which may be partially responsible for 
their beneficial effects in preventing disease. In this study a novel organosulfur 
compound from garlic, diallyl pentasulfide (DAPS), was investigated. DAPS strongly 
activated the Nrf2 pathway. Furthermore, it was a much more powerful activator of 
heme oxygenase-1 than any diallyl sulfides reported to date.  
Nrf2 is regulated by Keap1, which targets it for degradation. Disruption of the 
Nrf2/Keap1 interaction results in Nrf2 activation. In this study, a novel cell-
penetrating peptide, based on the Keap1-binding site of Nrf2, disrupted the 
Nrf2/Keap1 interaction, and activated the Nrf2 pathway. Furthermore, it 
demonstrated anti-inflammatory activity, significantly inhibiting LPS-induced TNF 
expression in THP-1 monocytes, suggesting that the interaction is a valid 
therapeutic target in inflammation.  
In cancer, Nrf2 plays a dual role. Activation of Nrf2 protects cells from carcinogens. 
However, once a tumour has developed, Nrf2 can be hijacked by cancer cells to 
induce chemoresistance. This study examined the role of Nrf2 in malignant 
melanoma cells. Nrf2 was found to be overexpressed in 11 human melanoma cell 
lines in comparison with melanocytes. Chemoresistance to dacarbazine, 
doxorubicin and cisplatin correlated with Nrf2 expression, and Nrf2 siRNA increased 
the susceptibility of M202 and SK-MEL-5 cells to cisplatin, suggesting that Nrf2 plays 
a role in chemoresistance in melanoma.  
In conclusion, this study has identified novel activators of Nrf2, including a dietary 
compound and a cell penetrating peptide which inhibits inflammation in vitro. In 
addition, Nrf2 inhibition sensitises melanoma cells to chemotherapy. These results 
suggest that targeting Nrf2 is a viable strategy in both inflammation and cancer.    
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Chapter 1: Introduction 
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1.1 The role of Nrf2 in protection against disease 
Oxidative stress and inflammation are major causative factors in a wide 
range of diseases. They are central in the pathogenesis of chronic age-related 
diseases, such as cardiovascular diseases, neurodegenerative diseases, and 
cancer, but are also major factors in other non-age related diseases, such as 
asthma, or inflammatory bowel disease (Koskela et al., 2012; Elnakish et al., 
2013; Paschos et al., 2013; Sanders and Greenamyre, 2013; Stoner et al., 
2013; Read and Douglas, 2014; Zhang and Li, 2014). 
Inflammation and oxidative stress involve a wide variety of processes that, if 
left unregulated, can cause cellular damage. This leads to either 
malfunctioning cells or cell death, which can cause a variety of problems 
(Gafter-Gvili et al., 2013; Hanus et al., 2013). In the most extreme cases these 
include the development of tumour cells or necrosis, which can cause organ 
failure and eventually death (Ma et al., 2013; Zhang et al., 2014).  
There are many mechanisms by which cells protect themselves from damage, 
and reduction of oxidative stress and inflammation is an effect that many of 
them share. Drug metabolism is one such process, which can detoxify 
oxidants to prevent them from causing oxidative stress (Copple et al., 2010). 
Likewise, transcription of pro-inflammatory mediators can be inhibited, 
which prevents excessive damage from inflammation (Di Paola et al., 2013).  
One molecule that plays a key role in regulating these processes is Nuclear 
factor erythroid 2 related factor 2 (Nrf2). Nrf2 is a transcription factor that 
induces expression of a wide range of proteins including heme oxygenase-1 
(HO-1), NAD(P)H:Quinone oxidoreductase 1 (NQO1), Ferritin, glutathione 
synthesis enzymes, and multidrug-associated resistance proteins (Pietsch et 
al., 2003; Vollrath et al., 2006; Li et al., 2009; Liang et al., 2013). Many of the 
enzymes induced by Nrf2 are phase II and III detoxification enzymes, which 
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convert toxins into less harmful metabolites and/or facilitate their export 
from the cell (Cornejo et al., 2013). Others, such as HO-1, have both 
antioxidant and anti-inflammatory effects (Rushworth et al., 2008; Zhao et 
al., 2013a). The most striking element of Nrf2-regulated genes is that 
although they have different specific roles, almost all of those roles prevent 
cellular damage (Table 1.1). 
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Table 1.1 Examples of Nrf2 target genes. Nrf2 regulates transcription of many genes 
involved in cellular protection.  
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Nrf2, therefore, is considered a master regulator of cytoprotection, and this 
is backed up by disease models in vivo and in vitro.  Although Nrf2 is not 
essential for development, Nrf2 knockout mice display increased sensitivity 
to a range of adverse conditions including respiratory disease, autoimmune 
diseases, and sepsis (Chan et al., 1996; Chan and Kan, 1999; Yoh et al., 2001; 
Iizuka et al., 2005; Kong et al., 2010) (Table 1.2). This is backed up by in vivo 
models showing that upregulation of Nrf2 activity protects against disease 
and tissue damage, including but not limited to brain injury, ischemia, and 
inflammatory diseases (Zhao et al., 2011; Kudoh et al., 2014; Lee et al., 
2014a; Mo et al., 2014; Xu et al., 2014a). Nrf2 has also been shown to 
provide protection against carcinogenesis, most likely via inhibition of 
oxidative stress (Kavitha et al., 2013; Cheung et al., 2014; Tasaki et al., 2014). 
Nrf2 is just one member of a family of transcription factors that bind to 
similar regulatory regions, and therefore share overlap in the genes they 
regulate and processes that they are involved in (Motohashi et al., 2002; 
Jaiswal, 2004; Biswas and Chan, 2010). 
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Table 1.2 Nrf2 knockout mice studies. Nrf2 knockout mice are susceptible to numerous 
diseases.  
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1.2 Cap ‘n’ Collar Transcription Factors 
Nrf2 is a member of the cap ‘n’ collar (CNC) family of transcription factors, 
which are defined by two overlapping motifs. The first is a basic leucine 
zipper (bZip), and the second is a CNC motif, homologous to a similar 
sequence in the drosophila protein of the same name. CNC family members 
do not necessarily have any homology outside of these motifs (Caterina et 
al., 1994; Itoh et al., 1995). 
The bZip functions as both a protein binding and a DNA binding motif (Fig 
1.1). Alone, it is incapable of inducing transcription, but as a dimer, it forms a 
full DNA binding domain, activating the transcription factor. bZip cofactors 
that dimerise with CNC proteins are typically small maf proteins, but can also 
include other bZip transcription factors, such as Fos or c-Jun (Newman and 
Keating, 2003). Different combinations of bZip transcription factors (which 
may or may not include a CNC transcription factor) bind different DNA 
sequences, but there is enough overlap that these sequences share 
homology. They include the antioxidant response element (ARE), the maf 
recognition element (MARE), the NF-E2 site, and the 12-O-
tetradecanoylphorbol-13-acetate response element (TRE) (Rushmore et al., 
1991; Kataoka et al., 1994; Nguyen et al., 1994; Xie et al., 1995; Koyanagi et 
al., 2011) (Table 1.3).    
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Several of the CNC transcription factors, including Nrf2, bind to the ARE, and 
are able to activate or suppress transcription of genes containing this 
sequence in their promoter. The ARE was discovered in 1990, and recognised 
as a cis-acting regulatory region of antioxidant gene expression a year later 
(Rushmore and Pickett, 1990; Rushmore et al., 1991). It is now known to 
regulate a variety of genes in addition to antioxidant enzymes, almost all of 
them protective (Chen and Kunsch, 2004; Reddy, 2008; Nquyen et al., 2009). 
The core ARE sequence is 5’-TGACnnnGC-3’ although the importance of each 
base varies. For example, the 5’ terminal thymine is essential for all ARE-
dependant transcription, but the 3’ terminal guanine is required only for 
inducible activity (Rushmore et al., 1991). 
 
Fig 1.1 The bZip motif. Nrf2 binds small maf proteins and the ARE using the bZip motif, 
outlined in red.  bZip dimerization is required to form the DNA binding site. 
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Nrf2 is by far the best characterised member of the CNC family, but all 
members are related in structure and function. These include NF-E2, Nrf1, 
Nrf3, Bach1 and Bach2.  
 
1.2.1 NF-E2 
Nuclear factor, erythroid 2 (NF-E2) was originally reported to bind the 
porphobilinogen deaminase promoter in mouse erythroleukemia cells in 
1989 (Mignotte et al., 1989). It contains a transactivation domain and a CNC 
bZip domain, and forms a functional heterodimer with small maf proteins 
(Blank et al., 1997). It binds a DNA sequence very similar to the TRE (Table 
1.3), which is GCTGA(G/C)TCA (Ney et al., 1990).  
It is expressed primarily in hematopoietic cells (Andrews et al., 1993; Ney et 
al., 1993). Little is known about its regulation, but it has been shown that NF-
Table 1.3 The antioxidant response element and its related sequences. ARE-like elements 
(shown in bold) overlap with other sequences, showing that transcription factors may be 
able to share the same promoter region, and raising the possibility of cross-pathway 
regulation.  
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E2 plays a non-vital role in transcription of globin genes, and is important for 
megakaryocyte development (Andrews et al., 1993; Blank et al., 1997; 
Andrews, 1998). 
 
1.2.2 Nrf1 
Nrf1 was the first of the NF-E2 related proteins to be discovered, and was 
originally considered responsible for constitutive ARE-dependent gene 
expression (Chan et al., 1993). Although it has been shown that this is not 
quite true, Nrf1 has much more stable regulation than Nrf2. It has a half life 
of 5 hours, and is regulated by switching between three isoforms. The 
largest, p120, contains a 30-residue N-terminal sequence which confines it to 
the endoplasmic reticulum (Wang and Chan, 2006). Cleavage of the N-
terminal sequence is controlled by deglycosylation, and is required for 
transcriptional activation. The cleaved form, p95, is the active form of Nrf1, 
which induces ARE-dependent gene expression (Zhang et al., 2007). The final 
form of Nrf1, p65, is truncated. While it retains its ability to bind DNA, it lacks 
a transactivation domain and inhibits activation of ARE activity (Wang et al., 
2007a). 
Functionally, Nrf1 shares a lot of redundancy with Nrf2. However, unlike 
Nrf2, Nrf1 knockout mice are not viable suggesting that the two transcription 
factors have their own distinct functions (Chan et al., 1998). Although their 
differential regulation may account for part of this, Nrf1 has been shown to 
have its own transcriptional targets. Metallothionein-1, metallothionein-2 
and proteasomal subunits are regulated by Nrf1, but not Nrf2 (Ohtsuji et al., 
2008).  
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1.2.3 Nrf2 
In 1994, Moi and coworkers detailed the discovery and characterisation of 
Nrf2. The Nrf2 gene was cloned in K562 cells, and was found to consist of 
1807 base pairs, which predicts a 66.1kDa protein consisting of 589 amino 
acids (Moi et al., 1994). One of the main features of Nrf2 is that it is inducible 
(Table 1.4a and b). Under normal conditions it is targeted for degradation by 
a protein called Kelch-like ECH-associated protein 1 (Keap1) (Itoh et al., 1999; 
Itoh et al., 2003). When a protective response is required, Nrf2 degradation is 
halted by disrupting the interaction between Nrf2 and Keap1. This allows it 
to initiate transcription of genes containing the ARE sequence in their 
promoter (Jaiswal, 1994; Itoh et al., 2003).  
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Table 1.4a Activators of the Nrf2 pathway.  
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Table 1.4b Activators of the Nrf2 pathway. 
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Nrf2 has been classically considered to contain 6 domains, named Neh1-6. 
Recently Neh7 has been identified as an additional domain with a unique 
function (Itoh et al., 1999; Wang et al., 2013a) (Table 1.5). Neh1 is the 
domain containing the bZip and CNC motifs, and is therefore the domain 
responsible for heterodimerisation with bZip transcription factors and DNA 
binding (Itoh et al., 1999). Neh2 and 6 are negative regulatory domains that 
target Nrf2 for degradation. Neh2 is the Keap1 binding domain, whereas 
Neh6 promotes Keap1-independent Nrf2 degradation (Itoh et al., 1999; Rada 
et al., 2011). Neh3, 4, and 5 are transactivation domains, which can be 
phosphorylated to interact with transcription cofactors and enhance 
transcription (Nioi et al., 2005; Apopa et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.5 A summary of domain functions in Nrf2. Each of the 7 domains in Nrf2 has a 
specific function. A graphical representation of the relative position of each domain within 
the protein is also provided.  
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1.2.4 Nrf3 
Nrf3 (nuclear factor-erythroid 2 related factor 3) contains an N-terminal 
Neh3-like domain and a transactivation domain similar to that of Nrf1. Like 
Nrf1, it contains an N-terminal sequence that targets it to the ER. Not much is 
known about Nrf3, but it is highly expressed in the placenta, and not at all in 
the heart or liver. Nrf3 null mice show no obvious phenotype, and no 
differences were observed compared to the wild type after viral infection. 
Nrf1/Nrf2 double knock-outs show residual ARE expression, which may be 
due to Nrf3. Data showing a 4-5 fold increase in Nrf3 expression in skin cells 
in Nrf2-/- mice seems to support this, but other data shows that double 
knock-outs of Nrf3/Nrf2 and Nrf3/p45 did not increase mortality over knock-
outs of Nrf2 or p45 alone. Nrf3 is not well characterised, but it may play a 
role in protecting against inflammation and carcinogenesis (Derjuga et al., 
2004; Zhang et al., 2009a; Chevillard and Blank, 2011). 
 
1.2.5 Bach1  
Bach1 (BTB and CNC homology 1) is a CNC bZip transcription factor that is 
highly involved in Nrf2 regulated gene expression. It is unlike the Nrf- 
transcription factors because it contains a Broad-Complex, tramtack and bric 
à brac (BTB) domain, which is a protein-binding domain. In the case of Bach1 
it is used to bind small maf proteins (Oyake et al., 1996; Igarashi et al., 1998).  
Bach1 binds to the ARE, and suppresses gene transcription in an antagonistic 
relationship with Nrf2 (Sun et al., 2002). 
Bach1 has been shown to negatively regulate ARE dependent gene 
transcription in many cell types. For example, bach1-/- mice expressed more 
HO-1 in the brain, increased HO-1 mediated suppression of atherosclerosis, 
and increased HO-1 expression after ischemia in cardiac cells, which led to 
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increased protection of heart tissue (Yano et al., 2006; Sakoda et al., 2008; 
Watari et al., 2008). 
Although the absence of bach1 has a beneficial effect when protecting the 
cell from damage, it is not desirable to have a constitutively active 
antioxidant response. Firstly, constitutive activation of Nrf2 leads to 
hyperkeratosis (Satoh et al., 2009). Secondly, although cytoprotection is 
important when the cell is under threat from toxins and oxidative stress, 
these processes tend to inhibit apoptosis, which is an important mechanism 
in tumour prevention (Hayes and McMahon, 2001). 
 
1.2.6 Bach2 
Bach2 (BTB and CNC homology 2) is very similar to bach1, although its 
expression is constrained mainly to B cells and neuronal cells (Hoshino and 
Igarashi, 2002; Chen et al., 2013). Like bach1, it mainly acts as a transcription 
repressor. There are two isoforms of Bach2. A 110kDa form, and a 136kDa 
form. For most of its known functions, it forms heterodimers with MafK, and 
binds the MARE promoter sequence, although it can also form a homodimer 
to bind the TRE (Oyake et al., 1996). 
 Current research suggests that the role of Bach2 is somewhat different from 
the other CNC transcription factors, and despite the sequence similarity 
between the MARE and the ARE there is no evidence that it plays a role in 
Nrf2-related cell signalling. Bach2 is mainly involved in maturation and 
differentiation of B cells into plasma cells. Expression profiles show that 
Bach2 is highly expressed in early stages of B cell development, but levels 
drop once the fate of the cell has been decided (Ochiai et al., 2008).  
 
34 
 
1.2.7 CNC transcription factors regulate the antioxidant response 
The antioxidant response is induced by, and combats, oxidative stress 
(Nguyen et al., 2009). A common theme of CNC transcription factors is that 
they regulate antioxidant enzymes, often via binding the ARE (Jaiswal et al., 
1994; Sankaranarayanan and Jaiswal, 2004; Dhakshinamoorthy et al., 2005; 
Zhang et al., 2007; Chowdhury et al., 2009; Chen et al., 2013b).  
It is Nrf2, however, which is considered the primary regulator of the 
antioxidant response (Nguyen et al., 2009). This is because of the large array 
of enzymes that it regulates, ranging from phase II and III detoxifying 
enzymes to anti-inflammatory mediators and DNA repair enzymes (Cornejo 
et al., 2013; Singh et al., 2013a).  
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1.3 Nrf2 in Oxidative Stress 
Although Nrf2 is credited with many beneficial biological effects, it is most 
commonly associated with the antioxidant response. This is unsurprising; 
oxidative stress is involved in many diseases, including inflammatory 
diseases, neurodegenerative diseases and cardiovascular diseases (Dumont 
and Beal, 2011; Berg et al., 2011; Rosenbaugh et al., 2013). Combating 
oxidative stress is a key mechanism (although often not the only mechanism) 
by which Nrf2 has been shown to protect against them (Howden, 2013; Ruiz 
et al., 2013; Gan and Johnson, 2014).  
Oxidative stress is an imbalance in cellular redox homeostasis, and is 
characterised by an excessive amount of reactive oxygen species (ROS) 
which, unless detoxified, cause damage to cellular components. ROS are 
oxygen-containing molecules which are reactive. Many are free-radicals, and 
can react with many molecules around the cell, disrupting their function 
(Baker and Staecker, 2012; Sin et al., 2013; Zuo et al., 2013). 
Oxidative stress has many causes, largely because ROS have useful functions 
in the body provided that they are properly regulated. For example, ROS are 
used by the immune system to combat pathogens (Zurita et al., 2013; 
Genestet et al., 2014). They are also used as second messenger molecules in 
cell signalling pathways (Valko et al., 2007; Ray et al., 2012). Oxidative stress 
tends to occur when this balance is upset. Major causes of this often come 
from outside sources, such as food, radiation, or pollution. UV light, for 
example, causes free-radical production (Jurkiewicz et al., 1994; Murapa et 
al., 2012; Menichini et al., 2013) and is thought to be a major cause of skin 
cancer. A high fat diet is also known to cause oxidative stress (Charradi et al., 
2013).  
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Nrf2 is a key regulator of oxidative stress. Nrf2 knockout mice are more 
susceptible to oxidative stress-related diseases, are badly equipped to deal 
with injured tissue, and have an overactive inflammatory response (Kong et 
al., 2010; Wruck et al., 2011; Okada et al., 2013; Zhang et al., 2013a). Nrf2 
knockdown in vitro renders cells susceptible to ROS accumulation and 
induced toxicity, whereas Nrf2 induction has been shown to reduce ROS and 
increase cell viability in their presence (Li et al., 2012a; Deng et al., 2013; Hao 
et al., 2013). 
Both Nrf2 and its inhibitor, Keap1, can act as a ROS sensor. ROS can cause 
disruption of the Nrf2/Keap1 interaction and the activation of Nrf2 
transcriptional activity (Wakabayashi et al., 2004). Therefore, Nrf2 acts as a 
negative feedback mechanism to reduce cellular ROS. A large number of Nrf2 
target genes have antioxidant activity, but the specific functions that they 
perform are diverse.  
 
1.3.1 HO-1, Ferritin and Iron Homeostasis 
HO-1 is a well-studied Nrf2 target gene, which is responsible for the rate 
limiting step in the conversion of heme to bilirubin (Fig 1.2) in a reaction that 
also produces carbon monoxide and Fe2+ ions (Kirkby and Adin, 2006). 
Bilirubin is a powerful antioxidant that directly scavenges free radicals 
(Stocker et al., 1987). It also inhibits the production of superoxide by NADPH 
oxidase (Fujii et al., 2010). Although no single study has linked Nrf2, HO-1 and 
bilirubin to antioxidant activity, there are many smaller studies that strongly 
support this theory when the research is combined.  
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Increased HO-1 expression is often linked with protection against oxidative 
stress. Induced pluripotent stem cells lacking HO-1 have been shown to be 
more susceptible to oxidative damage than their HO-1 expressing 
counterparts (Lin et al., 2012a). Blood plasma was analysed in HO-1 knockout 
mice, which revealed elevated lipid peroxidation in the knockouts, suggesting 
increased oxidative stress (Ishikawa et al., 2012). Inducers of HO-1 such as 
sulforaphane, salvianolic acid A, and genistein have all been shown to protect 
against oxidative stress via the Nrf2 pathway, suggesting that Nrf2 is a key 
regulator of the protection provided by HO-1  (Kleszcyński et al., 2013; Wang 
et al., 2013a; Zhang et al., 2014a).  
Another product of HO-1 activity is carbon monoxide (CO), which can also be 
protective at sub-cytotoxic levels. CO has been shown to inhibit ROS 
Fig 1.2. HO-1 and iron homeostasis. HO-1 catalysis the rate-limiting step in the catabolism 
of heme. The products of the breakdown of heme, CO and bilirubin, have been shown to 
play roles in defending against oxidants and inflammation. Ferritin, another Nrf2 driven 
enzyme,  plays a key role in neutralising the harmful effects of Fe2+. 
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production in RAW264.7 cells stimulated with LPS (Srisook et al., 2006). In a 
model of hyperoxia CO was able to inhibit apoptosis and caspase-8 
activation, possibly by the inhibition of ROS (Wang et al., 2007) 
However, not every product of HO-1 is an antioxidant. Fe2+ is produced from 
the degradation of heme. Fe2+ can become oxidised to Fe3+ by H2O2 in a 
reaction that produces a hydroxyl radical (Jomova et al., 2010). Fortunately, 
another Nrf2-mediated enzyme, Ferritin, is able to detoxify free Fe3+, 
protecting the cell from any damage it may cause. Ferritin consists of 24 
subunits, of which there are two types. The role of the H subunit is to 
catalyse an alternative reaction for the oxidation of Fe2+ which does not 
involve the production of hydroxyl radicals, whereas the L subunit binds and 
stores Fe3+ in a non-toxic state, controlling its bioavailability (Alkhateeb and 
Connor, 2013).  
The antioxidant activity of ferritin has been documented in several in vitro 
studies. Ferritin correlates with improved cell viability after porcine aortic 
endothelial cells were incubated with H2O2 and hematin. Furthermore, 
preloading cells with ferritin confers protection against cytotoxicity caused by 
H2O2/hemin, which an inactive ferritin H mutant does not (Balla et al., 1992). 
In addition, overexpression of both ferritin H and ferritin L has been shown to 
protect against doxycycline-induced ROS accumulation in HeLa cells (Orino et 
al., 2001). In a model of acute pancreatitis in Wistar rats and AR42J 
pancreatic cells, ferritin was subject to degradation, which correlated with 
increased ROS production (Sledzinski et al., 2013).  
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1.3.2 NQO1 
Another Nrf2 target, NQO1, provides a more direct way of tackling ROS and 
oxidative stress. The primary role of NQO1, as the name suggests, is to 
reduce quinones to hydroquinones using NADPH as a reductant. This has the 
effect of preventing the unfavourable reduction of quinones by reactions 
which produce free radicals (Bianchet et al., 2004). Quinones are common 
molecules, and sources of quinone-induced oxidative stress can range from 
environmental toxins (Laskin et al., 1995; Prisby et al., 2008) to hormones 
(for example, metabolites of oestrogens (Singh et al., 2012)). NQO1 may also 
have a secondary role as a direct scavenger of superoxide (Siegel et al., 
2004). 
NQO1 has been shown to protect against oxidative stress caused by a large 
range of inducers. For example, both tectorigenin and glycitein are NQO1 
inducers that protect rat astrocytes from H2O2-induced ROS and cell death. 
The NQO1 inhibitor dicoumarol prevented the protective effects of these 
compounds (Park et al., 2011a). Furthermore, NQO1 silencing exacerbated 
cisplatin-induced ROS in human renal tubular cells (Gang et al., 2013). NQO1 
is also believed to play an integral role in the detoxification of the 
metabolites of benzene, many of which are quinones. A C609T mutation in 
NQO1 has been associated with an increased risk to the toxic effects of 
benzene, possibly by inhibiting the production of NQO1 (Moran et al., 1999). 
In addition to detoxifying quinones from external sources, a potential role for 
NQO1 is arising in protecting against neurodegenerative diseases. 
Metabolites of dopamine are thought to be involved in the development of 
Parkinson’s disease by blocking 20s proteasome activity, a process that 
NQO1 can prevent (Zafar et al., 2006).  
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1.3.3 Glutathione 
Glutathione (GSH) is probably the most direct regulator of ROS, and is 
extremely prevalent in animal cells, available at concentrations in the mM 
range. GSH is a tripeptide of glutamic acid, cysteine and glycine, although the 
cysteine and glutamic acid are bound through the carboxyl group of the 
glutamate side chain, rather than its backbone. GSH exerts its activity 
through the thiol group of the cysteine residue, which can directly neutralise 
oxidants by acting as a reducing agent. Although the oxidised form of GSH is 
a reactive free radical, it doesn’t exist in this form, and instead reacts with 
itself to form a stable disulfide, GSSG. This is normally catalysed by GSH 
peroxidises (Deponte, 2013). 
Biologically, GSH has been well documented to regulate redox homeostasis, 
and Nrf2 has been shown to act upstream of GSH activity (Hayes and 
McLellan, 1999; Jozefczak et al., 2012). The role of Nrf2 in GSH biochemistry 
is to induce enzymes that are involved in the production of GSH. Nrf2 
knockout mice are susceptible to oxidative stress because they have 
impaired GSH production, which has been attributed to an inhibition of 
glutamate cysteine ligase (GCL) and GSH synthetase expression (Chan et al., 
2001). Similarly, isorhamnetin was able to induce Nrf2 and GCL in HepG2 
cells. Depletion of Nrf2 inhibited GCL expression. t-BHP-induced GSH 
depletion, oxidative stress and cytotoxicity were all inhibited by isorhamnetin 
(Yang et al., 2014a). 
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1.4 Inflammation 
In the last decade, Nrf2 has also been shown to have anti-inflammatory 
effects (Kong et al., 2010; Foresti et al., 2013). Inflammation is a key process 
that protects the body by creating localised areas of stress, which is 
important for activating the immune system and wound healing, and creating 
a hostile environment for pathogens (Shi and Pamer, 2011). However, left 
unchecked, this can rapidly become harmful to host tissue (Mu et al., 2013). 
Chronic inflammation plays a major role in a wide variety of diseases, ranging 
from those for which inflammation is a primary factor, such as inflammatory 
bowel disease or sepsis, to those where inflammation is an underlying 
component of the pathogenic process, such as neurodegenerative diseases 
and cardiovascular diseases (Lohner et al., 2013; Stoner et al., 2013; Amor et 
al., 2014; Zhang and Li, 2014). Even conditions that appear unrelated, such as 
depression, have been linked with inflammatory mediators (Vogelzangs et 
al., 2012). This wide range of effects makes inflammation an important 
process to target therapeutically, and over the last decade it has become 
increasingly apparent that activation of Nrf2 is a very promising avenue to 
pursue.  
 
1.4.1 The inflammatory response 
Inflammation has been characterised for approximately 2000 years by its 
cardinal signs of redness, heat, swelling and pain, originally noted by 
Cornelius Celsus. Today inflammation is better understood mechanistically as 
a response of the body to damage, which can refer to anything from a 
physical wound to an invasion of pathogens. The inflammatory response 
encompasses a wide array of processes ranging from recognition of the 
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threat, up to activation of the adaptive immune system (Alessandri et al., 
2013) (Fig 1.3).  
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1.4.1.1 Pattern recognition receptors. 
 
Pattern recognition receptors (PRRs) are expressed in a wide range of 
immune cells. They bind “pathogen-associated molecular patterns” (PAMPs), 
which are essentially common structures found in a wide range of pathogens. 
An example would be lipopolysaccharide (LPS), which is expressed in all gram 
negative bacteria. Although there are many types of LPS, they all share the 
same basic structure, which can be recognised by the PRR toll-like receptor 4 
(TLR4). PRRs can be externally expressed on the cell membrane or internally 
expressed in the cytoplasm. Typically PRRs on the cell membrane recognise 
PAMPs which are externally expressed by pathogens. Cytoplasmic PRRs 
recognise PAMPs that become exposed to the cell’s cytoplasm, which can 
occur when a pathogen is internalised by the cell either by invasion or 
phagocytosis (Takeda and Akira, 2005). PRR activation activates signalling 
pathways that result in the transcription and translation of pro-inflammatory 
cytokines. The specific PAMP and PRR involved will often activate specific 
pathways, which control the cytokines that are produced (Teixeira-Coelho et 
al., 2014). 
The TLR family are a versatile set of PRRs that can recognise molecules 
belonging to bacteria, fungi or viruses (Table 1.6). They are expressed by a 
wide range of leukocytes and epithelial cells (Brigotti et al., 2013; Krejsek et 
al., 2013; Ling et al., 2014; Ortega-González et al., 2014; Teixiera-Coelho et 
al., 2014). Lipopolysaccharide (LPS), a component of gram negative bacterial 
cell walls, is a powerful activator of monocytes and binds TLR4 (Hoshino et 
al., 1999). LPS activation of monocytes will be utilised as an in vitro model of 
inflammation in this study. 
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TLR4 uses adaptor proteins to bind LPS. The first of these is LPS binding 
protein (LBP), which facilitates the binding between LPS and a second 
adaptor protein, CD14. LBP may be able to extract LPS from bacteria directly 
(Jerala et al., 2007).  CD14 has been implicated in activating differential 
signalling pathways depending on the structure of the LPS (Regen et al, 
2011). The final adaptor protein required for LPS signalling via TLR4 is a 
member of the ML superfamily called MD-2. When MD-2 is bound to TLR4 its 
affinity for LPS increases (its affinity for TLR4 is constant whether LPS is 
bound or not) (Mitsuzawa et al, 2006). LPS, bound to CD14, will bind MD-2 
monomers, of which there are two bound to a TLR4 homodimer. This is 
essential for LPS signalling, and no role for TLR4 has been identified without 
MD-2 (Shimazu et al, 1999). 
 
 
 
 
Table 1.6 Toll-like receptors. A non-exhaustive list of the PAMPs that are commonly 
associated with each TLR.  
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1.4.1.2 TLR4 Signalling 
 
TLR4 signals through two major pathways (Fig 1.4). These are known as the 
myeloid differentiation primary response gene (88) (MyD88) dependent 
pathway and the MyD88 independent pathway. Most TLRs signal through the 
MyD88 dependent pathway (Kumar et al, 2009). MyD88 is an adaptor protein 
that is recruited to the cytoplasmic domain of TLR4 upon its activation. A 
second adaptor protein, TIRAP (also known as MAL), acts to increase the 
affinity of the interaction between MyD88 and TLR4. This complex, and the 
downstream targets that it recruits, is called the myddosome (reviewed in: 
Gay et al., 2011). 
MyD88 then recruits IL-1 receptor associated kinase-4 (IRAK-4) to the 
receptor complex. IRAK-4 is essential for MyD88 signalling but other IRAK 
proteins may not be. IRAK-4 interacts with IRAK-1, although IRAK-1 knockout 
mice only had a partially inhibited MyD88 dependent pathway. IRAK-2 may 
also play a role in signalling downstream of IRAK-4 (Wesche et al., 1997; 
Suzuki et al., 2002; Keating et al., 2007; Lu et al., 2008). 
TNF receptor associated factor 6 (TRAF6) lies downstream of IRAK-4 and 
IRAK-1, and has been reported to be essential for MyD88 dependent 
signalling. This suggests that any variance in substrates of IRAK-4 converge 
again on TRAF6. TRAF6 forms a complex with Tab1 and Tab2 to activate TAK1 
(Jiang et al., 2002). This results in activation of IκB Kinases (IKKs), which 
phosphorylate inhibitor of κB proteins (IκBs). IκBs are inhibitors of nuclear 
factor-κB (NF-κB), which are deactivated by phosphorylation (Lu et al., 2008; 
Avila et al., 2012).  
NF-κB is the most important transcription factor for the inflammatory 
response, but others are also activated by the MyD88 dependent pathway. 
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These include interferon regulatory transcription factor 5 (IRF5), activator 
protein-1 (AP-1), and mitogen activated protein kinases (MAPK) (Guha and 
Mackman, 2001; Moynagh, 2005; Lu et al., 2008). 
TLR4 is unique among the TLRs in that knocking down MyD88 does not 
completely abolish NF-κB activation. Instead, NF-κB is activated by the 
MyD88 independent pathway (also known as the TRIF dependent pathway), 
which happens to be the same pathway through which TLR3 signals (Piao et 
al., 2013).  
Upon TLR4 activation both TIR-domain-containing adaptor-inducing 
interferon β (TRIF) and TRIF-related adaptor molecule (TRAM) are recruited 
to the receptor complex. Both are essential for MyD88 independent 
signalling. TRIF recruits TRAF3. TRAF3 controls downstream signalling by 
activating a complex of TRAF family member-associated NF-κB activator 
(TANK), TANK binding kinase 1 (TBK1) and IKKi. TBK1 and IKKi are involved in 
dimerization and nuclear translocation of the transcription factor IRF3, which 
results in production of type I interferons (IFN α/β) (Youn et al., 2005; Lu et 
al., 2008). 
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TRIF also activates the serine/threonine kinase RIP1. RIP1 is involved in the 
MyD88 independent activation of NF-κB and MAPK (Youn et al., 2005).  
 
1.4.1.3 Cytokines, chemokines and NF-κB 
 
NF-κB refers to a small family of transcription factors comprising v-rel avian 
reticuloendotheliosis viral oncogene homolog A (RELA; also known as p65), 
RELB, C-Rel, p50 and p52, which all contain an N-terminal Rel homology 
domain. p50 and p52 contain no transactivation sites of their own, and 
frequently form heterodimers with RelA, RelB, or c-Rel (Hoesel and Schmid, 
2013).  
Fig 1.4. TLR4 Signalling. TLR4 signals via the MyD88 dependent and MyD88 independent 
pathway.  
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NF-κB is an important mediator of inflammation. Constitutive activation of 
NF-κB in mice caused death after 7-10 days. The mice had severe dermatitis, 
increased concentrations of monocytes and macrophages in the spleen, and 
overproduction of inflammatory mediators (Klement et al., 1996).  
Furthermore, anti-inflammatory mediators are often linked with inhibition of 
NF-κB (Ivanenkov et al., 2011; Oh et al., 2013; Wang et al., 2014a).   
The reason that NF-κB is so important for inflammation is that its function is 
to initiate transcription of cytokines that regulate the innate and adaptive 
immune responses (Hoesel and Schmid, 2013; Gerondakis et al., 2014). 
Cytokines are messengers of the immune system, and are usually secreted by 
leukocytes to regulate processes of surrounding leukocytes. Common 
cytokines include the interleukin family, tumour necrosis factor (TNF), and 
the interferons (Table 1.7). Once these are produced at the site of damage or 
infection, they are secreted into the extracellular environment to find and 
activate other immune cells. IL-1β does exactly this by stimulating the 
production of adhesion molecules in endothelial cells, and by stimulating 
further release of pro-inflammatory cytokines in other leukocytes (Tsang et 
al., 1997; Kasza et al., 2013). TNF plays a similar role, and also activates 
phagocytes. Some cytokines, called chemokines, regulate chemotaxis (Zelová 
and Hošek, 2013). These typically activate leukocyte extravasation, and 
subsequent migration to the site of infection. Neutrophils are the first to 
arrive. Neutrophils release defensins, which are proteases and lysozymes 
that are secreted to kill bacteria from range (Baines et al., 2011). In addition, 
neutrophils also release reactive oxygen species to kill pathogens. These 
mediators, and the debris caused by destroyed bacteria, can harm host cells 
and are the cause of the fourth cardinal sign of inflammation, pain (Dupré-
Crochet et al., 2013). 
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In addition to leukocyte recruitment, cytokines stimulate the release of acute 
phase proteins (APPs). These are proteins that are either upregulated 
(positive APPs) or downregulated (negative APPs) in inflammation. If 
cytokines are the messengers of the immune system, positive acute phase 
proteins can be considered those that carry out the functions.  
Some of the first APPs to be activated in the inflammatory response are 
Opsonins. Opsonins are proteins that enhance phagocytosis. Phagocytosis is 
Table 1.7 Important cytokines in inflammation. Many cytokines play an important role in 
inflammation, but these are important in the amplification of inflammatory signalling. 
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the process by which leukocytes can engulf and break up pathogens (Sjöwall 
and Wetherö, 2007). Neutrophils, monocytes, dendritic cells and 
macrophages are capable of phagocytosis. Monocytes are large phagocytes, 
which are precursor cells to macrophages and dendritic cells. Upon arriving 
at the site of infection monocytes differentiate into one of these types of cell 
depending on the cytokines that are present in the extracellular matrix 
(Huber et al., 2014). Macrophages and dendritic cells are antigen presenting 
cells, meaning that they can activate the adaptive immune system via T-cell 
activation by presenting fragments of pathogens on their cell membrane 
(Dresch et al., 2012; Altaf and Revell, 2013).    
Opsonins include C-reactive protein and components of the complement 
system. C-reactive protein is a PRR that recognises phosphocholine on 
apoptotic cell membranes, and is largely involved in initiating clearance of 
dead tissue, but is also involved in bacterial recognition. The complement 
system is a protein cascade that interacts directly with bacteria and fungi. It 
plays several roles in the immune system including marking bacterial cells for 
phagocytosis, and killing pathogens directly. One part of the complement 
system, the membrane attack complex, makes pores in the cell membrane of 
the pathogen, causing cell contents to leak and apoptosis to occur (Sjöwall 
and Wetherö, 2007; Tegla et al., 2011; Barratt-Due et al., 2012).  
Other APPs include coagulants, which function to clot blood. In inflammation, 
the function of this is to isolate the infected area from the rest of the body 
(O’Brien, 2012; Woel-A-Jin et al., 2012).  
Some APPs are negative regulators of inflammation and contribute to the 
resolution of inflammation. The resolution of inflammation is the process by 
which inflammation is ended when it is no longer needed. For example, 
serpins are anti-coagulants, and work to restore the vascular system. Another 
important process in the resolution of inflammation is induction of apoptosis 
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and subsequent clearance of accumulated leukocytes. If resolution of 
inflammation doesn’t occur then inflammatory diseases can manifest. 
 
1.4.1.4 The development of inflammatory diseases 
 
Inflammation is an essential function of the body to defend against injury and 
infection, but if it is not properly regulated it can manifest into an 
inflammatory disease. Inflammatory diseases are characterised by conditions 
whereby leukocytes over-produce ROS, which causes extensive damage to 
host tissue, and over-stimulate lymphocytes, which can lead to 
autoimmunity.  
 
Sepsis is a good example of the consequences of an unregulated 
inflammatory response. It is a systemic inflammatory disease, which is 
normally caused by an over-reaction to bacterial or fungal infection. In sepsis, 
an unregulated inflammatory response can lead to necrosis, multiple organ 
failure and death (Wiersinga et al., 2014). The first problem is overproduction 
of inflammatory mediators and ROS by leukocytes. ROS react with host 
tissue, causing necrosis. This causes more ROS production from processes 
such as lipid peroxidation (Andrades et al., 2011). The overproduction of 
inflammatory mediators further exacerbates the inflammatory response. 
Blood pressure can be drastically lowered due to increased vascular 
permeability, leukocytes can harm host tissues, but perhaps the most 
damaging aspect is the overproduction of coagulants. This leads to blood 
clotting and ischemia, eventually causing multiple organ failure and 
subsequent death (Takala et al., 2010; Semeraro et al., 2012; Wiersinga et al., 
2014).  
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1.4.2 Nrf2 in inflammatory diseases 
 
Nrf2 is known to protect against inflammation and down-regulate pro-
inflammatory cytokines in vivo. Nrf2 knockout mice display characteristics of 
an unregulated inflammatory response, and lupus-like autoimmune 
symptoms (Ma et al., 2006). In a mouse model of elastin-induced 
emphysema Nrf2 knockout was accompanied with susceptibility to the 
disease, which was linked with a high level of inflammation. This was 
characterised by alveolar oedema, haemorrhage, and neutrophil infiltration. 
Furthermore, increased neutrophils and macrophages were found in 
bronchiolar fluid compared to WT mice (Ishii et al., 2005). In a model of 
ConA-induced liver inflammation in mice, hepatocyte-specific Keap1 
knockout inhibited macrophage and neutrophil accumulation in the liver. 
Furthermore, hepatocytic pro-inflammatory cytokines, IFN-γ, TNF, Mip-2, and 
MCP-1 were inhibited compared to WT mice (Osburn et al., 2008). In vitro, 
Nrf2 plays a natural role in regulating inflammation. For example, our lab has 
previously shown that Nrf2 knockdown by siRNA leads to an exacerbation of 
LPS-induced TNF and IL-1β in THP-1 monocytes (Rushworth et al., 2008). 
Several studies have shown that induction of Nrf2 with different classes of 
Nrf2 activators in vitro and in vivo provide protection against pro-
inflammatory mediators. In RAW264.7 macrophages dihydro-CDDO-
trifluoroethyl amide activated Nrf2 and inhibited LPS-induced MCP-1 and 
MIP-1β. The suppression of pro-inflammatory cytokines was lost in the 
presence of Nrf2 siRNA (Li et al., 2014a). LPS is not the only activator of 
inflammation to be inhibited by Nrf2. S100b-induced TNF and IL-1 in THP 
monocytes is blocked by dimerumic acid, except in the presence of Nrf2 
siRNA (Lee et al., 2013a). 
54 
 
There has therefore been a lot of interest in finding activators of Nrf2 that 
can provide these protective effects. Nrf2 activation has been associated 
with anti-inflammatory effects caused by epigallocatechin-3-gallate (EGCG) in 
mice with lupus (Tsai et al., 2011) and in a rat model of bleomycin-induced 
pulmonary fibrosis (Sriram et al., 2009). Although no causal relationship with 
Nrf2 has been observed, EGCG-mediated inhibition of TNF-induced ICAM-1 
and ROS in A549 cells was abrogated by HO-1 siRNA (Lee et al., 2013b). 
Although causal relationships are important to show, correlation of Nrf2 
activation with anti-inflammatory activity is common. In May 2014 alone 
diallyl sulfide, 3,4,5-trihydroxycinnamic acid, zinc, α-viniferin, rutin, 
ulinastatin, and osthole have all been suggested to protect against 
inflammation via the Nrf2 pathway (Dilshara et al., 2014; Ho et al., 2014; Lee 
et al., 2014a; Pan et al., 2014; Song et al., 2014; Yang et al., 2014b; Zhang et 
al., 2014b).  
The mechanisms behind Nrf2-mediated anti-inflammatory activity are 
complex and numerous, with many studies proposing different processes. 
However, they can be split into two main groups: those that act via Nrf2 
target genes, and those that do not. 
Nrf2 target genes are known to inhibit inflammatory mediators. We have 
previously shown that overexpression of NQO1 and/or HO-1 inhibits TNF and 
IL-1β expression in monocytes in response to LPS, whereas knockdown of 
HO-1 and NQO1 has the inverse effect (Rushworth et al., 2008). HO-1 in 
particular has been linked with anti-inflammatory effects, potentially linked 
to CO production (Onyiah et al., 2013; Anyanwu et al., 2014). Peritoneal 
macrophages from HO-1 deficient mice produce increased levels of ROS and 
inflammatory mediators including IL-6 and MCP-1. This has been linked with 
an increased susceptibility to atherosclerosis (Orozco et al., 2007). HO-1 has 
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also been linked to protection from ischaemia (Richards et al., 2010; Park et 
al., 2013; Huang et al., 2014).   
However, it has become apparent that Nrf2 target genes are not the only 
mechanism by which Nrf2 exerts anti-inflammatory effects, and crosstalk 
between the Nrf2 signalling pathway and the NF-kB pathway in particular has 
been proposed by numerous lab groups. Furthermore, Keap1 may be a key 
regulator of this anti-inflammatory activity, rather than Nrf2 itself (Lee et al., 
2009a; Kim et al., 2010). 
The Nrf2 inhibitor, Keap1 is also a negative regulator of IKKβ and interacts 
with it using the same core binding sites as it does when it binds Nrf2 (Kim et 
al., 2010). Although they use the same binding site, computational docking 
research has suggested that the binding of both Nrf2 and IKKβ are slightly 
different (Jiang et al., 2013). IKKβ is a positive regulator of NF-κB. Keap1 
siRNA has been shown to activate IL-6 via NF-κB signalling and exacerbate 
TNF-induced NF-κB activity in HEK293 and breast cancer cells (Lee et al., 
2009a; Kim et al., 2010; Lv et al., 2013). However, Keap1 silencing has been 
used to cause Nrf2 overexpression, which has been shown to protect against 
inflammation in the vast majority of the literature, so the significance of this 
is debatable (Osburn et al., 2008; Blake et al., 2010; Lu et al., 2014a).  
Not every study agrees that Nrf2 is protective against inflammation, 
however. Nrf2 may be involved in the NLRP3 inflammasome formation. Nrf2 
knockout mice showed a decrease in inflammatory response, which was 
believed to signal through ROS production (Zhao et al., 2014). Furthermore, 
the involvement of Nrf2 in the NLRP3 inflammasome may also play a role in 
atherosclerosis (Freigang et al., 2011). Interestingly, some evidence that 
points to anti-inflammatory roles of Nrf2 may act by inhibiting the NLRP3 
inflammasome (Tsai et al., 2011; Yang et al., 2013). More research is required 
to bring these opposing roles together, but it is possible that Nrf2 plays a 
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larger role in regulating the NLRP3 inflammasome that goes beyond simple 
inhibition of inflammatory activity.    
It is difficult to reconcile the research that shows a pro-inflammatory role for 
Nrf2 with that which shows that Nrf2 is an important anti-inflammatory 
mediator, although evidence supporting the latter overwhelms the former. 
Understanding regulation of Nrf2 activity will be important if Nrf2 is to be 
seriously considered as a drug target for inflammatory diseases.  
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1.5 Nrf2 Regulation 
Nrf2 expression is tightly regulated by several mechanisms, and typically Nrf2 
only mediates gene transcription under conditions of cellular stress. Under 
normal conditions Nrf2 is found in the cytoplasm in a complex with its 
inhibitor Keap1, and only when this interaction is disrupted, Nrf2 
accumulates in the nucleus (Itoh et al., 1999). Keap1 is the primary regulator 
of Nrf2, but it is not the only mechanism by which Nrf2 activity is controlled. 
Other regulators include microRNAs, Nrf2 phosphorylation, de novo synthesis 
of Nrf2 mRNA, and other CNC transcription factors (Huang et al., 2002; 
Rushworth et al., 2008; Kaspar and Jaiswal, 2010; Cheng et al., 2013). 
 
1.5.1 Keap1 
Keap1 was originally identified in 1998 as a protein consisting of 624 amino 
acids with five domains. Keap1 is classified as a member of the kelch repeat 
superfamily due to the presence of six double glycine repeat (also known as 
kelch repeat) motifs in the kelch domain (Table 1.8). Kelch domains form 
propeller-like structures called β-propellers. Each kelch repeat consists of 44-
56 amino acids and forms an anti-parallel β-sheet, which consists of 4 β-
strands. Repeats in a kelch domain will then form a ring—like structure with 
each individual repeat becoming a propeller blade of the larger structure 
(Adams et al., 2000). The kelch domain is a protein binding domain, and has 
been shown to anchor keap1 to the actin cytoskeleton and to bind directly to 
the Neh2 domain of Nrf2. Actin binding has been shown to be essential for 
keap1 activity (Itoh et al., 1999; Kang et al., 2004).  
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1.5.2 The E3 ubiquitin ligase complex 
Keap1, although considered an inhibitor of Nrf2 activity, is actually an 
adaptor protein for the E3 ubiquitin ligase complex, which transfers ubiquitin 
from E2 ubiquitin ligase to a substrate protein (Zhang et al., 2004; Furukawa 
and Xiong, 2005). Polyubiquitination acts as a marker for protein degradation 
(Fig 1.5). An E3 ubiquitin ligase complex typically consists of a scaffold, an E2 
binding RING protein, a bridge and an adaptor protein. The variability of the 
individual components of the complex allow for some degree of specificity 
within the system. The cullin family forms the scaffold of the ubiquitin ligase 
complex, and acts as adaptor protein binding sites. Cul3 is an interesting 
member of the cullin family, because it is thought that in Cul3 based 
ubiquitin ligase complexes the adaptor protein contains both the Cul3 and 
Table 1.8 A summary of domain functions in Keap1. The functions of both terminal 
domain have not attracted much interest, but the BTB, IVR, and Kelch domains are integral 
to Keap1 function.  
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substrate binding domains, eliminating the need for a bridge (Cullinan et al., 
2004; Furukawa and Xiong, 2005). 
In the case of Keap1, the Nrf2 binding Kelch domain acts as the adaptor, and 
the Cul3 binding BTB domain acts as the bridge (Pintard et al., 2004; Cullinan 
et al., 2004). Rbx1 is a RING protein that associates with Cul3 and Keap1, and 
its presence increases ubiquitination of Nrf2 (Small et al., 2010). Its function 
is to bind E2 ubiquitin ligase, which brings it into close proximity with Nrf2 
(Furukawa and Xiong, 2005).   
 
 
 
 
 
Fig 1.5 Nrf2 ubiquitination and degradation. (A) Nrf2 is constitutively expressed, and binds 
Keap1 homodimers in the cytoplasm. (B) Keap1 facilitates Nrf2 ubiquitination by the E3 
ubiquitin ligase complex. (C) This targets Nrf2 for degradation by the 26S proteasome, and 
(D) allows ubiquitin to be recycled. 
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Ubiquitination of Nrf2 occurs on multiple lysine residues, supported by data 
showing that lysine to alanine substitutions at positions 19, 23, and 30 
blocked degradation of Nrf2. This supports the same group's predicted 
structure of the Neh2 domain, in which the N-terminal sub domain is α-
helical with these three lysine residues clustered on one side of the helix. A 
conserved region throughout CNC transcription factors is a DLG motif at 
residues 29-31. The leucine appears to be the most important residue 
because a mutation, L30A, inhibited the Nrf2-Keap1 interaction and 
subsequent Nrf2 ubiquitination (Katoh et al., 2005). Displacement of this 
motif may cause a conformational change in Nrf2, which prevents 
ubiquitination of the nearby lysine-rich region (Tong et al., 2006). 
 
Keap1, therefore, is a chief negative regulator of Nrf2 activity. There are 
several proposed mechanisms for the regulation of the Nrf2/Keap1 complex. 
However, they all have the same underlying principles. In essence, disrupting 
Nrf2/Keap1 binding blocks Nrf2 ubiquitination (Fig 1.6). This prevents Nrf2 
degradation. Newly synthesised Nrf2 is no longer sequestered in the 
cytoplasm by Keap1, and can enter the nucleus to promote transcription.   
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1.5.3 The Nrf2/Keap1 interaction 
Since the discovery of Keap1 there have been several proposed models for 
the disruption of the Nrf2/Keap1 interaction (Tong et al., 2006a; Baird et al., 
2013). The first of which is the sequester and release model, which originally 
proposed that activation of Nrf2 was caused by its complete dissociation of 
Keap1. This was more of an assumption than a supported model, and was 
largely based on observations showing that Keap1 anchors Nrf2 in the 
cytoplasm, and Nrf2 nuclear accumulation can be caused by conformational 
changes in Keap1 (Itoh et al., 1999; Zipper and Mulcahy, 2002; Itoh et al., 
2003).  
Fig 1.6 Nrf2 activation. (A) Nrf2 is constitutively expressed, and binds Keap1 homodimers 
in the cytoplasm. (B) Modification of Keap1 by inducers cause a conformational change in 
the Nrf2/Keap1 interaction, blocking ubiquitination and subsequent degradation. (C) This 
results in Keap1 saturation, causing accumulation of newly created Nrf2. (D) Nrf2 can now 
translocate to the nucleus to start transcription. 
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The problem with this model of Nrf2 regulation became apparent as it was 
shown that Nrf2 nuclear accumulation could be induced without altering its 
binding to Keap1 (Kobayashi et al., 2006). In addition, it was shown that the 
Neh2 domain of Nrf2 contains two Keap1 binding sites, each of which binds 
one Kelch domain in a Keap1 homodimer (Fig 1.7). The two sequences are 
29DLG31 and 79ETGE82. The strong binding ETGE sequence anchors Nrf2 to 
Keap1, whereas the weak binding DLG sequence acts as a regulatory element 
for Nrf2 ubiquitination (Katoh et al., 2005; McMahon et al., 2006; Tong et al., 
2006b; Tong et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.7 The Nrf2/Keap1 interaction. The N-terminal Neh2 domain of Nrf2 contains two 
Keap1 binding sites. The DLG motif binds one kelch domain of a Keap1 homodimer, and the 
ETGE motif binds the other. 
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This configuration of the Nrf2/Keap1 interaction led to a new explanation for 
how Nrf2 is regulated. This was called the hinge and latch mechanism, and 
proposed that activation of Nrf2 is caused by displacement of the weaker 
DLG motif while the ETGE motif remains bound to Keap1. The displacement 
of the DLG motif blocks Nrf2 ubiquitination, and Keap1 becomes saturated 
due to the lack of Nrf2 degradation. This allows newly synthesised Nrf2 to 
enter the nucleus. The key implication of this model is that a drug designed 
to induce Nrf2 activation would only need to inhibit the weaker DLG/Kelch 
interaction, which is a much easier task and may be possible using ETGE-like 
sequences (Tong et al., 2006a; Hancock et al., 2012). This hinge and latch 
model is also purely hypothetical with little experimental evidence backing it 
up, and recent evidence suggests that it is only half right. 
The Nrf2/Keap1 interaction is slightly more dynamic than previously thought. 
Using a FRET-based technique the binding between Nrf2 and Keap1 was 
examined experimentally, and has led to the suggestion of a conformational 
cycling model. Under resting conditions Nrf2 binds Keap1 in two 
conformations, an open conformation and a closed conformation. Like the 
hinge and latch mechanism, the open and closed conformations revolve 
around the binding of the DLG motif. However, in contrast to the implications 
of the hinge and latch model, Nrf2 activators were shown to induce the 
closed conformation. Based on this evidence, the authors propose a 
mechanism whereby Nrf2 binds Keap1 via the stronger ETGE motif first (the 
open conformation), and then binds with the weaker DLG motif (the closed 
conformation). This means that at any one time there are two conformations 
of the Nrf2/Keap1 interaction. The closed conformation brings Nrf2 into 
proximity of the E3 ubiquitin ligase complex, promoting ubiquitination and 
degradation of Nrf2. In the presence of inducers, the closed conformation is 
still promoted, but it is proposed that these inducers cause conformational 
changes to Keap1 by reacting with cysteines around the Kelch and IVR 
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domains. These conformational changes are suggested to alter the positional 
relationship between Nrf2 and the E3 ubiquitin ligase complex, inhibiting its 
ubiquitination. The details concerning the E3 ubiquitin ligase complex have 
not been shown experimentally (Baird et al., 2013). 
Current research suggests that the conformational cycling method is the best 
suggested mechanism of the Nrf2/Keap1 interaction, although it is difficult to 
see how this method would work with competitive inhibitors. Therefore, 
neither the hinge and latch or the sequester and release model can be 
completely discarded yet as a secondary mechanism of Nrf2 regulation. 
Blockage of Nrf2 ubiquitination by the above mechanisms is proposed to 
come about by inducers causing conformational changes in Keap1 or Nrf2, or 
by competitive inhibition for the Keap1 binding site. The two broad 
mechanisms by which this occurs are by modification of Keap1 cysteine 
residues, and by Nrf2 phosphorylation.  
 
1.5.4 Modification of Keap1 cysteine residues 
Human Keap1 contains 27 cysteine residues (Eggler et al., 2005), including 
several in its kelch and IVR domains. These are thought to be modified by 
electrophiles and oxidants, which cause a conformational change in Keap1, 
blocking ubiquitination of Nrf2 and inducing its nuclear accumulation. The 
best studied cysteine residue in Keap1 is C151, which is located in the BTB 
domain. A C151S mutation in the mouse protein rendered Nrf2 signalling 
non-responsive to tBHQ in mouse embryonic fibroblasts, highlighting the 
importance of the residue (Yamamoto et al., 2008). However, the mutation 
did not affect Nrf2 levels under basal conditions, suggesting that it did not 
affect the Nrf2/Keap1 interaction or Keap1 binding to Cul3. Due to the 
position of C151 in the BTB domain of Keap1, it has been hypothesised that 
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the residue might work as a molecular switch. Modification of C151 by 
reactive oxygen species may cause a minor alteration in Keap1 structure to 
redirect degradation from Nrf2 to Keap1. This is backed up by evidence that 
shows C151S mutations block Keap1 dissociation from Cul3, and other 
evidence that shows mutations in the BTB domain increasing degradation of 
Keap1 and decreasing degradation of Nrf2 (Sekhar et al., 2010). 
Caution should be exercised when interpreting Keap1 cysteine data, 
however. It has been noted that while C151 modification is well supported as 
a mechanism of Nrf2 activation, this appears to be inducer-dependent. It has 
been shown, for example, that C151 is not required for induction of Nrf2 by 
arsenite or monomethylarsonic acid (Wang et al., 2008a). In addition, 
experimental data can also be method-dependent (Eggler et al., 2007), 
suggesting that some research on the reactivity of Keap1 cysteine residues 
may be flawed.  
Other cysteine residues have also been suggested to play a role in the 
regulation of Nrf2 activation. Most of these lie either in the IVR domain or 
the Kelch domain, and are generally believed to affect Nrf2 ubiquitination 
(Table 1.9).  
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Table 1.9 Keap1 cysteine residues. Keap1 contains 27 cysteine residues, which are believed 
to be modified prior to Nrf2 activation.  
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Although cysteine modification is suggested by many to be the primary 
mechanism of regulating the Nrf2/Keap1 interaction, it has been shown that 
in response to antioxidants C151 modification alone is not sufficient for Nrf2 
release from Keap1. It seems that phosphorylation of Nrf2 is also required 
(Niture et al., 2009). Another interesting hypothesis put forward by Li and 
Kong (2009) is that a cysteine residue at position 183 in Nrf2 may also be a 
redox sensor. It certainly has been shown to be susceptible to modification, 
although its importance in unknown (Sekhar et al., 2010). 
 
1.5.5 Nrf2 phosphorylation 
Nrf2 activation is often blocked by inhibition of various kinases (Rushworth et 
al., 2005; Rushworth et al., 2006; Niture et al., 2009).  Although there is much 
research linking upstream kinases to Nrf2 activation, the mechanisms 
involved are unclear. So far, the only phosphorylation site shown to be 
involved in disruption of the Nrf2/Keap1 complex is serine 40 (S40) within 
the Neh2 domain. This was originally shown in vitro using rat proteins by 
competitively inhibiting protein kinase C (PKC)-dependent phosphorylation of 
Nrf2 using small peptide sequences of amino acids 35-44 of Nrf2. It was then 
found that mutating the serine residue at position 40 prevented 
phosphorylation without affecting ARE binding (Huang et al., 2002). These 
results were verified in cell culture, and it was shown that although S40 was 
not essential for nuclear translocation of Nrf2, mutating the serine residue to 
alanine caused Nrf2 to have a much tighter association with Keap1 (Bloom 
and Jaiswal, 2003). Therefore, the evidence suggested that phosphorylation 
of S40 was important for preventing Nrf2 from being sequestered by Keap1 
in the cytoplasm. Although PKC was the first, several kinases have been 
implicated in inducing Nrf2 activity, and these will be briefly discussed below. 
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1.5.5.1 PKC 
PKC has been implicated in Nrf2 activation in response to many stimuli 
including epigallocatechin, phorone, curcumin, LPS, and tBHQ (Numazawa et 
al., 2003; Rushworth et al., 2005; Rushworth et al., 2006; Ogborne et al., 
2008; Niture et al., 2009). There are 11 isoforms of PKC, all of which can be 
categorised into one of three subtypes. Classical PKCs are those that require 
diacylglycerol (DAG) and Ca2+ for activation, novel PKCs require DAG but not 
Ca2+, and atypical PKCs require neither. Due to the differing requirements for 
activation, isoforms from the three subtypes can be activated by different 
mechanisms (Liu and Heckman, 1998). It is therefore noteworthy that at least 
one isoform from all three subtypes has been implicated in Nrf2 activation.  
Although direct phosphorylation by PKC has never been shown in cell culture, 
in vitro kinase assays using purified proteins have revealed that PKC isoforms 
α, η, δ, and θ are all capable of phosphorylating Nrf2 (Niture et al., 2009).  
Although the only known PKC site is S40, three other possible sites exist at 
positions S387, S447, and S597 (Numazawa et al., 2003). 
PKC-δ has been shown to be involved in Nrf2 activation in response to more 
stimuli than other isoforms. These stimuli include NO, curcumin and 
epigallacatechin (Rushworth et al., 2006; Ogborne et al., 2008; Zhang et al., 
2009b). In response to NO, Nrf2 seems to be regulated as a negative 
feedback mechanism via PKC-δ to protect cells from NO-induced apoptosis. 
Curcumin, an anti-inflammatory compound found in turmeric, also 
upregulates ARE dependent gene expression via a PKC-δ mediated pathway. 
Rottlerin, a PKC-δ inhibitor, abolished HO-1 gene expression and ARE binding 
induced by curcumin, which indicates that at some stage downstream of 
PKC-δ, Nrf2 was activated (Rushworth et al., 2006). PKC-δ was also required 
for Nrf2 activation by tBHQ. Interestingly, this was shown to be insufficient 
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for Nrf2 activation, with covalent modification of C151 on Keap1 also 
required (Niture et al., 2009). 
Previous work from our laboratory has shown that a pan PKC inhibitor, Ro-
31-8220 completely inhibited LPS induced HO-1 mRNA expression in THP-1 
cells, but rottlerin, a PKC-δ inhibitor, did not. Instead Go6976, a PKCα/β1 
inhibitor did inhibit HO-1 expression, but a PKCβ inhibitor did not. This 
indicates that PKC-α is involved in Nrf2 activation (Rushworth et al., 2005). 
PKC-ι has also been implicated in Nrf2 activation. Phorone and 4-HNE 
induced Nrf2 nuclear translocation and ARE reporter gene activity in WI-38 
and COS-7 cells were abolished in cells expressing a null mutant of PKC-ι. 
Furthermore, the same group have cited unpublished data that shows a 
similar effect with another atypical isoform of PKC, PKC-ζ (Numazawa et al., 
2003). 
 
1.5.5.2 Other Kinases 
 
There is evidence supporting a role for MAP kinases (Mitogen Activated 
Protein Kinases) in Nrf2 activation, although the exact mechanisms involved 
are unknown. p38 and ERK (extracellular signal-regulated kinase) inhibitors 
have been shown to block Nrf2 expression induced by diallyl sulfide and apo-
8’-lycopenal (Ho et al., 2012; Yang et al., 2012). Inhibition of p38 also blocked 
Nrf2 expression caused by myocardial infarction in Wistar rats, whereas ERK 
has been shown to contribute to the upregulation of Nrf2 expression by 
deprenyl (Xiao et al., 2011; Mitra et al., 2014). A JNK (c-jun N-terminal kinase) 
inhibitor blocks protocatechuic acid-induced Nrf2 expression in J774A.1 
macrophages (Vari et al., 2011).  
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PI3K (phosphatidylinositol-3 kinase) acts upstream of Nrf2 activation in 
response to deprenyl and hexabromocyclodecanes (Xiao et al., 2011; Zou et 
al., 2013). In addition, Nrf2 has been shown to play a role in the unfolded 
protein response, and is regulated by PERK (PKR-like endoplasmic reticulum 
kinase) (Cullinan and Diehl, 2006). 
These studies all block Nrf2 accumulation by kinase inhibition, but they offer 
no insights into the phosphorylation sites involved, nor do they offer any 
evidence to suggest whether they interact directly with Nrf2. It is unknown, 
therefore, whether they act by disruption of the Nrf2/Keap1 interaction. 
 
1.5.6 Sequestosome 1 
A cellular regulator of autophagy, sequestosome 1 (p62 or SQSM1) is also 
believed to activate Nrf2 expression by competing directly for the Keap1 
binding site, although the Keap1 binding sequence of SQSM1 does not have 
the same affinity as that of Nrf2 (Copple et al., 2010; Jain et al., 2010; Lau et 
al., 2010; Hancock et al., 2012). Overexpression of SQSM1 leads to an 
increase in Nrf2 expression and a decrease in Keap1 expression. Crucially, 
knockdown of SQSM1 does not affect Nrf2 activation by tBHQ or 
sulforaphane, showing that it is not part of the “canonical” mechanisms. 
Instead, SQSM1 binding to Keap1 targets Keap1 for degradation by 
autophagy (Jain et al., 2010).  
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1.5.7 Other mechanisms of Nrf2 regulation 
It has been suggested that Keap1 may be able to enter the nucleus. Keap1 is 
not required for Nrf2 transcriptional activity (Kim et al., 2012a; Williamson et 
al., 2012), but there is some evidence suggesting that Keap1 nuclear import 
can play an inhibitory role. Nuclear import of Keap1 has been shown to 
inhibit Nrf2 transcriptional activity in two independent studies, one of which 
associates this with an increase in Nrf2 ubiquitination in nuclear extracts of 
HepG2 cells (Nguyen et al., 2005; Sun et al., 2011). Currently there is no 
evidence that the Keap1/Nrf2 complex enter the nucleus together. 
There are other regulators of Nrf2 activity besides the Nrf2/Keap1 
interaction. For example, our group has previously shown that LPS induces 
Nrf2 mRNA expression in THP-1 cells (Rushworth et al., 2008). MicroRNAs 
have been shown to regulate Nrf2 translation. So far Nrf2 translation has 
been shown to be inhibited by miR-153, miR-27a, miR-142-5p, MiR-144, 
MiR28, and miR-34a (Sangokoya et al., 2010; Li et al., 2011; Yang et al., 
2011b; Narasimhan et al., 2012). In addition, the transcription repressors 
Bach1 and potentially Bach2 compete with Nrf2 for the binding of the ARE. 
Bach1 in particular has been shown to play a key role in the regulation of the 
Nrf2 target gene HO-1 (Miyazaki et al., 2010). Bach1 may bind to the ARE 
more strongly than Nrf2, and there is some evidence to suggest that its 
phosphorylation and subsequent nuclear export is required prior to the 
activation of Nrf2-dependent transcription (Kaspar and Jaiswal, 2010). Nrf2 
also has phosphorylation sites in its Neh4 and 5 domains that are believed to 
alter its transcriptional ability, possibly by enhancing its ability to bind other 
transcription apparatus (Pi et al., 2007; Apopa et al., 2008). 
The final mechanism by which Nrf2 is regulated is in its deactivation. 
Currently little has been reported on nuclear export of Nrf2. Two 
independent lab groups have uncovered a key role for GSK-3, although they 
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each assign a different mechanism to it. Jaiswal showed that GSK-3β 
activation results in the activation of Fyn, a tyrosine kinase that 
phosphorylates nuclear Nrf2 on Y568 (Jain and Jaiswal, 2007). This causes 
Nrf2 to lose affinity for the ARE and associate with the nuclear export protein 
Crm1 instead (Jain and Jaiswal, 2006).  
However, GSK-3β has also been shown to phosphorylate Nrf2 directly on 
serine residues in its Neh6 domain. Nrf2 then binds SCF/β-TrCP, an adaptor 
protein for a Cul1 based E3 ubiquitin ligase complex, and is subsequently 
degraded (Rada et al., 2012; Chowdhry et al., 2013). This research is 
consistent with previous work by the same group showing that the function 
of the Neh6 domain is to promote Keap1 independent degradation of Nrf2 
(McMahon et al., 2004; Rada et al., 2011). Together, this evidence suggests a 
dual role for GSK-3β in which it induces Nrf2 nuclear export via Fyn, and then 
later induces its degradation via the E3 ubiquitin ligase complex (Fig 1.8).  
The strict regulation of Nrf2 combined with its protective effects, especially 
in oxidative stress and inflammation, makes it a promising target for 
protecting against disease. Currently a significant amount of research is being 
conducted on investigating the role of dietary components in activating Nrf2 
and their potential as nutraceuticals in the prevention of chronic diseases. 
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Fig 1.8 An overview of the Nrf2 signalling pathway. (A) Under basal conditions Nrf2 is 
bound to the Keap1 homodimer, and ubiquitinated by the E3 ubiquitin ligase complex. (B) 
The absence of Nrf2 results in the suppression of transcription of ARE containing genes. 
Sometimes Bach1 is bound to the ARE, which suppresses transcription further. (C)Inducers 
of Nrf2 result in the disruption of the Nrf2/Keap1 interaction. This prevents ubiquitination 
of Nrf2 and its subsequent degradation, leading to saturation of Keap1. (D) With no Keap1 
to bind, Nrf2 translocates to the nucleus, where it forms heterodimers with small Maf 
proteins on the ARE to initiate transcription (E). Bach1, on the other hand dissociates from 
the ARE, and is exported from the nucleus. (F) GSK-3β activates Fyn, which then 
translocates into the nucleus to phosphorylate Nrf2 on Y-568 (G). This initiates nuclear 
export of Nrf2, and suppression of transcription of ARE containing genes. (H) Once in the 
cytoplasm, Nrf2 is phosphorylated again in its Neh6 domain by GSK-3β. This results in a 
high affinity for β-TrCP (I). Once bound to β-TrCP, Nrf2 is ubiquitinated by a Cul1-based E3 
ubiquitin ligase complex and subsequently degraded. 
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1.6 Activation of the Nrf2 pathway by dietary compounds 
The diet has been identified as significant contributory factor to general 
health, and protection against disease. For example, a diet high in fat and 
simple sugars has been identified as a risk factor in cardiovascular disease 
and diabetes. In contrast a diet high in fruits, vegetables, and wholegrain 
foods, or a Mediterranean diet are associated with a decreased risk of these 
conditions (Salas-Salvado et al., 2011; Rees et al., 2013; Van Baak, 2013)  
These foods have been linked with molecules that carry out these effects. For 
example, flavonoids have been identified as bioactive components of fruits 
and vegetables, which may protect against cardiovascular disease (Toh et al., 
2013).  
Molecules such as these are sold as health supplements, used for health 
advice, and have been used either as drugs or drug precursors in medical 
research (Marik and Flemmer, 2012; NHS, 2012; Lenzi et al., 2014). 
Therefore, it is in the public interest to pursue dietary components for 
potential protective effects. Nrf2 can be activated by a wide range of dietary 
compounds, and many have been implicated in Nrf2-mediated 
cytoprotective effects in vitro and in vivo (Table 1.10).  
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For example, sulforaphane is an isothiocyanate most commonly found in 
cruciferous vegetables, which include broccoli, cabbage and Brussels sprouts 
(Zhang et al., 1992). In vitro, sulforaphane activates the Nrf2 pathway, which 
has been linked to protection from ionising radiation-induced damage in 
human skin cells (Kleszczyński et al., 2013; Mathew et al., 2014). It also has 
anti-inflammatory effects via the Nrf2 pathway in smooth muscle cells and 
peritoneal macrophages (Lin et al., 2010; Zhao et al., 2013b). Curcumin, a 
compound found in turmeric, has shown similar effects via the Nrf2 pathway. 
TNF-induced adhesion between monocytes and keratinocytes was inhibited 
Table 1.10. Dietary compounds that activate Nrf2 in vivo.  
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by inhibiting the adhesion molecule, ICAM-1. Nrf2 siRNA prevented this 
effect (Youn et al., 2013). The flavonoid quercetin, commonly found in 
capers, radish, dill and red onion, inhibits ROS generation and NF-κB 
activation by ochratoxin A in HepG2 cells. This was accompanied by Nrf2 
activation (Bhagwat et al., 2011; Ramyaa et al., 2014). In addition, HaCaT 
keratinocytes were protected from UV-induced ROS production and cell 
death by quercetin in a Nrf2-dependent manner (Kimura et al., 2009). 
In vitro studies are useful for finding new compounds and targets, and for 
investigating mechanisms. In support of the in vitro research, there are many 
in vivo models that support a protective role for Nrf2 activators in the diet. 
Oral administration of sulforaphane in mice showed that it has high 
bioavailability, reaching many tissues including the liver, kidney, brain and 
colon (Clarke et al., 2011). Feeding mice with a diet containing 300ppm 
sulforaphane causes anti-inflammatory effects. Extracted aortic epithelium 
from mice fed with a sulforaphane rich diet did not bind monocyte-derived 
macrophages as strongly as mice on a normal diet. Furthermore, monocyte-
derived macrophages from the mice demonstrated lower expression of 
ICAM-1 after TNF stimulation in mice fed with a sulforaphane rich diet 
(Nallasamy et al., 2014). Sulforaphane also has protective effects against 
mental and neurodegenerative conditions, adipogenesis, thrombosis and 
mutagenesis (Chen et al., 2012; Abel et al., 2013; Jayakumar et al., 2013; 
Morroni et al., 2013; Choi et al., 2014; Lee et al., 2014b). Activation of Nrf2 is 
thought to regulate many of sulforaphane’s effects, although much of the in 
vivo evidence is circumstantial. In a mouse model of type 2 diabetes mellitus, 
4 months sulforaphane treatment alleviated some of the effects of the 
disease, including fibrosis and an increase in arterial wall thickness. In 
addition, it was found that mice with type 2 diabetes had decreased aortic 
SOD1 and HO-1 expression, which accompanied increased apoptosis and 
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oxidative damage. Sulforaphane reversed these effects, and was found to 
increase levels of aortic Nrf2 (Wang et al., 2014b). In a mouse model of 
induced stroke, sulforaphane was shown to protect the blood brain barrier, 
and induce Nrf2 activity (Alfieri et al., 2013).  
Like sulforaphane, quercetin has also been shown to have therapeutic effects 
in vivo. The vast majority of the effects of quercetin are anti-inflammatory. 
For example, examination of livers revealed that inflammation induced by 
feeding mice with a high fat diet is alleviated by quercetin supplementation. 
Nuclear NF-κB, iNOS, TNF, IL-6 were among the inflammatory mediators that 
were inhibited, and GST, catalase, and SOD were among the antioxidant 
enzymes that were induced by quercetin. Encouragingly, leaf extract of 
moringa oliefera, a plant in which quercetin is believed to be a bioactive 
component, had the same effect (Das et al., 2013). In mouse livers, 
steatohepatitis-induced inflammatory mediators including TLR4, TNF, NF-κB 
and MMP9 were also inhibited by quercetin (Marcolin et al., 2012).  
Inflammation may play a role in type 2 diabetes, and obese mice fed with 
quercetin were shown to regain some insulin sensitivity. In addition, GLUT4 
receptor expression was increased in mice treated with quercetin, whereas 
inflammatory mediators TNF, iNOS and NF-κB were inhibited (Anhê et al., 
2012). Despite the evidence linking quercetin to Nrf2 in vitro, Nrf2 dependent 
effects have not been shown in vivo. However, Nrf2 has been shown to be 
induced by quercetin in rat liver, which correlated with inhibition of CCL4-
induced NF-κB, TNF and Cox2 (Domitrović et al., 2012).  
Allicin and diallyl sulfide have been shown to protect mice from various 
conditions, possibly involving Nrf2 upregulation. Cognativie impairment in 
aged mice was significantly reduced by allicin, which was accompanied with a 
rise in Nrf2 expression in the hippocampus. Diallyl sulfide was shown to 
protect rats from inflammation induced by the antibiotic gentamicin in the 
78 
 
kidney, possibly by inhibiting NF-κB signalling (Kalayarasan et al., 2009; Li et 
al., 2012c). Similarly, Epigallocatechin-3-galate ameliorates nephrotoxicity in 
rats by activating Nrf2 and inhibiting NF-κB (Sahin et al., 2010).  
Some Nrf2 activators have been used in epidemiological and clinical trials in 
humans to assess their use in disease prevention. The potential therapeutic 
effects that have been demonstrated by sulforaphane have led to human 
epidemiological trials involving broccoli to investigate whether sulforaphane 
may help to detoxify carcinogens. Subjects were fed a sulforaphane-rich 
broccoli derived beverage, and had their urine tested for mercapturic acids of 
known carcinogens that are commonly found in pollution. Urine after 
treatment with the beverage had higher levels of mercapturic acids than 
urine before treatment began, suggesting an activated detoxification system 
caused by the high-sulforaphane beverage (Kensler et al., 2012). The effect of 
sulforaphane on phase II detoxification enzymes has also been observed in 
humans. After consumption of a broccoli homogenate, subjects had higher 
expression of HO-1, NQO1, GSTM1 and GSTP1 in nasal cells (obtained by 
nasal lavage). Furthermore, this occurred in a dose dependent manner, and 
did not occur after consumption of control alfalfa sprouts, which do not 
contain sulforaphane (Riedl et al., 2009).  
Quercetin has also been used in human clinical trials, with varying levels of 
success. 72 type 2 diabetic women received quercetin supplementation for 
10 weeks. This lowered systolic blood pressure, but did not affect other 
markers of cardiovascular disease such as serum cholesterol levels. In 
addition, the inflammatory mediators IL-6 and TNF were not significantly 
affected compared to placebo (Zahedi et al., 2013). Systolic blood pressure 
was also lowered by quercetin after eating a lipid rich meal. Subjects treated 
with quercetin had lower systolic blood pressure and 11% lower 
triacylglycerol levels 4h after eating. These effects did not last. Interestingly, 
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like the findings of Zahedi and co-workers, inflammatory markers measured 
did not change with quercetin treatment (Pfeuffer et al., 2013).  
Although dietary compounds such as quercetin and sulforaphane are exciting 
molecules, they may have off-target effects. For example, in LPS-induced 
inflammation sulforaphane has been suggested to inhibit TLR4 signalling by 
binding cysteine residues in the receptor itself, inhibiting oligomerization 
(Youn et al., 2010). Further complicating matters is the controversial role of 
Nrf2. Youn and co-workers (2010) claim that Nrf2 is not involved in the anti-
inflammatory role of sulforaphane in mouse embryonic fibroblasts (MEFs), 
whereas in mouse peritoneal macrophages, Nrf2 knockout abrogated the 
effects of sulforaphane (Lin et al., 2010).  
There is strong evidence that Nrf2 activators can help defend against 
diseases, especially inflammatory diseases and oxidative stress related 
conditions. Although the role of Nrf2 in in vivo studies is less conclusive, at 
minimum they show that Nrf2 is worthy of research interest, and is a very 
promising drug target. 
 
 
 
 
 
 
 
 
80 
 
1.7 Targeting the Nrf2/Keap1 interaction 
1.7.1 The shortcomings of Nrf2 activators 
Targeting the Nrf2 pathway to protect against disease shows a lot of promise 
both for therapeutic action in disease, and preventative measures in dietary 
health. However, a distinction must be made between drug targeting and 
dietary targeting. The aim of dietary research is to improve general health, 
and to introduce measures into peoples’ lifestyle as a means of lowering the 
risk of disease. As such, while the diet can be altered to alter intake of 
specific substances, the amount that is eaten will typically be quite low. In 
vitro studies use much higher concentrations of compounds than would be 
consumed, which is practical for identifying effects and targets but is not an 
accurate model from which to formulate conclusions on health. Drugs, on the 
other hand, are needed to help fight a disease that has already occurred, and 
thus are required to have a potent, acute effect. Therefore, the body is 
exposed to much higher concentrations of the molecule, and is much more 
susceptible to undesirable side effects. Interest in Nrf2 is high in both these 
fields, but the approach and conclusions from each may not be compatible 
with each other. It is not a coincidence that some of the most successful Nrf2 
activators are derived from natural products, but are not dietary compounds. 
One of the recent success stories is dimethyl fumarate, which has been 
successfully used in clinical trials to treat multiple sclerosis, and has been 
approved for use by the U.S Food and Drug Administration (Ruggieri et al., 
2014). The protective effects of dimethyl fumarate have been attributed to 
its ability to downregulate inflammatory mediators and oxidative stress. Both 
of these functions in the central nervous system are dependent on Nrf2 
(Linker et al., 2011; Scannevin et al., 2012). Dimethyl fumarate has other 
protective effects. It is used in combination with other molecules to treat 
psoriasis, and has been linked with functions for which it has not yet been 
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medically approved. These include cardioprotection and prevention of 
vascular calcification (Ashrafian et al., 2012; Ha et al., 2014).  
Although the broad range of activators of Nrf2 in protection looks promising, 
it is not necessarily as good as it first appears. Many of the molecules that 
activate Nrf2 are not protective, and even those that have promising results 
in the lab have failed at clinical trial. Recently bardoxolone methyl (also 
known as CDDO-Me), a synthetic triterpenoid, was used in clinical trials for 
stage 4 chronic kidney disease. Bardoxolone methyl is known to activate Nrf2 
and, if it acts in a similar manner to CDDO, then it may do so by modifying 
C151 in the BTB domain of Keap1 (Cleasby et al., 2014; Wu et al., 2014). The 
clinical trial was stopped because of serious side effects, including heart 
failure (de Zeeuw et al., 2013). 
The reason that a lot of these molecules fail is that Nrf2 is a stress sensor, 
and so its activation and subsequent protective effects are products of cell 
damage. This causes production of reactive molecules, including ROS and 
electrophiles, which cause conformational changes in the structure of Keap1 
and Nrf2, resulting in the activation of protective genes. A lot of molecules 
that activate Nrf2 like this, and any protective effects caused by Nrf2 are a 
response to initial stress caused by the drug. It’s not necessarily a bad 
approach, and there is evidence that it can work. Both sulforaphane and 
quercetin are widely considered to prevent oxidative stress, but have also 
been shown to induce Nrf2 expression by inducing ROS (Lapidot et al., 2002; 
Lee et al., 2012a). The problem with activating Nrf2 in this way is not just the 
production of reactive molecules, however. It can result in non-specific 
interactions and activation of other mediators. To use one of the most 
promising examples, sulforaphane directly binds to TLR4 (Koo et al., 2013) 
and Hsp90 (Li et al., 2012b), activates TGFβ/Smad signalling (Kaminski et al., 
2010), and has been shown to both protect against and induce apoptosis (Mi 
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et al., 2007; Hsu et al., 2013; Ziaei et al., 2013; Jiang et al., 2014b). Drugs 
derived from these molecules should be expected to have adverse effects in 
clinical trials, and should be treated with caution. Ideally drugs targeting the 
Nrf2 pathway would do so without the accompanying damage, and with 
higher specificity (Fig 1.9 and 1.10). Therefore, research is currently 
underway to inhibit the Nrf2/Keap1 interaction directly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.9 Targeting the Nrf2/Keap1 with ROS/electrophiles. (A) Nrf2 is produced and binds 
Keap1. (B) ROS/electrophiles modify the structure of Keap1, blocking Nrf2 degradation. (C) 
These molecules also react with other molecules in the cell, activating other signalling 
pathways and producing reactive compounds which have the potential to cause cell 
damage. (D) Nrf2 is activated and can initiate transcription. Under the right conditions the 
advantages of increased Nrf2 expression can outweigh the effects of the cell damage. 
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1.7.2 Competitive inhibitors of Keap1 
In 2006, Lo and co-workers found that small peptide sequences mimicking 
the ETGE-containing motif of the Neh2 domain are capable of binding Keap1 
and inhibiting the interaction between Keap1 and Nrf2. This work showed 
that it is possible to displace Nrf2 from the Nrf2/Keap1 complex, and showed 
that competitive inhibition is a viable strategy in targeting Nrf2. Since then 
there have been several strategies to find suitable inhibitors, and to 
investigate the biological effects of targeting the Nrf2/Keap1 interaction in 
this way.  
Fig 1.10 Targeting the Nrf2/Keap1 interaction with competitive inhibitors. (A) Nrf2 is 
produced and binds Keap1. (B) A direct inhibitor blocks the Keap1 binding site. (C) Nrf2 
builds up and translocates to the nucleus to (D) initiate transcription. 
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There have been two approaches used to find small inhibitors to target the 
Nrf2/Keap1 interaction. The first is to use the Neh2 mimetic peptides as a 
template, and modify the sequence and structure accordingly. Using this 
approach, Hancock and co-workers were able to improve upon the Keap1 
binding site of Nrf2 by introducing elements from the binding site of 
sequestosome 1 (Hancock et al., 2012; Hancock et al., 2013). This method is 
the slower of the two methods, but is more likely to produce a specific drug, 
because it is basing the structure on existing binders of Keap1. 
The second method that has been used to find small molecules to target the 
Nrf2/Keap1 interaction is screening large libraries of compounds. Wang and 
co-workers (2012) narrowed down a screen of over 300,000 compounds to 
two using a fluorescence polarization assay. One was discounted because it 
was believed to be a electrophilic, which means that there is a strong chance 
it would react with non-specific nucleophiles, causing off-target effects. The 
other was tested for biological activity. It was found to activate an ARE-driven 
beta-lactamase reporter assay in HepG2 cells. It was also non-toxic in both 
HepG2 cells and HEK293 cells. Surface plasmon resonance was used to 
calculate its binding affinity for Keap1, which was 1 µM. Another molecule 
was found by narrowing down a >300,000 compound search by structure 
based virtual screening. The remaining 65 compounds were narrowed down 
by Fluorescence polarization. The most active compound was found to 
induce nuclear accumulation of Nrf2 in PC12 cells at a concentration of 4 µM 
(Zhuang et al., 2014). By far the most promising compound, however, was 
found from a library of 250,000 compounds by fluorescence polarization. Of 
the 18 hits, one induced ARE-luciferase activity and NQO1 expression, which 
was inhibited by Nrf2 siRNA. Furthermore, the compound does not modify 
cysteine residues, which suggests that it would not have many non-specific 
effects (Marcotte et al., 2013). This compound was then modified by adding 
two CH2COOH groups in order to reach additional binding pockets in the 
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Kelch domain. In addition to being the strongest small-molecule binder of 
Keap1 to date, it also induced ARE-luciferase activity in HepG2 cells and HO-
1, NQO1, and GCLM in HCT116 cells (Jiang et al., 2014).  The main drawback 
with this method is that target specificity is less assured. They are not derived 
from anything that binds Keap1 under normal conditions, and therefore off 
target effects are more likely despite measures to reduce reactivity in the 
compound structures. 
Research into Nrf2 activators is making rapid progress, which is looking very 
promising for several diseases. However, this is not the case in cancer.  
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1.8 Cancer 
1.8.1 The hallmarks of cancer 
Cancer one of the major causes of death worldwide. In 2012 14.1 million 
adults were diagnosed with cancer, and it was the cause of 8.2 million deaths 
worldwide (CRUK, 2014a). In the UK, lung, breast, bowel and prostate 
cancers caused approximately 46% of all cancer deaths in 2011, with lung 
cancer causing 22% alone (CRUK, 2014b). 
Cancer is defined by the World Health Organisation as “the uncontrolled 
growth and spread of cells”, which is a simplistic but accurate definition. 
Typically cancer cells lose their ability to control their own growth, replication 
and function which invades surrounding tissues, eventually obstructing 
essential bodily functions, causing death. More specifically, cancer is more 
difficult to define although the prevailing opinion is that there are eight 
hallmarks of cancer (Table 1.11), as proposed by Hanahan and Weinberg 
(2000; 2011). 
Cancer is caused by mutations which affect the function of genes involved in 
regulating mitosis, and therefore promoting one or more of the eight 
hallmarks. Therefore, only mutations which promote the hallmarks of cancer 
will contribute to its onset. For example, a mutation that impairs the function 
of p53 will promote tumour-like characteristics (Wang et al., 2014c). On the 
other hand, a null mutation will have no physiological effect, and mutations 
that activate apoptosis will prevent tumour progression. Despite this, cancer 
is still extremely difficult to treat, because there is still a near infinite 
combination of mutations that can cause cancer. Therefore, each cancer has  
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 Table 1.11 The hallmarks of cancer. Cancer cells acquire abilities to survive and propagate 
better than normal cells (Hanahan and Weinberg, 2011).    
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the potential to be unique. There are patterns, however. Over 60% of 
melanomas contain a mutation in the BRAF gene. The vast majority of these 
are a V600E substitution (Sclafani et al., 2013). Therefore, a targeted 
approach is viable for large portions of the population. Alternatively, cancer 
cells can be killed by non-specific chemotherapeutics, such as cisplatin or 
doxorubicin. These work by activating apoptosis mechanisms, usually by 
strongly damaging DNA to overpower aberrant survival mechanisms (Siddik, 
2003). The problem with these drugs is that often they are not effective at 
concentrations that are safe for the patient. This is due to off-target effects. 
For example, cisplatin causes nephrotoxicity, which limits its usefulness in 
chemotherapy (Zirak et al., 2014).   
Although it is impossible to prevent cancer completely, it is certainly possible 
to reduce the chances of it developing by minimizing exposure to carcinogens 
and by increasing antioxidant defences. The latter may be possible to achieve 
by activation of Nrf2.  
 
1.8.2 Nrf2 promotes both cytoprotection and chemoresistance in cancer 
The Nrf2-mediated antioxidant defence is known to detoxify carcinogens and 
prevent DNA damage. For example several studies have linked Nrf2 
expression to protection against UV damage. Nrf2 knockout mice are more 
susceptible to sunburn and show higher formation of 8-
hydroxydeoxyguanosine (8-OHdG) lesions in DNA (Kawachi et al., 2008). They 
are also susceptible to DMBA and TPA induced skin tumourigenesis (Xu et al., 
2006). Nrf2 upregulation protects keratinocytes from UV radiation (Tian et 
al., 2011). 6-thioguanine is a drug used to treat inflammatory bowel disease, 
but is also thought to be a carcinogen. High Nrf2 expression reduces its 
incorporation into DNA (Kalra et al., 2011). Furthermore, Nrf2 can upregulate 
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DNA repair enzymes. Both BHA and Vitamin C restore oestrogen inhibited 8-
oxoguanine glycosylase (OGG1) expression, which is dependent on Nrf2. 
OGG1 expression is accompanied by a decrease in 8-OHdG lesions (Singh et 
al., 2013a). 
Crucially, several upregulators of Nrf2 found to protect against cancer are 
found in the diet, including sulforaphane and curcumin, suggesting that there 
may be protective measures against cancer that can be taken through the 
diet (Lee et al., 2013c).  
Unfortunately, Nrf2 plays a dual role in some cancers. While it protects 
against tumour development, if a cell becomes cancerous Nrf2 promotes the 
survival of that cell. Several human cancers have been shown to overexpress 
Nrf2 (Table 1.12), and Nrf2 has been verified to protect cancer cells against 
chemotherapy in vitro. Inhibiting Nrf2 in lung cancer cells renders them more 
susceptible  a range of cytotoxic therapies including mitoxantrone, topotecan 
(Singh et al., 2010a), cisplatin, doxorubicin and etoposide (Wang et al., 
2008b). Cervical cancer cells were found to become more sensitive to 
treatment with doxorubicin, cisplatin, paclitaxel, and 5-fluorouracil. Nrf2 
deficiency combined with cisplatin was also shown to inhibit tumour growth 
in vivo (Ma et al., 2012). Type II endometrial cancer cells derived from 
patients also showed similar patterns. Cell lines derived from patients with 
high Nrf2 expression were more resistant to chemotherapeutic drugs than 
those derived from patients with low Nrf2 expression. Overexpression of 
Keap1 in cells with high expression of Nrf2 inhibited Nrf2 expression, which 
rendered cells more susceptible to cisplatin and paclitaxel treatment (Jiang et 
al., 2010). 
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The function of Nrf2 is not different in cancer cells to normal cells, but the 
cytoprotective pathways can be hijacked by cancer cells to protect against 
various forms of therapy. The reason for this is that anti-cancer therapy is 
designed to drive the cancer cells towards apoptosis, a function that Nrf2 can 
inhibit by several mechanisms. Nrf2 upregulates detoxification enzymes and 
drug transporters, which reduces the bioavailability of any 
chemotherapeutics. Nrf2 expression and chemoresistance in A549 and H460 
lung cancer cells has been linked to the expression of ABCG2, a drug 
transporter (Singh et al., 2010a). Nrf2 has also been shown to regulate 
expression of other ABC transporters, including MRP1, 2, 3, and 4 (Aleksunes 
et al., 2008; Ji et al., 2013a; Wang et al., 2014d). Radiotherapy and many 
drugs cause DNA damage by inducing ROS, which Nrf2 is capable of 
removing. Nrf2 has been shown to protect A549 and H460 cells from the 
effects of ionizing radiation (Singh et al., 2010b). Nrf2 has also been 
suggested to mediate chemoresistance by activating autophagy, the 
Table 1.12 Nrf2 in cancer patients. Nrf2 is often overexpressed in cancer, which is often 
linked with mutations in Keap1.    
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inhibition of which was linked to decreased resistance to cisplatin in ovarian 
carcinoma cells (Bao et al., 2014).  
Nrf2 can be overexpressed in cancer cells by several mechanisms. Keap1 
mutations are associated with increased Nrf2 expression and have been 
found in 31% of gallbladder cancers (Shibata et al., 2008a), 19% of non-small-
cell lung carcinomas (Singh et al., 2006), and 29% of clear-cell ovarian 
carcinomas (Konstantinopoulos et al., 2011). Keap1 mutations commonly 
occur in the IVR/Kelch domain, and research into some of these mutations 
has revealed that mutant Keap1 cannot sequester Nrf2 (Hast et al., 2014). 
Keap1 can also be silenced in cancers. Breast cancer cells were shown to 
silence Keap1 through expression of a microRNA, miR-200a (Eades et al., 
2011). Another mechanism of Keap1 silencing is through hypermethylation of 
its promoter, inhibiting its transcription, which has been shown in lung 
cancer and prostate cancer cells (Wang et al., 2008b; Zhang et al., 2010). 
Keap1 is not the only member of the Nrf2 pathway to be affected in cancer. 
Out of 103 lung cancers and 12 head and neck cancers, 10% of lung cancer 
patients and 25% of head and neck cancer patients had mutations in Nrf2. 11 
of the 14 mutations found were in either the DLG or ETGE binding sites 
(Shibata et al., 2008b). 
These observations show that Nrf2 is upregulated in a significant number of 
cancer patients, and that this confers chemoresistance and apoptosis-
evasion properties to the cancer cells. Chemotherapy supplemented with 
Nrf2 inhibition is more effective than chemotherapy alone, raising new 
possibilities for cancer treatment (Ren et al., 2011). 
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1.8.3 Inhibitors of the Nrf2 pathway. 
The dual role of Nrf2 in cancer has provided a possibility for the use of Nrf2 
inhibitors as supplemental drugs. Unfortunately, there has not been as much 
progress in the field of Nrf2 inhibition as there has been in targeting it for 
activation. A few small molecules have been found to inhibit Nrf2 nuclear 
accumulation. One of these is brusatol, which was shown to inhibit ARE-
driven luciferase activity, Nrf2 expression and Nrf2 target gene expression. It 
was then shown to increase Nrf2 ubiquitination, while decreasing Keap1 
ubiquitination. Its effectiveness on cancer cells was also investigated, and 
was found to sensitise A549 cells to cisplatin. In cells without Nrf2 there was 
no difference between the effectiveness of cisplatin with or without brusatol, 
but in cells expressing Nrf2, cisplatin and brusatol was superior to cisplatin 
alone (Ren et al., 2011). Another small molecule, trigonelline, has also been 
shown to inhibit the Nrf2 pathway in HT29 cells (Boettler et al., 2011). 
The current standard of evidence clearly shows that Nrf2 is an important 
regulator in health and disease that is simultaneously a mediator that 
requires consideration in a wide range of diseases and a promising drug 
target. In a healthy individual, the overwhelming consensus is that it is a 
helpful mediator of protective pathways, and shows a lot of promise as a 
drug target in many diseases.  
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1.9 Summary 
Nrf2 is a key regulator of important cytoprotective mechanisms that protect 
against diseases, which can include respiratory diseases, inflammatory 
diseases and bacterial infections (Iizuka et al., 2005; Reddy et al., 2009; Kong 
et al., 2010). Nrf2 activity is regulated by a cellular inhibitor, Keap1. 
Disruption of the Nrf2/Keap1 interaction is an inducible process that 
activates the Nrf2 pathway when protective mechanisms are required 
(Turpaev, 2013). It is therefore possible that Nrf2 can be activated through 
the diet to improve general health, or that the Nrf2/Keap1 interaction can be 
targeted specifically for medical intervention (Eggler et al., 2008; Hancock et 
al., 2012).    
Cancer is an exception to the benefits of Nrf2-mediated protection. Although 
Nrf2 protects against the onset of cancer, once cancer has already developed 
the protective mechanisms that it promotes can be hijacked by cancer cells, 
which gain resistance to chemotherapy and radiotherapy (Fig 1.11). Nrf2 has 
been reported to be elevated in many cancers, including lung (Yang et al., 
2011), breast (Hartikainen et al., 2012), endometrial (Li et al., 2013) and 
pancreatic cancer (Soini et al., 2014), and inhibiting Nrf2 expression has been 
shown to improve susceptibility of some cancer cells to therapy in vivo and in 
vitro (Singh et al., 2010a; Singh et al., 2010b; Ma et al., 2012; Arlt et al., 
2013). 
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Research on inhibiting the Nrf2 pathway is not as well developed as 
activating it. There are few known inhibitors of Nrf2 activity (Ren et al., 2011; 
Arlt et al., 2013), and evidence to support further research into it is not as 
well documented. Currently researchers are focusing on improving 
understanding of the potential roles an Nrf2 inhibitor could play in the clinic, 
with drug design considered a long-term prospect. 
 
 
 
 
 
Fig 1.11 The dual roles of Nrf2. The main function of Nrf2 is to protect against reactive 
oxygen species (ROS). In Inflammation, ROS cause cell damage which harms the host. In 
cancer, these protective effects of Nrf2 prevent drugs from killing tumours.  
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1.10 Aims of this study 
 
1. Establish a reporter assay for Nrf2 for use in further laboratory 
studies. 
 
2. Investigate the effects of garlic oils and a novel long chain diallyl 
polysulfide on Nrf2 activation and examine the mechanisms involved. 
 
3. Examine the effects of novel cell-penetrating peptides targeted to 
Nrf2/Keap1 and validate this protein-protein interaction as a 
therapeutic target in inflammation. 
 
4. Examine the expression of Nrf2 in malignant melanoma cells and 
investigate the role of Nrf2 in chemoresistance in these cells. 
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Chapter 2: Materials and methods 
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2.1 Consumables and chemicals 
Contents of all buffers can be found in Appendix I. 
 
2.1.1 General reagents and consumables  
Dimethyl sulfoxide (DMSO), hydrogen peroxide, N-acetylcysteine (NAC), tert-
Butylhydroquinone (tBHQ), cisplatin, doxorubicin, and dacarbazine were 
obtained from Sigma-Aldrich (Poole, UK). Dulbecco’s PBS was obtained from 
PAA (Yeovil, UK). Lipopolysaccharide (Calbiochem® E.Coli 0111: B4) was 
purchased from Merck Chemicals Ltd (Nottingham, UK). The p38 MAP kinase 
inhibitor, SB203580, was obtained from Tocris (Bristol, UK).  
 
1.5 mL eppendorf tubes were obtained from Starlab (Milton Keynes, UK). 15 
mL and 50 mL falcon tubes, 24-well tissue culture plates, and 96-well tissue 
culture plates were obtained from Corning (Amsterdam, The Netherlands). 
Pipettes were purchased from Gilson (Luton, UK). All other reagents, 
equipment, plastics, and disposables (including those listed in Appendix I) 
were purchased from Fisher Scientific (Loughborough, UK) unless stated 
otherwise. 
 
2.1.2 Keap1 targeting peptides 
TAT-10, TAT-14, TAT-sc, 14mer and TAT-16 (Table 2.1) were synthesised and 
purified as previously described (Steel et al., 2012), by Richard Steel, a 
member of Professor Mark Searcey’s lab group (School of Pharmacy, 
University of East Anglia, UK).  
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2.1.3 Garlic oils and diallyl polysulfides 
Diallyl polysulfide compounds and a diallyl polysulfide mixture (PS Mix) were 
synthesised and purified by Miriam Arbach, a member of Dr Chris Hamilton’s 
lab group (School of Pharmacy University of East Anglia, UK) (Wang et al., 
2012b). The garlic oil Naturex was supplied by Naturex (Avignon, France), 
whereas the garlic oil Stringer was sourced from Stringer Flavours Ltd (Tring, 
UK). 
 
2.2 Cell Culture 
All cell lines were cultured at 37oC, 5% CO2 under humidified conditions. Cell 
culture media was pre-warmed to 37oC before use. Foetal bovine serum 
(PAA, Yeovil, UK)  was heat-inactivated at 56oC for 50 min and filter-sterilised 
using a 0.45 µm filter (Corning) before it was used for supplementation of 
media. 
 
 
Table 2.1. Keap1 targeting peptides. 
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2.2.1 Cell Maintenance 
THP-1 is a human monocytic cell line derived from a 1-year-old male 
leukemia patient, and was obtained from the European Collection of Cell 
cultures (Salisbury, UK) (Tsuchiya et al., 1980). THP-1 cells were cultured in 
RPMI 1640 with 10% foetal bovine serum, 2 mM L-glutamine, 100 U/mL 
penicillin and 100 µg/mL streptomycin (PAA). THP-1 cells were maintained in 
T75 tissue culture flasks (Corning) at concentrations between 2.5x105 and 
8x105 cells/mL and passaged every 3.5 days. To passage, the cell density was 
calculated, and the cells were diluted to 2.5x105 cells per mL in fresh media. 
THP-1 cells were not used after passage 25. 
MCF-7 is a human breast cancer cell line derived from a 69-year-old 
Caucasian woman, and was obtained from the European Collection of Cell 
cultures (Salisbury, UK) (Soule et al., 1973). MCF-7 cells were grown in DMEM 
(PAA) with 10% foetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin 
and 100 µg/mL streptomycin. They were passaged every 3.5 days. The MCF-7 
cells were not used after passage 50. 
HepG2 is a human liver carcinoma cell line derived from a 15-year-old 
Caucasian male, and was obtained from the European Collection of Cell 
cultures (Salisbury, UK) (Knowles et al., 1980). HepG2 cells were cultured in 
DMEM with 10% foetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin 
and 100 µg/mL streptomycin. They were passaged every 3.5 days. The HepG2 
cells were not used after passage 20. 
The human malignant melanoma cell lines A375, A2058, Colo 829, M202, 
M238, M263, M308, Mel 501, SK-MEL-5, SK-MEL-28, and UACC 1273 (Table 
2.2) were a kind donation from Dr Toni Ribas (UCLA, USA) (Niehr et al., 2011). 
All of the melanoma cell lines were cultured in RPMI 1640 with 10% foetal 
bovine serum, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL 
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streptomycin. They were passaged every 3.5 days. The melanoma cells were 
not used after passage 20. 
HepG2, MCF-7 and all melanoma cells were passaged by removing the 
media, washing the cells for 10 seconds with 10 mL pre-warmed PBS and 
then adding 2.5 mL trypsin/EDTA (PAA). After incubation at room 
temperature for 10 seconds, 2 mL trypsin was removed, and the cells were 
incubated at 37oC for 1-2min until they were detached from the flask. The 
cells were resuspended in 10 mL fresh media and diluted as required. 
 
 
 
 
HEMa-LP are human epidermal melanocytes from lightly pigmented adult 
skin, which were obtained from Life Technologies (Paisley, UK) (Bhawan et 
al., 1997). HEMa-LP cells were grown in medium 254 (Life Technologies) 
supplemented with 1% HMGS-2 (Life Technologies). Media was changed 
Table 2.2. Melanoma cell lines. 
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every 2 days, and cells were passaged when they reached 90% confluency. To 
passage, media was removed from the cells and 4 mL of 1x trypsin/EDTA was 
added. The flask was briefly rocked to ensure all the cells were covered. 3 mL 
trypsin/EDTA was removed. The cells were incubated at room temperature 
until the cells appeared round with no processes. The flask was tapped gently 
to detach the cells. 6 mL trypsin neutralizer solution was added to the cells, 
and the entire contents of the flask were transferred to a 15 mL falcon tube. 
The cells were centrifuged at 180 x g for 7min. The supernatant was 
removed, and the cells were resuspended in 4 mL media. The cells were 
counted and reseeded at 1.25 x 105 cells per 25cm2 flask. Cells were not used 
past passage 6. 
 
2.2.2 Calculating cell density 
Cells were counted using a Malassez haemocytometer (Fisher Scientific), 
which contains a gridded chamber. Each grid counted holds 0.1 µL, and 
therefore the number of cells within the confines of a grid is the number of 
cells in 0.1 µL of the sample being counted.  
Before counting, the cells were diluted in trypan blue (Sigma-Aldrich) in a 1:1 
ratio. 20µL cells were loaded onto the hemocytometer and viewed under a 
light microscope. The cells in four chambers were counted and recorded. 
Cells stained blue were ignored (the blue staining only affects dead cells). In 
the case of cells on the border of the grid, only cells on the top or the left 
hand side were counted. Once four grids were counted, the cell count was 
averaged and the cell density was calculated using the following equation. 
Cell Density (cells/mL) = (Average cell count x 10, 000)/2 
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In the event that a variant of this equation was needed, it could be adjusted 
by altering the following parameters. 10, 000 is the amount to multiply the 
chamber size (0.1 µL) by to reach 1 mL. 2 is the trypan blue dilution factor. 
 
2.2.3 Freezing Cells 
For suspecsion cells, 5 x 106 cells were collected from a stock density of 3 x 
105 cells/mL. For adherent cells, 1 flask of cells at approximately 70% 
confluency was trypsinised. Cells were centrifuged at 300 x g for 5min. The 
supernatant was removed and the cells were resuspended in 1 mL freezing 
media. The cells were then transferred to ice immediately. The cells were 
stored in a polystyrene box, wrapped in tissue paper at -80oC for 24h. The 
cells were permanently stored in liquid nitrogen. 
 
2.2.4 Thawing Cells 
The cells were removed from liquid nitrogen and immediately thawed in a 
37oC waterbath. Once thawed, the cells were added to 9 mL media. The cells 
were then centrifuged at 300 x g for 5min. The media was removed, and the 
cell pellet was resuspended in 6 mL media. THP-1 cells were transferred to a 
T25 cell culture flask (Corning) and cultured at 37oC. Adherent cells were 
transferred to a T75 cell culture flask, and a further 6 mL media was added. 
The cells were then cultured at 37oC. 
 
2.3 Cell Stimulation 
The following methods were used unless a variant is stated elsewhere in this 
chapter. 
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2.3.1 THP-1 cells 
THP-1 cells were counted and diluted to 5 x 105 cells per mL. 2 mL cells were 
added to each well of a 24 well plate. Any unused well was filled with 2 mL 
sterile H2O. The plate was incubated at 37
oC for 24h. Without disturbing the 
cells, 1 mL media was removed from the top of each sample. This was to 
reduce the total cell volume to 1 mL, in order to reduce the amount of any 
compounds needed for treatment. The cells were then treated in an 
experiment-specific manner (details can be found in the relevant figure 
legends). Common treatments are described in Table 2.3. Previous 
experiments in the laboratory have documented that none of the vehicle 
controls used have any effect on Nrf2 or its target genes compared to 
unstimulated cells.  
 
 
 
2.3.2 Adherent cells 
Following trypsinisation, the cells were resuspended in 10 mL media and 
transferred to a 15 mL Falcon tube. The cells were counted and the cell 
density calculated. The required volume of cells required for the experiment 
Table 2.3. Common cell treatments.  
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was centrifuged at 300 x g for 5min. The supernatant was removed and the 
cells were resuspended to the desired concentration (Table 2.4). Cells were 
plated out as stated and empty wells were filled with H2O before the plate 
was incubated at 37oC for 24h.  
 
 
2.4 RT-qPCR 
 
2.4.1 Sample collection 
Cells were stimulated as previously described. After cell treatment the media 
was removed either by pipetting (adherent cells) or by transferring them to a 
1.5 mL eppendorf tube and centrifuging at 5000 rpm for 5min and pipetting 
off the supernatant. The cells were resuspended in 1 mL Tri-Reagent (Life 
Technologies) and incubated at room temperature for 5min to allow for cell 
lysis. The samples were then stored at -80oC.   
For the expression data in Chapter 6 the cells were not seeded. Instead, cells 
were detached from the flask using trypsin/EDTA and counted. 1 x 106 cells 
Table 2.4. Common cell seeding densities. 
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were transferred to a separate tube and centrifuged at 300 x g for 5min. The 
supernatant was removed, and the cells were resuspended in 1 mL Tri-
Reagent. The samples were incubated at room temperature for 5min before 
storage at -80oC.  
 
2.4.2 RNA extraction 
The samples were thawed before adding 100 µL 1-bromo-3-chloropropane 
(BCP) (Sigma-Aldrich). The samples were shaken vigorously for 10 seconds, 
and incubated at room temperature for 10min. The samples were 
centrifuged for 20min at 12, 000 x g at 4oC.  The aqueous layer was 
transferred to a new tube; the rest was discarded. 500 µL 2-propanol (Sigma-
Aldrich) was added to each sample followed by a harsh vortex for 10 
seconds. The samples were incubated at room temperature for 15min before 
centrifuging at 12,000 x g at 4oC. The supernatant was discarded, and 1 mL 
70% molecular biology grade ethanol (Sigma-Aldrich) was added to the 
pellet. The samples were gently vortexed with 6 short pulses before 
immediately centrifuging at 4oC for 10min. All ethanol was removed from the 
pellet by pipetting and evaporation. 20 µL nuclease free H2O was added to 
each sample before storing at -80oC overnight. 
 
2.4.3 Nanodrop 
The RNA concentration for each sample was measured by nanodrop using a 
ND-1000 Spectrophotometer (Labtech, Ringmer, UK). 1 μL was loaded, and 
the absorbance spectrum from 200-300 nm was measured. From the 
absorbance at 260 nm the quantity of RNA was calculated using the Beer-
Lambert law. RNA purity is calculated using absorbance at 230 nm to 
measure phenol contamination and 280 nm to measure protein 
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contamination.  Dividing the absorbance at 260 nm by the absorbance at 230 
nm or 280 nm should give a value of 1.8-2.0 in a purified RNA sample. All 
RNA samples were diluted to a concentration of 200 ng/μL. In cases where 
this was not possible, the samples were diluted to either 100 ng/µL, 66 
ng/µL, or 50 ng/µL (which ever was largest). 
 
2.4.4 cDNA 
For each sample, 200 ng RNA was diluted with nuclease free H2O (Fisher 
Scientific) to a total volume of 4.5 µL. A mastermix was made up of 45% 
MgCl2, 18% 10xRT buffer, 18% deoxyribonucleotide triphosphate, 4.5% 
Reverse Transcriptase, 4.5% RNase inhibitor, and 9% random hexamers 
(Applied Biosystems, Paisley, UK). 5.5 µL master mix was added to each 
sample. The samples were then loaded into a PTC-100 thermal cycler 
(Labcare Service, Braintree, UK) and cycled through the following 
temperatures: 21oC for 10min, 42oC for 15min, 99oC for 5min, 4oC for 5min. 
Upon completion, the samples were diluted with 20 µL nuclease free H2O. 
 
2.4.5 Real-time PCR 
5 µL of each sample was added to an empty 0.1 mL PCR tube (Qiagen, 
Crawley, UK) for each gene of interest. For each gene, a separate mastermix 
was made up, consisting of 66.7% SYBR green (Sigma-Aldrich), 26.7% H2O and 
6.7% primers (Life Technologies; table 2.5). 15 µL of primer mix was added to 
each sample. The samples were probed for the expression of specific genes 
by real time PCR using a QIAGEN Rotor-Gene Q Series 5-Plex. The following 
temperature cycle was used: 2min at 95oC, 40 cycles of {15s at 95oC followed 
by 40s at 60oC}, finishing off with a melting assay ramping from 60oC -94oC. 
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The results were analysed using the standard curve method and Rotor-Gene 
Q Series Software 1.7 (Build 94). 
 
 
 
 
 
 
 
 
 
 
 
 
2.5 Western immunoblotting 
 
2.5.1 Sample preparation 
Cells were stimulated as previously described. 30min before the cells were 
due to be harvested, 2x NuPAGE SDS sample buffer (Life Technologies) and 
sterile PBS (PAA) were pre-warmed to 37oC. 1x SDS sample buffer was made 
by diluting 2x SDS sample buffer in PBS in a 1:1 ratio.  After cell treatment the 
media was removed either by pipetting (adherent cells) or by transferring 
Table 2.5. Primer sequences. 
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cells to a 1.5 mL Eppendorf tube and centrifuging at 5000 rpm for 5 min. The 
cells were resuspended in 100 µL 1x SDS sample buffer and boiled in a water 
bath for 5min. The samples were then either stored at -80oC or protein was 
quantified immediately.   
For the expression data in Chapter 6 the cells were not seeded. Instead, cells 
were detached from the flask using trypsin and counted. 1 x 106 cells were 
transferred to a separate tube and centrifuged at 300 x g for 5min. The 
supernatant was removed, and the cells were resuspended in 100 µL 1x SDS 
sample buffer. The samples were boiled in a water bath for 5min before 
storage at -80oC.  
 
2.5.2 Protein quantification 
Protein concentration of each sample was measured by absorbance at 280 
nm using a ND-1000 spectrophotometer. 2 μL was loaded, and the 
absorbance spectrum from 200-300 nm was measured. From the absorbance 
at 280 nm the quantity of protein was calculated using the Beer-Lambert law.  
This information was used to calculate the amount of each sample to load 
onto the SDS PAGE gel to ensure equal protein loading of all samples. 50µg of 
protein was used for each sample except in circumstances of dilute samples 
where 50µg would not fit onto the gel. In these cases the amount of protein 
loaded was reduced for all samples of the experiment to the highest possible 
amount.  
 
2.5.3 SDS PAGE Gel and transfer 
The Novex Western blotting system was used for Figures 4.2, 4.11, 4.13, and 
Chapter 5 
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The Bio-Rad Western blotting system was used for Figures 4.4, 4.6, 4.10, 
4.12, and Chapter 6 
2.5.3.1 The Novex system 
The SureLock® Mini-Cell gel rig (Life Technologies) was set up according to 
the manufacturer’s instructions, using pre-made NuPAGE 4-12% Bis-Tris gels 
(Life Technologies). NuPAGE running buffer (Life Technologies) was added to 
the inner chamber so that it covered the top of the gel. 500 µL antioxidant 
solution (Life Technologies) was added to the running buffer in the inner 
chamber. The outer chamber was filled with running buffer to approximately 
2/3 of the height of the gel. The wells of the gel were washed by pipetting 
running buffer into them.  
If samples were frozen they were first boiled for 5min. The required volume 
of sample was added to a fresh 1.5 mL Eppendorf tube. NuPAGE Sample 
Reducing Agent (10X) (Life Technologies) was added to make up 10% of the 
total volume. The samples were boiled for a further 5min. Each sample was 
loaded into the wells of the gel, and 3 µL pre-stained broad range molecular 
weight marker (Bio-Rad, Hemel Hempstead, UK) was loaded into a separate 
well. The gel was run at 150 V for 5min to ensure even running. Then the gel 
was turned up to 200V until the leading band reached the foot of the gel 
(approximately 50min). 
The polyvinylidene fluoride (PVDF) membrane (Bio-Rad) was activated by 
washing in methanol (Fisher Scientific) for 30 seconds. It was then rinsed in 
deionised H2O and washed in transfer buffer for 20min.  Blotting pads were 
soaked in NuPAGE transfer buffer (Life Technologies) and all air bubbles were 
removed. The gel was then removed from its case and placed adjacent to the 
PVDF membrane. Two pieces of Whatman blotting paper (Fisher Scientific) 
were soaked in transfer buffer before sandwiching the gel and membrane.  
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Two blotting pads were loaded into the deeper negative electrode of the 
XCell IITM blot module (Life Technologies). The gel “sandwich” was added on 
top with the membrane side facing away from the negative electrode. Four 
blotting pads were loaded on top, before adding the positive electrode. The 
XCell IITM blot module was then loaded into the SureLock® Mini-Cell cell and 
clamped shut. Transfer buffer was added to the inner chamber, submerging 
the gel, membrane and blotting pads. The transfer was run at 30 V for 1 
hour.  
 
2.5.3.2 The Bio-Rad system 
Polyacrylamide gels were made using the components described in Appendix 
I, using the apparatus supplied with the Mini PROTEAN Tetra Cell (Bio-rad). 
The Mini Protein spacer plates were cleaned with deionised H2O and ethanol, 
and clamped together in the gel casting equipment as specified in the 
manufacturer’s instructions. The resolving gel was made and added in 
between the glass plates using a pipette. A gap of about 1.5-2 cm was left at 
the top of the casting equipment. This gap was filled immediately with 2-
propanol. The gel was left to set for 30min. The 2-propanol was removed. 
The stacking gel was mixed and added to the top of the resolving gel. The 
comb was added immediately, and the gel was allowed to set for 30min. The 
comb was removed, and the plates removed from the clamp. The gel, still 
inside the spacer plates, was wrapped in damp tissue paper and cling film. It 
was stored at 4oC for up to 5 days. 
The Mini PROTEAN Tetra Cell rig (Bio-Rad) was set up according to 
manufacturer’s instructions. Running buffer (Appendix I) was added to the 
inner chamber, and the wells of the gel were washed out using a pipette. 
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Running buffer was added to the outer chamber up to a level specified by the 
chamber case.  
The samples were boiled for 5min and the desired amount was transferred to 
fresh Eppendorf tubes. NuPAGE Sample Reducing Agent (10x) was added to 
make up 10% of the final volume of the tube. The samples were boiled again 
and loaded into the wells of the gel. 3 µL pre-stained molecular weight 
marker was also added to a spare well. The gel was run at 120 V until the 
leading band was past the stacking gel. The voltage was increased to 200 V 
for approximately 1h, until the leading band reached the bottom of the gel. 
The PVDF membrane was activated by washing in methanol for 30 seconds. It 
was then rinsed in deionised H2O and washed in transfer buffer for 20min.  
Blotting pads were soaked in transfer buffer (Appendix I) and all air bubbles 
were removed. The gel was then removed from its case and placed adjacent 
to the PVDF membrane. The gel and membrane were then flanked by two 
pieces of Whatman paper and placed on a blotting pad. Another blotting pad 
was added on top, and the entire pile was clamped into a Bio-Rad Tetra 
Blotting Module (Bio-Rad). The membrane and gel were orientated so that 
the membrane was on the side of the positive electrode. The transfer 
chamber was filled with transfer buffer, and an ice pack was added. The 
transfer was run at 100 V for 1h. 
 
2.5.4 Immunoblotting 
The membrane was placed in 5% milk, made up from Marvel Original Dried 
Skimmed Milk Powder (Premier International Foods, Dublin, Ireland) and 
TBST, for 1 hour on a shaker at room temperature. The primary antibody 
(Table 2.6) was made up in 5 mL 5% milk in a Falcon tube. The membrane 
was then incubated in the antibody on rollers at room temperature for 1h. 
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This was followed by three 5min washes in 5% milk, and three 5min washes 
in TBST.  The membrane was incubated in the relevant HRP-conjugated 
secondary antibody (Table 2.7) for 30min at room temperature. This was 
followed by another 3 x 5min washes in 5% milk, and another 3 in TBST. 
Following this, Amersham ECL Prime solutions A and B (GE Healthcare, Little 
Chalfont, UK) were mixed and added to the membrane for 5min.  The ECL 
was blotted off and the membrane encased in acetate. The membrane was 
imaged using a Syngene G:Box (Cambridge, UK). 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.5 Reprobing 
All Westerns were re-probed for beta actin, which was used as a loading 
control. In order to do this stripping solution was made by diluting 2 mL 10x 
Table 2.6. Primary Antibodies. 
Table 2.7. Secondary Antibodies. 
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Reblot plus (strong) (Millipore, Watford, UK) in 18 mL ddH2O. The membrane 
was then incubated in the stripping solution for 30min on a shaker. Following 
this the membrane was washed twice for 5min in blocker. From here the 
membrane can be probed with a different primary antibody. 
 
2.6 MTS assay 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) is a tetrazolium dye that is used to measure 
cytotoxicity, which is a broad term that includes apoptosis, and inhibition of 
cell proliferation. It is reduced to a molecule that absorbs light at 490-500nm 
in a process that is dependent on NAD(P)H-dependant oxidoreductase 
enzymes. Therefore, the assay measures cytotoxicity by detecting the activity 
of metabolic processes that produce NAD(P)H.  
100 µL cells were seeded in a 96-well plate (Table 2.8). Adherent cells were 
incubated at 37oC overnight, suspension cells treated immediately. Cells 
were treated in triplicate with various concentrations of compounds of 
interest (details in figure legends). 3 wells were reserved for media alone 
(blank), and another 3 wells contained cells alone (positive control). Cells 
were incubated at 37oC for the indicated time period before 10 µL MTS (Cell 
Titer 96 Aqueous One solution Cell Proliferation Assay, Promega, 
Southampton, UK) was added to every well. Cells were then incubated for 3h. 
Absorbance was measured at 492 nm using a POLARstar Optima microplate 
reader (BMG Labtech; Aylesbury, UK).  
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2.7 TNF ELISA 
 
2.7.1 Cell stimulation and sample preparation 
1 mL THP-1 cells were seeded at a density of 0.5 x 105 cells/mL and incubated 
at 37oC for 24h. The top 500 µL medium was removed. Cells were treated 
with 75 µM TAT-14 or TAT-sc for 4h prior to addition of 50 ng/mL LPS for a 
further 4h. Cells were transferred to Eppendorfs, and pelleted by 
centrifugation at 5000 rpm for 5min. Supernatants were collected, and 
frozen at -80oC until use.    
 
2.7.2  ELISA 
The BD Bioscience TNF Elisa Kit (BD Bioscience, Oxford, UK) was performed 
according to manufacturer’s instructions.  TNF capture antibody was diluted 
1:250 in coating buffer. A Nunc F96 Maxi-sorb immune plate (Fisher 
Scientific) was coated with 100 µL anti-human TNF capture antibody solution. 
The plate was sealed and stored at 4oC overnight. The wells were aspirated 
and washed three times in wash buffer. The plates were then blocked in 
assay diluent and incubated at room temperature for 1h. The plate was 
washed three times in wash buffer. Standards were made up by diluting 
known concentrations of TNF in assay diluent. Samples were made up by 
diluting supernatants 1:2 in assay diluent. 100 µL of each standard and 
sample were added to the appropriate wells, and incubated for 2 hours at 
room temperature. The plate was washed five times in wash buffer. 100 µL 
detection antibody was added to each well for 1 hour at room temperature. 
The plate was washed seven times in wash buffer. 100 µL TMB substrate 
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solution (BD Bioscience) was added to each well for 30min in the dark at 
room temperature. 50 µL stop solution (0.5 M sulfuric acid) was added to 
each well. Absorbance at 450 nm was measured on a POLARstar Optima 
microplate reader.  
 
2.8 Preparation and purification of plasmids 
Detailed methods can be found in Chapter 3.2 
 
2.8.1 Preparation of LB Broth and Agar Plates 
Lysogeny broth (LB Broth) was prepared by dissolving 20 g LB broth powder 
(Sigma-Aldrich) in 1 L ddH2O. The LB broth was sterilised by autoclaving at 
123oC for 15min before use. Agar was prepared by adding 15 g 
bacteriological agar powder (Sigma-Aldrich) to 1 L LB broth. The solution was 
sterilised by autoclaving at 123oC for 15min. 500 µL Ampicillin (Sigma-Aldrich) 
from a 50 mg/mL stock was added to the agar to give a final concentration of 
50 µg/mL.  Agar plates were poured in a sterile LAF hood and left to set for 
45min.  
 
2.8.2 Extracting plasmids from blotting paper 
The 8xARE and 4xARE plasmids were a gift from Professor Roland Wolf 
(University of Dundee, UK), supplied on blotting paper. They were extracted 
from the blotting paper by resuspending in 50 μL nuclease free H2O and 
stored at 4oC overnight. The blotting paper was removed and the DNA 
concentration was measured by nanodrop. The pGL4.73 and pGL4.32 
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plasmids (Promega), and the GFP plasmid (Lonza, Slough, UK) were 
commercially sourced, and did not require extracting from blotting paper. 
 
2.8.3 Amplification of plasmids 
Silver efficiency α-select E. coli (Bioline, London, UK) were transformed with 
200ng of one of the plasmids by heat-shock transformation. The bacteria 
were grown in 960 µL SOC media (Sigma-Aldrich) at 37oC for 1h. 100 µL were 
spread over an agar plate, and colonies were grown overnight at 37oC. A 
colony was picked for each plasmid, and grown up in LB broth over 48h. In 
the first 24h the colony was grown in a total volume of 7 mL at 37oC with 
agitation. For the second 24h 2 mL of the bacteria was grown in 120 mL LB 
broth under the same conditions. 
 
2.8.4 Plasmid Purification  
Plasmids were harvested from the bacteria using an EndoFree Plasmid Maxi 
Kit (Qiagen) according to the manufacturer’s instructions. DNA concentration 
was then recorded by nanodrop before sending non-commercially sourced 
plasmids for sequencing for sequence verification at The Genome Analysis 
Centre (TGAC; Norwich, UK). Sequences were analysed using ApE v2.0.44 
(Downloaded from: www.biologylabs.utah.edu; Created by M.Wayne Davis). 
 
2.8.5 Measuring reporter gene activity 
THP-1, MCF-7, or HepG2 cells were seeded and transfected with the 
luciferase plasmids as described in Chapter 3.2 using Lipofectamine 
technology (Life Technologies). The cells were treated as described before 
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measuring reporter gene activity. The luciferase assay was carried out using 
the Promega Dual-Glo Luciferase Assay System (Promega) according to the 
manufacturer’s instructions. The cells were transferred to a solid white 96-
well plate (Fisher Scientific) as described in chapter 3.2 and added to an 
equal volume of luciferase substrate reagent. The cells were incubated in the 
dark for 10min and firefly luminescence was recorded using a POLARstar 
Optima microplate reader. Stop and Glo solution was added to the samples. 
The cells were incubated in the dark for 10min and renilla luminescence was 
recorded.  
For analysis, non-transfected cell readings were subtracted from all samples. 
Firefly luciferase luminescence was divided by renilla luciferase luminescence 
and expressed as fold induction over unstimulated cells. 
 
2.9 siRNA transfections 
Cells were seeded 48h before transfection and grown to between 3 x 105 and 
4 x 105 cells/mL (THP-1 cells) or 50-60% confluency (melanoma cells). Cells 
were counted, and 2 x 106 cells were transferred to a 15 mL falcon tube for 
each transfection sample required. The cells were centrifuged at 90 x g for 
10min. The media was removed, and the cells were resuspended in 92 µL un-
supplemented RPMI 1640 media. 200 nM (THP-1 and M202 cells) or 250nM 
(SK-MEL-5 cells) Nrf2 or negative control siRNA (Ambion®, Life Technologies) 
was added to each sample. The samples were transferred to a cuvette 
(Lonza) and electroporated in an Amaxa Nucleofector II Device (Lonza) on 
setting V-001. The cells were diluted to the desired density (Table 2.4) in fully 
supplemented RPMI 1640. The cells were incubated at 37oC for 24h and 
stimulated as described in the relevant figure legends. Cytotoxicity assays 
used the MTS assay protocol in section 2.2.7. 
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2.10 Fluorescence polarization assay 
The fluorescence polarization assay works on the principle that if a 
fluorophore absorbs polarized light, the light that is emitted will lose 
polarization if the fluorophore is able to move freely. A fluorophore attached 
to a larger molecule tumbles more slowly in solution, and therefore the light 
emitted will retain its polarization. This method can be used to measure 
whether a fluorescent peptide is bound to the Kelch domain of Keap1. If the 
fluorescent peptide is bound, it will emit highly polarized light compared to 
unbound fluorescent peptide.    
Plasmid DNA encoding the Kelch domain (residues 321-609) of Keap1 was a 
kind gift from Mark Hannink (University of Missouri, USA). This Keap1 protein 
was expressed and purified by Richard Steel. 
90 μL of interaction solution (Appendix I) was added to 50 wells of a low-
binding black 96-well microplate. The inhibitor solution was made up of 
either TAT-14 or 14mer diluted in sodium phosphate buffer to a 
concentration of 50 μM or 10 μM. For each starting concentration a total of 
seven ten-fold serial dilutions was produced in sodium phosphate buffer 
(Appendix I) for a total of 16 concentrations. 10 μL of each inhibitor solution 
was added in triplicate to the wells of the microplate containing the 
interaction solution. 10 μL sodium phosphate buffer was added to the final 
two control wells. Solutions were mixed by pipetting, and any bubbles were 
removed. Plates were incubated in the dark for 15min at room temperature. 
The fluorescence intensity of each well was read at 485/520 nm in order to 
ensure that the inhibitor did not interfere with the fluorescence of the 
reaction mix. The fluorescence polarization gain was adjusted to the control 
wells. Fluorescence polarization was read ten times for each well. These 
readings were averaged and the fluorescence polarization for each 
concentration of inhibitor was analysed in triplicate by non-linear regression.  
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2.11 ROS assay 
100 µL M202 cells were seeded at a density of 1 x 105 cells/mL in a 96 well 
black plate with a transparent bottom (Fisher Scientific). The cells were 
incubated at 37oC for 24h. The media was removed, and replaced with 50 µM 
2, 7’-dichlorodihydrofluoresceindiacetate (H2DCFDA) (Sigma-Aldrich) for 
40min. H2DCFDA was removed and replaced with fresh media. The cells were 
incubated at 37oC for 20min. Basal fluorescence was measured at 485/520 
nm on a POLARstar Optima. Cells were stimulated with 10 µM, 20 µM, 50µM, 
or 100 µM cisplatin for 4h. Fluorescence was read at 485/520 nm. Basal 
fluorescence was subtracted from the fluorescence in treated cells to 
calculate the amount of fluorescence caused by cisplatin.  
 
2.12 Statistical analysis and presentation of data 
All experiments were carried out at least three times and data presented as 
mean + SD, unless otherwise stated. Statistical analysis was performed using 
GraphPad Prism version 5.00 (GraphPad Software Inc, (C) 1992-2007). Unless 
stated otherwise, data was subjected to a one-way ANOVA with a Tukey’s 
multiple comparison test. Values of P≤0.05 were considered statistically 
significant. 
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Chapter 3: Development of luciferase reporter 
assays to measure NF-κB and Nrf2 transcriptional 
activity 
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3.1 Introduction 
In the last decade Nrf2 has emerged as a key regulator of protective 
mechanisms within the cell. These include drug detoxification and inhibition 
of inflammation. Nrf2 knockout mice are susceptible to inflammatory 
diseases such as sepsis, and are susceptible to oxidative damage. Nrf2 
activators are frequently examined for their ability to alleviate the effects of 
toxic molecules and inflammatory mediators (Kong et al., 2010; Khodagholi 
et al., 2011; Zhao et al., 2013b; Cheung et al., 2014).  
Nrf2 is a key regulator of these protective processes because it upregulates 
enzymes, such as HO-1, NQO1, and glutamine cysteine ligase, which all play 
roles in protecting against ROS-induced damage and inflammation 
(Rushworth et al., 2008; Noll et al., 2012; Huang et al., 2013a; Liang et al., 
2013). Nrf2 regulates these genes by binding to an ARE sequence in their 
promoters (Itoh et al., 1997). 
One key transcription factor involved in inflammatory processes is NF-κB, 
which is involved in the up-regulation of pro-inflammatory cytokines. 
Inhibition of NF-κB activation is often considered a marker of anti-
inflammatory activity. NF-κB is inhibited by Nrf2 activation, and this has been 
linked to Nrf2 target genes, including HO-1 and NQO1 (Rushworth et al., 
2008; Wang et al., 2014a) 
A large range of compounds activate Nrf2 including phenols (such as 
flavonoids), quinones (for example, tBHQ), and isothiocyanates (which 
include sulforaphane) (reviewed in Magesh et al., 2012). New activators are 
continually being found (Dassano et al., 2014; Joo Choi et al., 2014). Many of 
these molecules are protective. For example sulforaphane, quercetin, and 
tBHQ all inhibit oxidative stress and inflammation (Jin et al., 2010; 
Kleszczynski et al., 2013; Zhao et al., 2013b; Lu et al., 2014b; Ramyaa et al., 
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2014). Finding new Nrf2 activators is an important part of research into 
targeting the Nrf2 pathway to resolve inflammation. A reliable methodology 
that can be used for this is the luciferase assay.  
A Luciferase assay is an experiment that tests for the activation of a 
transcription factor by measuring transcription of a gene under control of a 
specific promoter sequence. The gene under control of this sequence is one 
that encodes for a luciferase protein. Luciferase proteins are found in a 
variety of organisms including fireflies and sea pansies. They oxidise 
compounds called luciferins to create oxyluciferin, in a reaction that 
produces light. Luciferases and luciferins are organism specific, which means 
that they are also specific to each other. This allows them to be used in 
bioluminescence assays in conjunction with each other. In the dual luciferase 
assay two plasmids are co-transfected into the cell line of interest. One 
contains firefly luciferase under control of the promoter of interest. The 
second contains renilla luciferase, which is constitutively expressed under 
control of the SV40 promoter. This allows the renilla luciferase to be used as 
a control for transfection efficiency and cell viability. The Promega Dual-Glo 
Luciferase Assay System is designed for exactly this purpose, and contains a 
substrate for firefly luciferase, and a substrate for renilla luciferase mixed 
with an inhibitor of firefly luciferase (Deluca and McElroy, 1974; Matthews et 
al., 1977).  
In this study two luciferase assays were established, using the Dual Luciferase 
Assay System as a detection mechanism. The first was to measure activation 
of the NF-κB response element (κB-RE), and the second was to measure 
activation of the ARE. 
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3.2 Aims 
1. To develop a luciferase assay for the laboratory that can be used to 
identify activators of ARE-dependent transcription. 
2. To develop a luciferase assay to measure activation of the NF-κB pathway 
in THP-1 cells. 
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3.3 Methods 
3.3.1 Bacterial transformations and plasmid purification. 
The renilla plasmid, pGL4.73, and the NF-κB-RE plasmid, pGL4.32, were 
purchased from Promega (Southampton, UK). 4xARE and 8xARE plasmids 
were a gift from Professor Roland Wolf (University of Dundee, UK). 8xARE 
and 4xARE plasmids were extracted from blotting paper by resuspending in 
50 μL nuclease free water and stored at 4oC overnight. The blotting paper 
was removed and the DNA concentration was measured. 
200 ng of each plasmid was added to 40 µL α-select bacteria (Bioline; 
London, UK). The bacteria were then put on ice for 30min, incubated at 42oC 
for 40 seconds, followed by a further 2min on ice. 960 µL SOC media was 
added to the bacteria before placing in a rotary incubator for 1 hour. 
100 µL of bacteria was added to an agar plate, and spread over the surface. 
Bacteria were then grown overnight at 4oC. A colony was then picked from 
one plate for each plasmid using a pipette tip and grown up overnight in 7 mL 
LB broth with 50 µg/mL ampicillin. The following day 2 mL of bacteria was 
grown up in 120 mL media.  
Plasmids were harvested from the bacteria using an EndoFree Plasmid Maxi 
Kit (Qiagen; Crawley, UK) according to the manufacturer’s instructions. DNA 
concentration was then recorded by nanodrop before sending for sequencing 
at The Genome Analysis Centre (TGAC; Norwich, UK) for analysis. 
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3.3.2 Transfections 
3.3.2.1 THP-1 cells 
1 mL THP-1 cells were seeded at a density of 1x106 cells per mL in a 24-well 
plate and incubated for 1h in a tissue culture incubator at 37oC, 5% CO2. For 
each sample 400 ng firefly plasmid DNA, 100 ng pGL4.73, and 0.5 µL PLUSTM 
reagent were added to 100 µL Opti-MEM medium (Life Technologies). The 
solution was incubated at room temperature for 15min before adding 2.25 
µL lipofectamine per sample. The mixture was incubated at room 
temperature for 25min. 100 µL solution was added to each transfected well. 
100 µL Opti-MEM was added to non-transfected controls. Cells were 
incubated at 37oC for 24h before stimulation. 
3.3.2.2 MCF-7 cells 
100 µL MCF-7 cells were seeded at a density of 8x104 cells per mL in a 96-well 
plate and incubated at 37oC for 24h. For each sample 80 ng firefly plasmid 
DNA, 20 ng pGL4.73, and 0.1 µL PLUSTM reagent was added to 20 µL Opti-
MEM medium. The solution was incubated for 15min at room temperature.  
0.45 µL lipofectamine per sample was added to the mixture and incubated at 
room temperature for 25min.  20 µL of the solution was added to each well 
of MCF-7 cells to be transfected. Non-transfected controls were treated with 
20 µL Opti-MEM instead. Cells were incubated for 24h before adding the 
desired stimulus.  
3.3.2.3 HepG2 cells 
500 µL HepG2 cells were seeded at a density of 4x105 cells per mL in a 24-
well plate and incubated at 37oC for 24h. For each sample 400 ng firefly 
plasmid DNA, 100 ng pGL4.73, and 0.5 µL PLUSTM reagent was added to 20 µL 
Opti-MEM medium. The solution was incubated for 15min at room 
temperature.  2.75 µL lipofectamine per sample was added to the mixture 
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and incubated at room temperature for 25min.  100 µL of the solution was 
added to each well of MCF-7 cells to be transfected. Non-transfected 
controls were treated with 100 µL Opti-MEM instead. Cells were incubated 
for 24h before adding the desired stimulus. 
 
3.3.3 Dual-Glo Luciferase Assay 
Luminescence was measured using the Dual-Glo Luciferase Assay System by 
Promega. This kit contains a luciferase substrate reagent and a Stop and Glo 
reagent. The first contains a lysis buffer and the substrate for firefly 
luciferase, and the second contains both an inhibitor of firfly luciferase 
activity and the substrate for renilla luciferase. 
3.3.3.1 THP-1 cells 
After transfected cells were incubated with the desired stimulus for the 
indicated period of time, they were centrifuged at 5000 rpm for 5min. Media 
was removed and cells were resuspended in 80 µL RPMI media (Fisher). 75 µL 
of each sample was transferred to a solid white 96-well plate, ensuring to 
keep a gap of at least one well between adjacent samples. 75 µL luciferase 
substrate reagent was added to each sample and mixed by pipetting. The 
plate was incubated in the dark for 10min. Luminescence was read using a 
POLARstar Optima (BMG Labtech; Aylesbury, UK). The plate was read a 
second time after a further 10min to ensure signal stability. 
3.3.3.2 MCF-7 Cells 
 After transfected cells were incubated with the desired stimulus for the 
indicated period of time, 100 µL luciferase substrate solution was added to 
each sample. Cells were incubated in the dark at room temperature for 
10min. Samples were transferred to a solid white 96-well plate, taking care 
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to avoid bubbles. Luminescence was recorded using a POLARstar Optima 
(BMG Labtech). 10min later luminescence was read again to ensure signal 
stability. 
 
3.3.3.3 HepG2 cells 
After transfected cells were incubated with the desired stimulus for the 
indicated period of time, 350 µL media was removed from each sample. 150 
µL luciferase substrate solution was added to each sample and incubated in 
the dark for 10min. Each sample was thoroughly mixed and 75 µL transferred 
to a solid white plate. Luminescence was read using a POLARstar Optima 
(BMG Labtech). Luminescence was read 10min later to ensure signal stability.    
3.3.3.4 Renilla Luciferase Activity 
75 µL (THP-1 and HepG2 cells) or 100 µL (MCF-7 cells) Stop and Glo solution 
was mixed into each sample by pipetting and incubated in the dark for 
10min. Luminescence was measured. This is the renilla luminescence. The 
plate was read a second time 10min later to ensure signal stability. Results 
were analysed by subtracting luminescence of the non-transfected control 
away from all other luminescence readings. Then firefly luminescence was 
normalised to renilla luminescence and expressed as fold induction over 
transfected cells containing vehicle control. 
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3.4 Results 
3.4.1 Optimising an NF-κB-RE driven luciferase assay in THP-1 cells 
Before setting up a luciferase assay, it was important to set up a reliable 
method of transfection. Lipofectamine was chosen because it was deemed 
appropriate for optimisation and large-scale studies. THP-1 cells were seeded 
in a 24-well plate at various concentrations before transfecting with 500ng 
GFP-plasmid, as advised by manufacturer’s instructions. After 24h, cells were 
viewed using fluorescence microscopy. There was a modest increase in the 
number of transfected cells in samples with higher seeding densities (Fig 3.1). 
There was no observed effect of seeding density on cell morphology. 
Therefore, total cells transfected was preferred over transfection efficiency in 
order to maximise the signal strength for the luciferase assay. The results 
suggest that there is little correlation between cell density and the amount of 
cells transfected. A seeding density of 1x106 cells/ml was used for all 
subsequent THP-1 luciferase experiments. 
 
 
 
 
 
 
 
 
 
 Fig 3.1. Transfection of GFP in THP-1 cells. The indicated number of THP-1 cells were 
transfected with 500ng GFP plasmid in 1 mL media using lipofectamine. Cells were pelleted 
and resuspended in PBS before observing fluorescence at 40x magnification.   
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LPS is an activator of monocytes and has been previously shown to activate 
NF-kB in THP-1 cells (O’Connell et al, 1998; Essafi-Benkhadir et al., 2012; 
Wang et al., 2013c). Therefore the conditions for an LPS-induced NF-κB-
driven luciferase assay were optimised. pGL4.32 (Fig 3.2A) is a plasmid that 
contains a firefly luciferase gene driven by five repeating NF-κB-RE 
sequences. pGL4.73 (Fig 3.2B) is a control plasmid which constitutively 
expresses Renilla luciferase under control of a SV40 promoter. THP-1 cells 
were transfected with pGL4.32 and pGL4.73 at a ratio of 4:1. A total of 500ng 
DNA was used per sample. 24h after transfection cells were stimulated with 
10 µg/mL LPS for up to 8h. Samples were pelleted and resuspended in 75 µL 
RPMI media before transferring to a solid white 96-well microplate. Firefly 
and renilla luciferase activity were measured using the Dual Glo Luciferase 
Assay System. The results show that LPS-induced NF-κB driven luciferase 
activity increased from 2-8h. Activity peaked at 7h with a 5.8 fold induction 
(p<0.001), but there was little difference between any of the time points 
tested from 4h onwards (Fig 3.2C). 7h was used for the remainder of the 
experiments. 
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To ensure maximal accuracy from luminescence readings it was important to 
optimise the luminescence created from the firefly luciferase plasmid. The 
easiest way to do this was to adjust the relative concentrations of the two 
plasmids. Therefore, THP-1 cells were transfected with various 
pGL4.32:pGL4.73 plasmid ratios in duplicate for 24h. One of each pair of 
samples was left untreated, and the other stimulated with LPS for 7h. The 
results show that LPS induces NF-κB-RE activity more effectively in samples 
with higher ratios of pGL4.32:pGL4.73, peaking at 6.8-fold for a ratio of 19:1 
(Fig 3.3A). However, the data produced by samples with a plasmid ratio of 
Fig 3.2. LPS activates the NF-κB-RE in THP-1 cells. Schematics of plasmids (A) pGL4.32 and 
(B) pGL4.73 (Copyright Promega, 2007). (C) THP-1 cells were transfected with 400ng 
pGL4.32 and 100ng pGL4.73. 24h after transfection cells were incubated with 10 µg/mL LPS 
for the indicated time period. Luminescence was read using the Promega Dual-Glo 
Luciferase Assay System, and firefly luminescence was normalised to renilla luminescence. 
N=3, mean±SEM; *p<0.05, ***p<0.001; One way ANOVA with Tukey’s multiple comparison 
test. 
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4:1 was much more consistent while still giving a strong induction of NF-κB-
RE activity (5.1-fold; p<0.01). Furthermore, the luminescence produced by 
the renilla luciferase was much more variable with other plasmid ratios than 
with 4:1 (Fig 3.3B).  For this reason, a plasmid ratio of 4:1 was selected for 
future experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.3. pGL4.32 and pGL4.73 are most reliable at a ratio of 4:1. (A) THP-1 cells were 
transfected with various ratios of pGL4.32:pGL4.73 totalling 500ng plasmid for each 
sample. 24h after transfection cells were incubated with 10 µg/mL LPS for 7h. 
Luminescence was read using the Promega Dual-Glo Luciferase Assay System, and firefly 
luminescence was normalised to renilla luminescence. (B) Table showing variance in renilla 
luminescence readings. N=3, mean±SEM; *p<0.05, **p<0.01, ***p<0.001; One way ANOVA 
with Tukey’s multiple comparison test. 
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A concentration response experiment was conducted to find the optimal 
concentration of LPS to use for the assay. THP-1 cells were transfected with 
400ng pGL4.32 and 100ng pGL4.73. After 24h cells were stimulated with 
various concentrations of LPS for 7h. LPS induced NF-κB luciferase activity at 
every concentration except 0.001 µg/mL. Two concentrations caused a peak 
5.6-fold induction of NF-κB-RE driven luciferase activity. These were 0.1 and 1 
µg/mL (p<0.05). Lower concentrations are preferable, so the recommended 
LPS concentration for use is 0.1 µg/mL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.4. 0.1 µg/mL and 1 μg/mL are the most effective concentrations of LPS for NF-κB-RE 
activity. THP-1 cells were transfected with 400ng pGL4.32 and 100ng pGL4.73. 24h after 
transfection cells were incubated with the indicated concentration of LPS for 7h. 
Luminescence was read using the Promega Dual-Glo Luciferase Assay System, and firefly 
luminescence was normalised to renilla luminescence. N=3, mean±SEM; *p<0.05; One way 
ANOVA with Tukey’s multiple comparison test. 
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The conditions optimised here (Fig 3.5) provide a functional LPS-induced NF-
κB-RE luciferase assay, which causes a consistent, strong induction of 
luciferase activity using 0.1 µg/mL LPS for 7h. The relevant assay conditions 
used in this assay were used as a starting point for the ARE-luciferase assay. 
 
 
 
 
 
 
 
 
Fig 3.5. A summary of the optimisation of LPS-induced NF-κB-RE-driven luciferase 
activity. Initial conditions were decided upon using manufacturer’s advice and instructions. 
10 µg/mL LPS has been used previously by our lab to induce NF-κB-driven target genes in 
THP-1 cells (Rushworth et al., 2008).  
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3.4.2 Optimisation of an ARE luciferase assay  
Two ARE-luciferase plasmids, 4xARE and 8xARE (fully characterised and 
functionally verified in human cells in: Wang et al., 2006) were a gift from 
Prof Roland Wolf (University of Dundee, UK). Firstly, before further 
experimentation, they were sent to The Genome Analysis Centre (Norwich, 
UK) for sequence verification. The core ARE sequence is 
(A/G)TGACnnnGC(A/G), and these plasmids contain the sequence 
GTGACAAAGCA from the murine GSTA2 promoter. The sequence is repeated 
4 times in the promoter of the 4xARE plasmid, and 8 times in the 8xARE 
plasmid. Promoter sequences for both plasmids were confirmed (Fig 3.6).  
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The 8xARE plasmid was used for early optimisation because it was expected 
to produce a stronger luminescence signal. Initially, THP-1 cells were 
transfected with 8xARE and pGL4.73 in a 4:1 ratio, as carried out for the NF-
κB luciferase assay. 24h after transfection they were stimulated with 50 µM 
tBHQ for 16h or 24h. The results demonstrated that tBHQ resulted in an 
increase in luciferase activity, as expected (Fig. 3.7A). However, upon closer 
examination, the change in luciferase was due to a change in Renilla, the 
control, rather than firefly luciferase activity. This may be due to instability of 
the transfected plasmids over time.  To test this, THP-1 samples were 
transfected with 8xARE and pGL4.73 for multiple time periods up to 48h. The 
luciferase activity for both plasmids dropped off after about 30h (Fig 3.7B 
and C), suggesting that the plasmids are not stable for the period of time 
needed for the cells to recover post-transfection and to stimulate ARE-
luciferase activity. 
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Fig 3.7. Plasmids are unstable in THP-1 cells over extended periods of time. THP-1 cells 
were transfected with 400ng 8xARE and 100ng pGL4.73. (A) 24h after transfection cells 
were incubated with 50 µM tBHQ or DMSO for 16 or 24h. Firefly and renilla luciferase 
activity was measured  using the Promega Dual-Glo luciferase Assay System. (B) Firefly and 
(C) Renilla activity was recorded in unstimulated cells at various time points up to 48h. N=3, 
mean±SEM. 
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Having shown that THP-1 cells are an unsuitable cell line for ARE-luciferase 
plasmids, different cell lines were selected. Wolf and colleagues have 
previously reported tBHQ-induced ARE activity using these plasmids in the 
MCF-7 breast cancer cell line and this was therefore selected as a positive 
control (Wang et al., 2006). HepG2 hepatocytes were selected because they 
are commonly used for ARE driven luciferase assays (Huang et al., 2011; Kim 
et al., 2011; Li et al., 2014b). 24h after transfection the cells were stimulated 
with 50 µM tBHQ for 18h. tBHQ induced a significant induction of 3.7-fold 
(p<0.01) in MCF-7 cells (Fig 3.8A) and 4.3-fold (p<0.001) in HepG2 cells (Fig 
3.8B). This time, only the firefly luciferase activity was affected by tBHQ, 
whereas renilla readings were constant. Because the renilla readings were so 
high in the MCF-7 cells, the entire plate was read in order to check for signal 
bleeding into surrounding wells. The luminescence signal does bleed into 
adjacent and diagonal wells (Fig 3.8C). Although this is minimal (0.26% for 
adjacent and 0.06% for diagonal wells), it was decided to keep all samples at 
least one well apart on the plates for luminescence readings.  
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The 8xARE plasmid was compared to the 4xARE plasmid. 24h after 
transfection HepG2 cells were stimulated with 50 µM tBHQ for 18h. The 
results show no significant difference between the two plasmids (Fig 3.9). 
Fig 3.8. tBHQ activates ARE-driven luciferase activity in MCF-7 cells and HepG2 cells. (A) 
MCF-7 or (B) HepG2 cells were transfected with 400ng 8xARE and 100ng pGL4.73. 24h after 
transfection cells were incubated with DMSO or 50 µM tBHQ for 18h. Luminescence was 
read using the Promega Dual-Glo Luciferase Assay System, and firefly luminescence was 
normalised to renilla luminescence. N=3, mean±SEM; **p<0.01, ***p<0.001; Student’s t-
test. (C) Renilla luminescence readings from MCF-7 cells. Red indicates wells containing the 
lysate from transfected cells, orange indicates empty wells with signal bleeding, yellow 
indicates unaffected empty wells.  
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Fig 3.9. The 4xARE plasmid and 8xARE plasmid respond similarly in HepG2 cells. HepG2 
cells were transfected with 400ng 4xARE or 8xARE and 100ng pGL4.73. 24h after 
transfection cells were incubated with 50 µM tBHQ or DMSO for 18h. Luminescence was 
read using the Promega Dual-Glo Luciferase Assay System, and firefly luminescence was 
normalised to renilla luminescence. N=3, mean±SEM; *p<0.05; One way ANOVA with 
Tukey’s multiple comparison test. 
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3.5 Discussion 
Reporter assays are useful tools for measuring regulation of promoter-driven 
transcription. This can be particularly relevant for transcription factors that 
use the same promoter sequence to regulate a large number of functionally 
similar genes, such as Nrf2 and the p65 subunit of NF-κB. Nrf2 targets have 
anti-inflammatory effects, and NF-κB regulates a large number of pro-
inflammatory cytokines. Reporter assays can be used to identify molecular 
regulators of these transcription factors, and may also have some predictive 
utility in identifying whether they are likely to have a broader pro- or anti-
inflammatory effects. 
This study has produced working experimental procedures to examine 
transcriptional activity of the transcription factors NF-κB and Nrf2 in vitro, 
which are both suitable for preliminary screening for compounds that may 
provide anti-inflammatory protection via Nrf2. These protocols were 
optimised taking into account ease of use, assay sensitivity, and reliability. 
The NF-κB-RE luciferase assay was set up in THP-1 cells, and was developed 
to produce a consistent response when stimulated with the TLR4 ligand LPS. 
The ARE-luciferase assay was shown to be poorly suited to THP-1 cells, but 
was established in MCF-7 and HepG2 cells.  
THP-1 cells were chosen for both luciferase assays. This is because there is 
considerable evidence provided by our group and others that Nrf2 plays an 
important role in the resolution of inflammation, and NF-κB is an important 
pro-inflammatory mediator (Rushworth et al., 2005; Rushworth et al., 2008; 
Reddy et al., 2011; Steel et al., 2012; Soetikno et al., 2013). When THP-1 cells 
were found to be unsuitable for the ARE-luciferase assay, HepG2 cells and 
MCF-7 cells were selected instead. There are several reasons for this. The 
first is that HepG2 cells are hepatocytes, which play a key role in 
detoxification processes. Nrf2, being a key regulator of detoxification 
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enzymes, is particularly relevant in the liver (Sahi et al., 2010; Cornejo et al., 
2013). In addition both cell lines are commonly used for luminescence assays, 
and therefore uncertainty over the effect of the cell line on the assay was 
minimized (Chen et al., 2004; Niture et al., 2009; Do et al., 2013; Jiang et al., 
2014; Wu et al., 2014). MCF-7 cells were specifically selected because they 
have been previously found to be a good cell line for use with the ARE 
plasmids in this study (Wang et al., 2006). 
Stable transfections were considered, but transient transfections were 
chosen for the assays because they allow for more versatility in assay 
conditions, and because several reporter plasmids were used. There are 
several transfection methods that can be used to transfect THP-1 cells. 
Electroporation and DEAE-dextran can be used and were considered, but 
both were rejected in favour of Lipofectamine (Maess et al., 2011; Makon-
Sebastien et al., 2014). Lipofectamine was chosen for several reasons. The 
first is that it is well-suited to optimising assays. A base protocol for each cell 
line used in this study has been published by Life Technologies, which is easy 
to adapt for optimisation purposes if necessary. The transfection protocol 
itself doesn’t take very long, which makes it suitable for use with a high 
number of samples. In addition, it did not have an effect on cell morphology 
and has been used to transfect the ARE plasmids used in the development of 
this assay in HepG2 cells and MCF-7 cells (Wang et al., 2006).  
The ARE reporter assay was established in HepG2 and MCF-7 cells. This is 
because the plasmids were not stable for long enough in THP-1 cells. The 
eventual conditions that were optimised are very similar to other luciferase 
assays that have been used for research into Nrf2. The 18h time point for 
tBHQ stimulation was decided upon because it has been used before in these 
cell lines (Wang et al., 2006). There is some variability with this among 
published assays. 16h and 24h have also been used to induce ARE-driven 
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luciferase activity with tBHQ in HepG2 cells (Niture et al., 2009; Do et al., 
2013). While this shows that tBHQ-induced luciferase activity in this assay is 
very similar to published assays, different inducers may require different 
time points and this may need to be optimised on a case-by-case basis. For 
example, diallyl polysulfides induce ARE-driven luciferase activity at 24h 
(Chen et al., 2004).  
The scale of induction of ARE-driven luciferase activity caused by 50 µM tBHQ 
in HepG2 cells is also comparable to assays in the literature. 4.3-fold in this 
study compares favourably to the 2.5-fold and 2.8-fold inductions reported 
by Niture and co-workers, and Wang and co-workers respectively (Wang et 
al., 2006; Niture et al., 2009). A higher induction of 8-fold was achieved by Do 
and co-workers (2013), and interestingly they used a concentration of 30 µM. 
In MCF-7 cells, the assay is less favourable. This study showed a 3.7-fold 
induction using tBHQ, whereas Wang et al. (2006) show a 50-fold induction. 
The reasons for this are unclear, and may have to do with the quantities of 
the plasmids used, because this is not made clear in the publication.  
There have been a few LPS-induced NF-κB-RE-driven luciferase assays set up 
in THP-1 cells. They are similar to the one developed in this study. They use 1 
µg/mL LPS as an inducer, which was found to be equal to 0.1 µg/mL LPS in 
this study. They also use similar LPS stimulation times, with one using 4h and 
the other using 6h. The 4h and 6h time points were not significantly different 
from 7h in this study, suggesting that the variance in LPS stimulation time 
periods has a negligible effect on the assay (Spellerberg et al., 1996; 
Baumann et al., 2005). However, the induction of reporter gene activity was 
lower in this study than it was in either published study, which reported 
inductions of approximately 10-12-fold. The differences may be to do with 
the plasmids used. One luciferase assay was driven by a cloned TNF promoter 
(Baumann et al., 2005). The other assay was a bit different, in that a dose 
144 
 
response assay was shown. 0.1 µg/mL LPS caused approximately 5-fold 
induction. However, this is difficult to assess due to the scaling on the graph. 
Similarly to this study, there is not much difference between the higher 
concentrations used – 20, 10, and 1 µg/mL LPS all cause a similar induction of 
NF-κB-RE-driven luciferase activity. Unlike this study it does not extend to 0.1 
µg/mL. This may be because of the type of LPS used or the plasmids used, 
which use a 2x murine NF-κB promoter sequence, and a minimal c fos 
promoter (Spellerberg et al., 1996). 
There are some limitations that must be considered. Luciferase assays use a 
known promoter to induce gene expression, but some promoter sequences 
are known to be regulated by several transcription factors, and some 
promoter sequences (including the ARE) are known to overlap (Friling et al., 
1992; Wasserman and Fahl, 1997; Kurokawa et al., 2009; Kaspar and Jaiswal, 
2010). Therefore, other experiments are required to verify that Nrf2 or NF-κB 
are the driving forces of transcription whenever a molecule affects luciferase 
expression. EMSAs, Western blots and PCRs along with inhibitor experiments 
(if one is available) can be used to back up data obtained from these assays. 
Furthermore, although biological context is provided by the environment of 
living cells, the very presence of the luciferase plasmid changes that 
biological context. Therefore, preliminary data gained from this assay must 
be backed up with complimentary experiments such as those described 
above.   
This assay is also fairly cumbersome. Adherent cells thus far have been grown 
in a standard tissue culture plate, and transferred to a solid white plate after 
cell lysis. Aside from being slow, this leads to pipetting errors and loss of 
sample. Now that the protocol has been shown to work, there should not be 
a problem growing the cells in a tissue culture treated solid white plate to cut 
out this step, but it has not yet been tried. The main disadvantage of doing 
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this is that it becomes difficult to monitor the state of the cells. The biggest 
issue, however, is that THP-1 cells need a high cell number to deliver a high 
signal. This means that they need to be seeded in a 24-well plate, and then 
pelleted at the time of harvesting before transferring to a solid white plate. 
Much like with the adherent cells, this is time consuming and leads to errors. 
This assay provides a framework upon which to develop a high-throughput 
assay, but it will require adapting if it is to be used as such. High throughput 
assays require efficiency in addition to scientific rigour. There are several 
ways in which these assays can become more efficient. The first, as 
mentioned above, is to seed directly onto a tissue culture treated white 
plate. This serves to cut down on errors in pelleting and transferring the cells, 
and also cuts down the time and reagents spent doing so. The second is to 
use 96-well plates whenever possible. More samples per plate is time-
efficient, and the size of the wells makes it cost-efficient. However, this 
would exclude certain cell lines from being suitable for high throughput 
research, such as THP-1 cells. Perhaps the biggest modification for high 
throughput is transferring the assay to stable transfections. Cutting out on 
the transfection step reduces errors and is both resource and time-effective, 
but is only viable if the assay conditions don’t need further optimisation.      
Expanding the assays into different cell lines may also be an option, 
especially if they can be established in a cell line that is relevant to both Nrf2 
and NF-κB in inflammation. One potential benefit to having both luciferase 
assays set up in the same cell line is that inhibitors of the NF-κB-RE assay can 
be linked with activators of the ARE assay. RAW 264.7 cells, for example, are 
a murine macrophage cell line in which Nrf2 activation has been linked to 
anti-inflammatory activity (Han et al., 2013; Lee et al., 2014a). 
Improving the current model is also important. Further experiments with the 
NF-κB assay can be improved by using an established NF-κB inhibitor to 
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compare experimental inhibitors to. Other inflammatory mediators such as 
TNF also activate NF-κB in THP-1 cells, and can be used to expand the assay 
to study other pathways (Desai et al., 2012). 
In conclusion, this study has developed two useful luciferase assays to 
investigate transcription driven by the ARE or NF-κB-RE promoters.  The NF-
κB-RE assay has been optimised to use LPS as a model of pro-inflammatory 
signalling in THP-1 cells. The ARE assay was developed in HepG2 and MCF-7 
cells after the plasmids were found to degrade rapidly in THP-1 cells. Both 
assays provide a framework for future development of a high-throughput 
reporter assay, and can be used to identify novel activators of ARE-driven 
genes and anti-inflammatory drug candidates. 
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Chapter 4: The effects of long chain diallyl 
polysulfides from garlic on the Nrf2 pathway in 
human monocytic cells 
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4.1 Introduction 
A diet rich in fruit and vegetables is widely accepted to have a positive effect 
on health and improve protection against a variety of diseases including 
coronary heart disease, stroke, rheumatoid arthritis, and COPD (Dauchet et 
al., 2006; Boeing et al., 2012). The nutrients that cause these effects are a key 
area of interest for both nutrition and medical researchers because they may 
have implications for disease prevention and drug design. For example, 
common fruits and vegetables such as onions and cranberries contain 
quercetin, which has been associated with anti-inflammatory activity (Askari 
et al., 2012; Boots et al., 2011), and diets high in fibre decrease risk of 
cardiovascular disease (Threapleton et al., 2013). 
For centuries it has been believed that garlic has therapeutic properties. 
Modern research has produced evidence to support these beliefs. Garlic 
consumption has been linked with protection against risk factors of 
cardiovascular disease, including lowering cholesterol and vascular 
calcification (Warshafsky et al., 1993; Durak et al., 2004). In addition, a 
number of human trials have shown that garlic lowers biomarkers of various 
conditions, including hypertension, inflammation and atherosclerosis (Zeb et 
al., 2012; Ried et al., 2013). 
Garlic contains high concentrations of organosulfur compounds which have 
been the subject of medical research in vitro and in vivo (Yoshida et al., 1999; 
Ichikawa et al., 2006; Quintero-Fabian et al., 2013). In particular, Allicin may 
play an important role in the bioactivity of garlic. Garlic itself does not 
contain high concentrations of allicin. Instead, allicin is produced when garlic 
is crushed. When this happens the enzyme alliinase is released from the 
vacuole, and converts alliin into allicin (Fig 4.1A) (Wang et al., 2011). 
However, allicin itself is unstable, and degrades into diallyl polysulfides 
(Munchberg et al., 2007). Both Allicin and its polysulfide degradation 
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products have been linked with many of the health benefits attributed to 
garlic in vivo. These include anti-inflammatory, antiproliferative, and 
antibacterial properties (Tsao and Yin, 2001; Kalayarasan et al., 2009; Li et al., 
2012c; Gu et al., 2013; Shin et al., 2013a). 
Diallyl polysulfides contain a polysulfide chain flanked by two allyl groups, 
giving the overall formula CH2CHCH2-Sx-CH2CHCH2 (Fig 4.1B). They vary in the 
length of their polysulfide chain; 1-4 sulfurs are common, whereas longer 
chains containing 5-7 sulfurs are increasingly less so (Taucher et al., 1996). 
Most research to date has focused on short chain (x≤3) polysulfides, and an 
increasing body of literature demonstrates that these compounds activate 
the cytoprotective transcription factor Nrf2 in a variety of tissue types. 
 
 
Fig 4.1. Garlic organosulfur compounds. (A) Alliinase converts alliin to allicin when garlic is 
damaged. (B) Chemical structures of diallyl polysulfides. 
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Diallyl Sulfide (DAS) shows upregulation of Nrf2 and inhibition of gentamicin-
induced TNF and NF-κB expression in rat kidneys (Kalayarasan et al., 2009).  
Diallyl disulfide and diallyl trisulfide upregulate Nrf2 and inhibit inflammatory 
mediators in RAW264.7 macrophages (Shin et al., 2013b; You et al., 2013). 
Long chain polysulfides are widely hypothesised to be more biologically 
active than short chain polysulfides (Chen et al., 2004; Munchberg et al., 
2007; Saidu et al., 2013), but this has not been confirmed with respect to 
Nrf2 activation.  Recent data show that diallyl tetrasulfide (DATTS) induces 
Nrf2 and HO-1 in human colorectal cells (Saidu et al., 2013), suggesting that 
longer chain diallyl polysulfides are biologically active, but due to the fact 
that DATTS was used in isolation it is difficult to draw conclusions about its 
relative activity. This study focused on the effects of the long chain 
polysulfides DATTS and diallyl pentasulfide (DAPS) on the Nrf2 pathway in 
human monocytes. DAPS was characterised as a novel inducer of the Nrf2 
pathway, and its activity was directly compared to shorter chain diallyl 
polysulfides. 
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4.2 Aims:  
Hypothesis: Long chain diallyl polysulfides activate Nrf2 expression more 
powerfully than short chain diallyl polysulfides. Long chain diallyl polysulfides 
confer protective effects to monocytes. 
 
Aims: 
 
1. To investigate whether the long chain polysulfides DATTS and DAPS 
induce the Nrf2 pathway in THP-1 monocytes. 
 
2. To examine/identify mechanisms involved in Nrf2 activation by diallyl 
polysulfides. 
 
3. To elucidate the relationship between polysulfide chain length and its 
effectiveness in inducing Nrf2 pathway activation.  
 
4. To investigate potential beneficial effects of long chain polysulfides. 
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4.3 Results 
4.3.1 Garlic oils activate the Nrf2 pathway in THP-1 monocytes. 
Previous work has shown that garlic oils contain high concentrations of diallyl 
polysulfides, but whether they activate the Nrf2 pathway in monocytes is 
unknown. To investigate this, two garlic oils were selected for experiments in 
human THP-1 monocytes. The garlic oils were selected based on their 
polysulfide content. Naturex was chosen because it had the highest amount 
of long chain polysulfides (DATTS, DAPS, DAHS) of all the garlic oils, and 
Stringer was chosen because it has comparatively low concentrations of long 
chain polysulfides (Table 1). Diallyl polysulfides can be synthesised by 
reacting diallyl disulfide with liquid sulfur (Wang et al., 2012b). This method 
was used to make a polysulfide mixture (PS Mix) which was used as a positive 
control for polysulfide activity. 
 
 
 
 
THP-1 cells were incubated with 10 μg/mL of each garlic oil for various time 
points up to 8h. Cells were lysed and total cell extracts were measured for 
Nrf2 protein expression by Western blot. Fig 4.2 demonstrates that Nrf2 is 
induced by both garlic oils and PS mix. All three upregulated Nrf2 after 4h of 
exposure. PS Mix induced Nrf2 expression more powerfully than either garlic 
Table 4.1. Diallyl polysulfide composition of garlic oils. Garlic oil components were 
separated by HPLC, and diallyl polysulfide content was measured by absorbance at 240nm. 
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oil, which may be due to the higher concentration of diallyl polysulfides 
present. Naturex induced Nrf2 earlier than Stringer, but neither garlic oil 
caused a sustained Nrf2 activation after 4h.  
 
 
 
 
 
 
 
 
To investigate whether the induced Nrf2 is transcriptionally active in THP-1 
cells, the effect of the garlic oils on expression of two downstream target 
genes, HO-1 and NQO1, was measured. THP-1 cells were incubated with 10 
μg/mL of the indicated garlic oil for up to 12h and HO-1 and NQO1 mRNA 
expression were measured by RT-qPCR. Fig 4.3A demonstrates that the garlic 
oils significantly induced HO-1 mRNA expression in THP-1 cells, with a peak 
induction at 8 hr. Furthermore, Stringer was twice as effective at inducing 
HO-1 as Naturex (18.4-fold vs 9.1 fold induction over control), although 
neither was as effective as the PS mix control.  Both garlic oils also 
significantly induced NQO1 mRNA expression in THP-1 cells (Fig 4.3B). 
Stringer induced a more powerful and prolonged activation of NQO1, with 
expression still increasing at 12 h post stimulation, topping even that of PS 
mix at 12 h (Stringer, 5.4-fold over control vs Naturex, 4.0 fold vs PS Mix, 3.8 
fold).  
 
Fig 4.2. Garlic oils induce Nrf2 accumulation in THP-1 cells. THP-1 cells were incubated 
with 10 μg/mL Naturex, Stringer or PS Mix for the indicated time point. DMSO was used as 
a vehicle control. Whole cell lysates were prepared and Nrf2 expression measured by 
western blot analysis. β-actin expression is shown as a loading control. Results are 
representative of three independent experiments; replicates are shown in Appendix II. 
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Fig 4.3. Garlic oils induce HO-1 and NQO1 mRNA expression in THP-1 cells. THP-1 cells 
were incubated with 10 μg/mL Naturex, Stringer or PS Mix for the indicated time point.   In 
the 0h samples the cells were incubated with the vehicle control, DMSO, for 12h. RNA was 
extracted and mRNA expression of (A) HO-1 or (B) NQO1 was measured by RT-qPCR and 
normalised to GAPDH. Mean + SEM, n=3; *p<0.05, **p<0.01, ***p<0.001; one way ANOVA 
with Tukey’s multiple comparison test. 
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In order to verify that transcriptional activity correlates with protein 
production, THP-1 cells were incubated with 10 μg/mL of the garlic oils or PS 
mix. HO-1 protein expression was analysed. Both garlic oils increased HO-1 
protein expression by 16h, which remained increased at 24h (Fig 4.4). 
Consistent with the mRNA expression data, Stringer was again more 
powerful than Naturex, but not as powerful as PS mix. 
 
  
 
 
 
 
 
 
 
4.3.2 Long chain polysulfides activate HO-1 in THP-1 cells. 
Taken together the results show that garlic oils activate the Nrf2 pathway in 
monocytes. Interestingly Stringer was the more effective of the two despite 
Naturex containing higher concentrations of long chain diallyl polysulfides. 
However, conclusions based on this evidence would be flawed because 
Stringer contains 8.5% more unidentified compounds. Therefore, a direct 
comparison between the diallyl polysulfides was performed. THP-1 cells were 
incubated with 20 μM DADS (2S), DATS (3S), DATTS (4S) or DAPS (5S) for 8h. 
Total RNA was extracted and HO-1 expression measured by RT-qPCR. The 
results revealed a strong correlation between chain length and the amount 
Fig 4.4. Garlic oils Induce HO-1 protein expression in THP-1 cells. THP-1 cells were 
incubated with 10 μg/mL Naturex, Stringer or PS Mix for the indicated time point. DMSO 
was used as a vehicle control. Whole cell lysates were collected and HO-1 expression was 
measured by Western blot. β-actin expression is shown as a loading control. Results are 
representative of three independent experiments; replicates are shown in Appendix II. 
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of HO-1 produced (Fig 4.5). DAPS was the strongest inducer with a 47-fold 
induction over control (p<0.001), over twice as effective (p<0.01) as DATTS, 
which showed a 20.7-fold induction over control (p<0.01). DATS caused a 16-
fold induction of HO-1 mRNA when compared to DMSO alone (p<0.05), 
whereas DADS caused a non-significant 3.1-fold increase in HO-1 production. 
Increase in activity from DADS to DATS and from DATTS to DAPS was larger 
than that from DATS to DATTS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The differences in effectiveness could be due to a difference in kinetics 
rather than activity. To account for this possibility, the long chain 
polysulfides, DATTS and DAPS, were incubated with THP-1 cells for up to 24h. 
HO-1 mRNA and protein expression was measured. A difference in kinetics 
Fig 4.5. Diallyl polysulfides induce HO-1 mRNA expression in THP-1 cells.   Cells were 
incubated with 20μM DADS, DATS, DATTS, or DAPS for 8h. DMSO was used as a vehicle 
control. Total RNA was extracted and HO-1 expression was measured by RT-qPCR and 
normalised to GAPDH. Mean ± SEM, n=3; *p<0.05, **p<0.01, ***p<0.001; One way ANOVA 
with Tukey’s multiple comparison test. 
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between the two compounds was observed at both mRNA and protein level. 
DATTS induced HO-1 mRNA and protein expression compared to DMSO 
alone, peaking at 8h (p<0.05) and 12h respectively (Fig 4.6A and C). In 
contrast DAPS produces a later, more sustained induction of HO-1 mRNA, 
peaking at 8-12h (p<0.01, 0.01 respectively), with protein peaking at 16h (Fig 
4.6B and C). At no point, however, does DATTS induce HO-1 more strongly 
than DAPS, confirming that DAPS is the more effective diallyl polysulfide of 
the two, despite the difference in kinetics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.6. DATTS and DAPS-induced HO-1 expression in THP-1 cells.   Cells were incubated 
with 20μM DATTS or DAPS for the indicated time points. DMSO was used as a vehicle 
control in the 0h samples. Total RNA was extracted and HO-1 expression in response to (A) 
DATTS and (B) DAPS was measured by RT-qPCR and normalised to GAPDH. Mean ± SEM, 
n=3. *p<0.05, **p<0.01; One way ANOVA with Tukey’s multiple comparison test. (C) Whole 
cell lysates were prepared and HO-1 expression measured by Western blot Analysis. 
Representative of three independent experiments; replicates are shown in Appendix II.  
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To test the ability of DAPS to induce HO-1 at lower concentrations, cells were 
treated for 8h with various concentrations of DAPS ranging from 0.5 µM – 20 
µM and HO-1 mRNA expression was examined. The lowest concentration of 
DAPS to induce HO-1 was 5 μM (Fig 4.7), which gave a 4.2-fold induction over 
control (not significant; p>0.05). The highest concentration tested, 20 μM, 
gave the highest induction (61.1-fold; p<0.001), which was approximately 4-
times more powerful than 10 μM (not significant; p>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.7. DAPS-induced HO-1 mRNA is concentration dependent.   THP-1 cells were 
incubated with 0-20 μM DAPS for 8h. DMSO was used as a vehicle control in the 0 μM 
sample. Total RNA was extracted and HO-1 mRNA expression measured by RT-qPCR and 
normalised to GAPDH. Mean ± SEM, n=3.  ***p<0.001; One way ANOVA with Tukey’s 
multiple comparison test. 
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4.3.3 Long chain polysulfides activate the Nrf2 pathway. 
To determine if other ARE-driven genes are also upregulated in response to 
long chain polysulfides in monocytes, THP-1 cells were incubated with either 
DATTS or DAPS for up to 24h and NQO1 and ferritin H mRNA expression 
examined. DATTS caused a non-significant induction of NQO1 over control 
(2.8-fold; p>0.05) which peaked between 12 and 16h after stimulation (Fig 
4.8A). In contrast, after DAPS stimulation NQO1 expression was high 
between 8-16h (Fig 4.8B), with the peak induction at 16h (3.7-fold; p<0.01). 
DAPS provoked a more sustained induction than DATTS; NQO1 mRNA levels 
were still over 2-fold above basal after 24h. Ferritin mRNA expression 
showed a similar pattern. DATTS caused an induction at 4h (Fig 4.8C), and 
mRNA levels peak at 16h (3.3 fold over control, p<0.05). DAPS caused a more 
powerful 4.3-fold induction (p<0.01) which peaked at 16h (Fig 4.8D). Similar 
to HO-1 and NQO1, Ferritin H is still raised at 24h in cells stimulated with 
DAPS, but not with DATTS. Interestingly, both NQO1 and ferritin H mRNA 
expression were induced later than HO-1 and DAPS caused a higher, more 
sustained induction than DATTS for all three genes. 
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All of the genes tested in this study were chosen because they contain ARE 
sequences in their promoters (Li and Jaiswal, 1992; Prestera et al., 1995; 
Iwasaki et al., 2007). To verify that long chain polysulfides activate this 
promoter region, a luciferase reporter assay was performed. HepG2 cells 
were transfected with an 8xARE firefly luciferase reporter and a renilla 
control vector, PGL4. 18h after transfection, cells were stimulated with DAPS 
for 18h and luciferase activity was measured using the Promega Dual-Glo® 
luciferase assay system. Fig 4.9 shows that DAPS significantly induces ARE-
Fig 4.8. Long chain polysulfide induction of  NQO1 and Ferritin H mRNA expression.  THP-
1 cells were stimulated with 20 μM (A) DATTS or (B) DAPS. After the indicated time period 
RNA was extracted and NQO1 mRNA expression was measured by RT-qPCR. RNA from cells 
stimulated with (C) DATTS and (D) DAPS was also analysed for ferritin expression.  Results 
shown are normalised to GAPDH, and show the mean±SEM of three independent 
experiments. *p<0.05, **p<0.01; One way ANOVA with Tukey’s multiple comparison test. 
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driven luciferase activity over DMSO (p<0.001), confirming that DAPS induces 
ARE promoter activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nrf2 is the key regulator of ARE-driven gene transcription (Itoh et al., 1997).  
Silencing Nrf2, therefore, should inhibit DAPS induced HO-1 expression in 
THP-1 cells. THP-1 cells were transfected with either Nrf2 or negative control 
siRNA using a validated protocol (Fig 4.10A). An electroporated THP-1 sample 
without any siRNA was used as a transfection control. After 24h, cells were 
Fig 4.9. DAPS induced ARE luciferase activity in HepG2 cells.  HepG2 cells were transfected 
with ARE-luciferase and PGL4 plasmids for 18h prior to incubation with DAPS for 18h. 
DMSO was used as a vehicle control. Luminescence was read using the Dual-Glo luciferase 
assay, and firefly luciferase was normalised to renilla luciferase activity. Mean ± SEM, n=3;  
***p<0.001; student’s t-test. 
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treated with 20 μM DAPS  for 24h and whole cell lysates were harvested and 
probed for HO-1 expression by Western blot analysis. Nrf2 siRNA suppressed 
DAPS-induced HO-1 protein expression compared with negative control 
siRNA (Fig 4.10B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.10. Nrf2 siRNA suppresses DAPS-induced HO-1 expression. THP-1 cells were 
transfected with 200nM Nrf2 siRNA or negative control siRNA. An electroporated sample 
with no siRNA was used as a control. (A) Nrf2 mRNA expression was measured 24 and 48h 
after transfection by RT-qPCR and normalised to GAPDH. Mean ± SEM, n=3;***p<0.001; 
One way ANOVA with Tukey’s multiple comparison test. (B) After 24h, cells were incubated 
with 20 μM DAPS for 24h. DMSO was used as a vehicle control. Cell lysates were collected 
and HO-1 expression was measured by Western blot. β-actin expression is shown as a 
loading control. Results are representative of three independent experiments; replicates 
are shown in Appendix II. 
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When Nrf2 is activated, its interaction with Keap1 is disrupted, resulting in 
nuclear accumulation of newly synthesised Nrf2. Therefore, Nrf2 protein 
expression in DATTS and DAPS-stimulated THP-1 cells was examined. Fig 4.11 
demonstrates that Nrf2 accumulated in cells incubated with DATTS or DAPS 
over the 8h period, with highest expression between 4 and 6 h for both 
molecules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.11. DATTS and DAPS induce Nrf2 protein expression in THP-1 cells.   THP-1 cells were 
incubated with 20 μM DATTS or DAPS for the indicated time period. DMSO was used as a 
vehicle control. Cell lysates were collected and Nrf2 expression was measured by western 
blot. β-actin expression is shown as a loading control. Results are representative of three 
independent experiments; replicates are shown in Appendix II. 
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4.3.4 Signalling mechanisms upstream of DAPS-induced Nrf2 
Short chain diallyl polysulfide compounds have been shown to induce HO-1 
via p38 MAP kinase (Gong et al., 2004; Ho et al., 2012). Whether this is a 
common form of activation for all diallyl polysulfides is unknown. THP-1 cells 
were pre-incubated with the p38 MAP kinase inhibitor SB203580 for 30min 
prior to addition of 20 μM DATTS or DAPS for 8h, and HO-1 mRNA expression 
measured. SB203580 inhibited HO-1 mRNA expression by both DATTS 
(64.1%; not significant) and DAPS (67.9%; p<0.01) (Fig 4.12A). To confirm that 
p38 is part of an Nrf2 dependent signalling mechanism, THP-1 cells were 
incubated with SB203580 for 30min prior to 20 μM DAPS for 4h. Cell extracts 
were probed for Nrf2 protein expression by Western blot. SB203580 blocked 
DAPS-induced Nrf2 protein expression, suggesting that p38 MAP kinase acts 
upstream of Nrf2 (Fig 4.12B). 
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ROS are an established mechanism of activating Nrf2 (Numazawa et al., 
2003) and diallyl polysulfide compounds have previously been found to 
induce production of ROS in erythrocytes (Munday et al., 2003).  To 
investigate whether ROS play a role in DAPS-induced Nrf2 activation, THP-1 
cells were treated with the ROS scavenger N-acetyl-cysteine (NAC) prior to 
Fig 4.12. p38MAP kinase regulates DATTS and DAPS-induced Nrf2 and HO-1 expression. 
(A) THP-1 cells were incubated with 10 μM SB203580 for 30min prior to addition of 20 μM 
DATTS or DAPS for 8h. In samples lacking DATTS, DAPS, and/or SB203580, DMSO was used 
as a vehicle control. Total RNA was extracted and HO-1 expression measured by RT-qPCR 
and normalised to GAPDH. Results show the mean±SEM of three independent 
experiments. (B) THP-1 cells were incubated with 10 μM SB203580 for 30min prior to 
incubation with DAPS for 4h. Cell lysates were probed for Nrf2 expression by western blot. 
Data shown is representative of three independent experiments; replicates are shown in 
Appendix II. **p<0.01; One way ANOVA with Tukey’s multiple comparison test. 
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DAPS incubation for 16 hr. Analysis of HO-1 protein expression revealed that 
NAC suppressed DAPS induced HO-1 protein production (Fig 4.13A). Similarly, 
NAC inhibited Nrf2 expression after 4h DAPS incubation (Fig 4.13B). These 
results indicate that DAPS induces ROS prior to Nrf2 activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.13. DAPS induces Nrf2 via ROS production. (A) THP-1 cells were incubated with 1mM 
NAC for 30min prior to addition of 20 μM DAPS for 24h. DMSO was used as a vehicle 
control. Cell lysates were probed for HO-1 expression by western blot.  (B) THP-1 cells were 
incubated with 1mM NAC for 30min prior to incubation with DAPS for 4h. Cell lysates were 
probed for Nrf2 expression by Western blot. β-actin is shown as a loading control. Data 
shown is representative of three independent experiments; replicates are shown in 
Appendix II.  
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4.3.5 Effect of DAPS on inflammation and cytotoxicity in THP-1 cells 
Short length diallyl polysulfides have been shown to downregulate 
inflammatory mediators (Kalayarasan et al., 2009; You et al., 2013). It is 
unknown whether long chain polysulfides have the same effect. Therefore, 
THP-1 cells were incubated with DAPS for either 4h or 20h prior to addition 
of 100 pg/mL LPS for 2h and TNF mRNA expression was measured. The 
results (Fig 4.14) show that DAPS had no effect on LPS-induced TNF 
expression after 4h pre-incubation, and even appears to increase LPS induced 
TNF after 20h pre-incubation although this is not significant.  
 
 
 
 
 
Fig 4.14. DAPS does not inhibit LPS-induced TNF. THP-1 cells were incubated 20 μM DAPS 
for 4 or 24h before stimulation with 100 pg/mL LPS. DMSO was used as a vehicle control for 
DAPS in unstimulated cells. TNF expression was measured by RT-qPCR and normalised to 
GAPDH. Mean ±SEM, n=3; One way ANOVA with Tukey’s multiple comparison test. 
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Nrf2 is known to protect against damage caused by oxidative stress, and 
lower cellular concentrations of free radicals (Ruiz et al., 2013; Zhang et al., 
2013d). DAS and DADS have been shown to protect against excessive 
hydrogen peroxide induced necrosis (Gong et al., 2004; Koh et al., 2005). 
DADS has also been shown to protect against H2O2-induced genotoxicity 
(Belloir et al., 2006). The effect of DAPS on H2O2 induced cell death was 
measured by MTS assay. In order to ensure that cytotoxicity rather than 
proliferation was measured, cells were seeded at a confluent density (0.5 x 
104 cells per well) and cell morphology was recorded at the end of the 
experiment (data not shown). DAPS was unable to prevent H2O2-induced cell 
death in THP-1 cells (Fig 4.15). Interestingly, two-Way ANOVA analysis 
revealed that although the differences between the cytotoxicity of THP-1 
cells with and without DAPS at each concentration of H2O2 are not significant, 
when the datasets were treated as a whole, DAPS exacerbated H2O2-induced 
cell death (p<0.05).  
 
 
 
 
 
 
 
 
 
 
Fig 4.15. DAPS does not protect THP-1 cells from hydrogen peroxide-induced toxicity. 20 
μM DAPS or DMSO was added to THP-1 cells for 4h before addition of H2O2 at various 
concentrations for 24h. MTS was added to the cells and absorbance readings were taken at 
492nM to calculate cell viability. Mean±SEM, n=3; Two way ANOVA with Bonferroni post 
test. 
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4.4 Discussion  
Garlic has been linked with numerous health benefits (Warshafsky et al., 
1993; Durak et al., 2004; Zeb et al., 2012; Ried et al., 2013). Some evidence 
suggests that diallyl polysulfides, a major component of crushed garlic and 
garlic oils, may be responsible for these effects by activating the Nrf2 
pathway (Kalayarasan et al., 2009; Shin et al., 2013).  This study focused on 
the effects of garlic oil and long chain diallyl polysulfides in THP-1 human 
monocytes. For the first time, it was shown that diallyl polysulfides activate 
the Nrf2 pathway in human monocytic cells. DAPS was identified as a novel 
activator of the Nrf2 pathway, which is much more effective than shorter 
diallyl polysulfides. However, the increased activation of the Nrf2 pathway 
did not inhibit LPS-induced TNF expression, or improve cell viability after 
incubation with H2O2. 
Garlic has been associated with activation of the Nrf2 pathway in vitro and in 
vivo.  Aged red garlic extract induces HO-1 and Nrf2 in RAW 264.7 cells, and 
inhibits LPS-induced COX-2 expression in mouse lung while inducing HO-1 
expression (Park et al., 2012), and garlic reduces oxidative stress in Wistar 
rats (Kalayarasan et al., 2008). In contrast, Fisher and co-workers (2007) 
report that garlic oil does not activate the Nrf2 pathway, although the 
conclusions of this study are debatable because although garlic oil induced 
Nrf2 and ARE gene products are not statistically significantly increased, they 
are generally higher than in untreated cells. In this project two independently 
sourced garlic oils were added to THP-1 human monocytic cells. Both garlic 
oils induced ARE-driven genes HO-1 and NQO1 and their primary regulator, 
Nrf2.  HO-1 was far more powerfully activated by the garlic oils than NQO1. 
This may be due to activation via different pathways that act synergistically 
to induce HO-1 but not NQO1, but it has been shown that  Nrf2-induced HO-
1 can be more powerfully increased than other ARE-driven genes (Rushworth 
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et al., 2006; Donovan et al., 2012), including by a specific Nrf2 activating 
peptide detailed in chapter 5 of this thesis. In this study it is explainable by 
the fact that the raw PCR data shows that basal levels of HO-1 are much 
lower than NQO1 in THP-1 cells, so while the fold induction of HO-1 higher, 
the actual production of both genes’ mRNA is very similar after incubation 
with the garlic oils.  
This data is consistent with the consensus that garlic oils do activate the Nrf2 
pathway. Interestingly Stringer, the garlic oil containing a higher total 
percentage of diallyl polysulfides, was more effective than Naturex in every 
experiment. The rest of this study focused on the effects of these diallyl 
polysulfides on the Nrf2 pathway in monocytes.  
Diallyl polysulfides are thought to be a major biologically active component 
of aged garlic extract and garlic oils. Many studies have noted the effects of 
diallyl sulfides on ARE dependent gene expression (Chen et al., 2004; Ho et 
al., 2012; Saidu et al., 2013), but none have done so in monocytes. This study 
identifies DATTS and DAPS as powerful inducers of the Nrf2 pathway in 
monocytes. Both were shown to induce Nrf2 protein expression and NQO1, 
Ferritin H, and HO-1 mRNA expression. A role for Nrf2 in the upregulation of 
some of these genes was confirmed by the upregulation of ARE-luciferase by 
DAPS, and inhibition of DAPS-induced HO-1 by Nrf2 siRNA. The most 
interesting aspect of these compounds was that comparing different diallyl 
polysulfides revealed a clear relationship between chain length and the size 
of HO-1 induction. In particular DAPS was over twice as powerful as DATTS. 
DAPS was also shown to be a more powerful inducer of NQO1 and ferritin 
than DATTS. This pattern is consistent with work showing that DATS is a more 
powerful activator of HO-1 and NQO1 mRNA than DADS and DAS in HepG2 
cells (Chen et al., 2004), but there are other studies showing the opposite. 
Fisher and co-workers (2007) found that DAS was an effective activator of 
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NQO1 in WKY rat liver and ARE-luciferase activity in C57BL6/J mice, but DADS 
and DATS were ineffective. The differences in effect may be due to the 
species used, or because Fisher and co-workers carried out their experiments 
in vivo. However, it should be noted that in the latter study the dose of DAS 
administered to the rats and mice was 3.75 times higher than DADS or DATS, 
and was also measured in mg/ kg body weight, which does not give a per 
molecule comparison of activity. In the present study, and that carried out by 
Chen and co-workers (2004), the diallyl polysulfide compounds were directly 
compared using equivalent molar concentrations.   
One notable advantage of this study is that it uses low concentrations of 
diallyl polysulfide compounds compared to some others, which have used 
concentrations greater than 100μM (Chen et al., 2004; Saidu et al., 2013; You 
et al., 2013). In this study DAPS induced HO-1 expression at concentrations as 
low as 5µM, which is important because long chain polysulfides are not as 
prevalent in garlic as short chain polysulfides. It is unknown why the long 
chain polysulfides are so effective, but there are a number of possibilities, 
and the most likely hypotheses involve ROS production, an established 
mechanism of Nrf2 activation (Numazawa et al., 2003; Li et al., 2014b), 
although other signalling mechanisms can’t be discounted. 
ROS are known to induce Nrf2 and p38 activation (Peus et al., 1999; 
Numazawa et al., 2003). Furthermore, diallyl polysulfides are inducers of ROS 
(Na et al., 2012; Chandra-Kuntal et al., 2013), and have been shown to induce 
hydrogen peroxide production in a manner that revealed a positive 
correlation between activity and polysulfide chain length in rat erythrocytes 
(Munday et al., 2003). NAC, a ROS scavenger blocks Nrf2 induction by DAS 
(Gong et al., 2004), DATS (Chen et al., 2004), and DATTS (Saidu et al., 2013), 
suggesting that this is a general mechanism by which diallyl polysulfides 
activate Nrf2. In this study NAC blocked DAPS-induced Nrf2 and HO-1 
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expression, showing that ROS act upstream of Nrf2. ROS induction by diallyl 
polysulfides is thought to be induced by metabolism of the parent 
compounds (reviewed in Munchberg et al., 2007). Therefore, ROS production 
is very likely to be a source of variation in the activity of the compounds, 
because the metabolism is known to differ for longer polysulfides.  
ROS production likely occurs due to the creation of hydropersulfide (RSSH) 
and hydropolysulfides (RSxH; x>2) when diallyl polysulfides containing three 
or more sulfurs react with a thiol (for example, GSH). RSxH (x≥2) can set off a 
chain of reactions with transition metal ions and O2 to produce O2
-. 
Furthermore, a perthiyl radical (RSx
) is produced (Chatterji et al., 2005). 
These can react with GSH to initiate a chain of reactions that not only 
produce O2
- but also recycle a polysufide molecule. Longer diallyl 
polysulfides may produce longer hydropolysulfides, which are considered 
more reactive (Munchberg et al., 2007), although production of 
hydropersulfides is considered more likely (Munday et al., 2003). Diallyl 
polysulfides with ≥4 sulfurs are also susceptible to homolytic bond cleavage, 
which produces yet more perthiyl radicals.  
If long chain polysulfides produce more perthiyl radicals and longer 
hydropolysulfides it is very likely that they produce more ROS, and therefore 
higher Nrf2 activation than short chain polysulfides. This has yet to be 
determined experimentally, however. 
Another possible mechanism which cannot be ignored is post-translational 
modification of the sulfurs in cysteine residues of Keap1. Keap1 is regulated 
by cysteine residues, which can be modified to prevent Nrf2 degradation 
(Zhang and Hannink, 2003; Wakabayashi et al., 2004; Wu et al., 2010; Hu et 
al., 2011). Diallyl polysulfides have been shown to modify cysteines in 
transient receptor potential cation channel, A1 (TRPA1) and β-tubulin 
(Hosono et al., 2005; Hinman et al., 2006). Recently Diallyl trisulfide has been 
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shown to modify cysteine residues in Keap1 (Kim et al., 2014). This reaction 
would likely produce a hydropolysulfide, which would cause ROS production. 
This mechanism of biological activity is considered an oversimplification of 
the complex chemistry capable by diallyl polysulfides (Munchberg et al., 
2007) but cannot be ruled out as a potential source of ROS production. This is 
almost certainly not the primary mechanism, however, because the ROS 
scavenger NAC and the p38 inhibitor SB203580 inhibited DAPS induced Nrf2 
expression. Instead, this suggests that there are signalling intermediates 
between the diallyl polysulfides and Keap1 cysteine modification. 
p38 is activated upstream of Nrf2 activation by a number of small molecules, 
including quercetin (Yao et al., 2007) and procyanidins (Bak et al., 2012). 
Importantly, p38 has also been shown to act upstream of Nrf2 in response to 
DAS in MRC-5 cells (Ho et al., 2012) and partially in HepG2 cells. This suggests 
that diallyl polysulfide compounds could act via a common pathway, 
although this hypothesis is challenged by Chen and co-workers (2004) who 
found that SB203580 did not affect DATS induced ARE-luciferase activity in 
HepG2 cells.  
It is apparent that many Nrf2 activators cause therapeutic effects via a 
negative feedback mechanism. The activator induces oxidative stress which 
activates the Nrf2 pathway. Nrf2 and its target genes then remove the stress 
caused by the inducer, and also provide other therapeutic effects that are 
required. This approach appears to work. Sulforaphane has anti-
inflammatory properties (Zhao et al., 2013b) and has been shown to activate 
Nrf2 via ROS production (Lee and Lee, 2011; Lee et al., 2012a). Quercetin and 
tBHQ have both been reported to induce oxidative stress (Lapidot et al., 
2002; Imhoff and Hansen, 2010) but are widely accepted to protect against 
oxidative stress (Eftekharzadeh et al., 2010; Ramyaa and Padma, 2013). 
Whether DAPS has a therapeutic effect is unknown. Short chain polysulfides 
174 
 
have all been shown to dampen inflammation. DAS inhibits gentamicin-
induced iNOS and TNF in Wistar rats (Kalayarasan et al., 2009), DADS inhibits 
LPS induced IL-1β and IL-6 in RAW264.7 cells (Shin et al., 2013), and DATS has 
been shown to inhibit LPS-induced IκBα phosphorylation and degradation, 
which leads to an inhibition of a number of pro-inflammatory mediators 
including TNF, IL-6 and MCP-1 in RAW 264.7 cells (You et al., 2013).  
In this study DAPS had no effect on LPS-induced TNF production and 
hydrogen peroxide induced cytotoxicity in THP-1 cells. This suggests that in 
this case Nrf2 activation caused by DAPS is insufficient to cause protection. 
This is an interesting result because clearly an increase in Nrf2 activation is 
not necessarily a guarantee of protective activity. It is possible that there is 
an optimal chain length that causes the highest ratio of Nrf2 activation to the 
stress required to achieve it. A lot of work has documented anti-cancer 
effects of diallyl polysulfides and while they protect against apoptosis via 
Nrf2 in some situations (Tsai et al., 2013b), they are also cytotoxic in others 
(Choi and Park, 2012; Chandra-Kuntal et al., 2013; Shin et al., 2013a). It may 
be that long chain polysulfides are more cytotoxic than short chain 
polysulfides, and it is entirely possible that despite the powerful effect on 
Nrf2 activation caused by long chain polysulfides, they are more suited for 
stress-inducing therapeutics such as anti-cancer therapy. Future work should 
focus on this relationship between chain length and activity because it is 
clearly more complex than the relationship seen with Nrf2 activation 
suggests. It is also very possible that DAPS has potential protective effects 
not investigated in this study, or that monocytes are a poor target for 
polysulfides. Finally, it is very interesting that almost all studies revealing an 
inhibitory effect of diallyl polysulfides on inflammatory mediators are 
conducted on mice and cell lines. Only a single study, which demonstrates an 
inhibition of COX-2 induced by IL-1β or monosodium urate crystals in OA 
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synovial cells and arterial chondrocytes, was conducted on human cells (Lee 
et al., 2009b).  
 In conclusion, garlic oils mainly composed of diallyl polysulfides activate the 
Nrf2 pathway in THP-1 cells. Comparing the diallyl polysulfides directly 
revealed that longer chain length resulted in a stronger induction of HO-1. 
DAPS is identified as a novel Nrf2 inducer, which signals via ROS and p38. 
However, it was unable to protect against LPS induced TNF or hydrogen 
peroxide induced cytotoxicity revealing a need to further investigate the 
relationship between polysulfide chain length and protective activity.  
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Chapter 5: Characterisation of the Nrf2/Keap1 
interaction as a drug target for inflammatory 
disease using a Neh2 peptide mimetic 
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5.1 Introduction 
 
Nrf2 is regulated by Keap1, an adaptor protein of the E3 ubiquitin ligase 
complex. When Nrf2 is bound to Keap1 it is targeted for degradation; if it is 
not continually degraded, it translocates to the nucleus to initiate 
transcription of its target genes (Cullinan et al., 2004). Nrf2 activation has 
been shown to inhibit pro-inflammatory mediators in vivo and in vitro, and 
relieve symptoms of inflammatory diseases in animal models, making it a 
promising therapeutic target (Rushworth et al., 2008; Kudoh et al., 2014). 
Indeed, bardoxolone methyl has recently been used in clinical trials for stage 
4 chronic kidney disease (de Zeeuw et al., 2013). The trial was stopped due to 
patient deaths, which is thought to be caused by increased fluid retention, 
leading to increased blood pressure and cardiovascular complications (Chin 
et al. 2014). These effects have not been attributed to Nrf2, and may be due 
to off-target effects of bardoxolone methyl. Most activators of the Nrf2 
pathway tend to do so via modification of cysteine residues in Keap1 and/or 
phosphorylation of Nrf2, but mechanistically this is not specific and can affect 
other proteins (Niture et al., 2009; Holland and Fishbein, 2010; Magesh et al., 
2012; Levonen et al., 2014; Wall et al., 2014). Therefore, inhibiting the 
Nrf2/Keap1 interaction using a competitive inhibitor may reduce side effects, 
and therefore lethality, of Nrf2-targeted therapeutics. 
The sequences of Nrf2 that bind Keap1 are highly conserved. One molecule 
of Nrf2 binds a Keap1 homodimer using two sequences in the Neh2 domain. 
One binding sequence is a strong binding ETGE motif, whereas the other is a 
weaker binding DLG motif. Both use the same binding site in the DGR region 
of Keap1’s Kelch domain (Tong et al., 2006).  
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Designing a small molecule to inhibit the Nrf2/Keap1 interaction is complex, 
even before time and cost are even considered. The binding site is large, 
polar and in a recent screen of 337,116 compounds in vitro, only two were 
shown to inhibit Nrf2 binding with an IC50 value of <2μM, and one of those is 
a predicted Michael acceptor (Wang et al., 2012a). A simple approach to 
validate the Nrf2/Keap1 interaction as a drug target before the academic 
field becomes too invested in the problem would be to use a peptide 
mimetic. The effect of peptides on the Nrf2/Keap1 interaction has been 
investigated in a chitin pull-down assay. Sequences of 10, 14, or 16 amino 
acids long (Table 5.1) were added to samples containing isolated Keap1/Nrf2. 
The 16mer and 14mer displaced Nrf2 much more strongly than the 10mer 
(Lo et al., 2006), suggesting that they may act as effective activators of the 
Nrf2 pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Keap1-targeting peptide sequences. For TAT-conjugated peptides, the TAT 
sequence is bound to the N-terminus. 
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Peptides are too large to diffuse across the cell membrane. However, specific 
peptide sequences can activate membrane transport mechanisms in order to 
shuttle large molecules in or out of the cell. One such mechanism is that used 
by the HIV protein Tat (transcription-transactivating protein). This protein 
contains an 11 residue sequence that causes cell penetration by endocytosis 
(Deshayes et al., 2005). By adjoining this TAT sequence to the Neh2 peptides, 
they should enter the cell by the same mechanism. The design of a cell-
penetrating peptide targeted to the Nrf2/Keap1 interaction will not only 
validate Nrf2 as a drug target, but will also be a valuable molecular biology 
tools to study Nrf2 activation. This study investigates cell-penetrating Neh2 
mimetic peptides in THP-1 monocytes. 
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5.2 Aims 
Hypothesis: Peptides mimicking the Keap1 binding sequence of the Neh2 
domain induce expression of Nrf2 and its target genes, and inhibit LPS-
induced cytokine production.    
 
Aims: 
 To verify that mimetic peptides matching the Keap1 binding sequence 
of the Neh2 domain of Nrf2 are biologically active. 
 
 To find the optimum peptide length for biological activity. 
 
  To provide a tool to activate Nrf2 with minimal non-specific activity. 
 
 To validate the Nrf2-Keap1 interaction as a potential drug target. 
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5.3 Results 
5.3.1 TAT-14 is a cell penetrating peptide that binds to Keap1 
To investigate the effects of Neh2 mimetic peptides on the Nrf2 pathway in 
THP-1 cells, they were conjugated to the TAT cell penetration sequence and 
tested for induction of HO-1 mRNA. HO-1 is a well characterised Nrf2 target 
gene, which can be induced by Nrf2 activation in THP-1 cells, and RT-qPCR 
can quantify the differences between the peptides (Rushworth et al., 2008). 
THP-1 cells were incubated with 75 μM TAT-10, TAT-14, or TAT-16 for either 
3h or 6h. Total RNA was extracted and measured for HO-1 expression by qRT-
PCR.  Of the three peptides, the most active was TAT-14 (Fig 5.1A), causing a 
rapid induction of HO-1 mRNA as early as 3h (3.5 fold; p<0.01), and a peak 
20.3 fold induction at 6h (p<0.01). TAT-16 also induced HO-1 expression, 
which was also highest at 6h. However, TAT-16 only induced HO-1 mRNA by 
6.3 fold (p<0.001), indicating that TAT-14 was three times more powerful 
(p<0.001). TAT-10 did show mild activity, but was by far the least active of 
the peptides. TAT-10 was the only peptide to have no effect at 3h, and 
showed a modest 2.6 fold induction at 6h (Not significant; p>0.05).  
Due to the fact that the 16mer has been previously shown to be the 
strongest disruptor of the Nrf2/Keap1 interaction (Lo et al., 2006), THP-1 cells 
were incubated with TAT-16 for an extended time course to find out whether 
it acts more slowly than TAT-14. The results show that TAT-16 was not as 
effective as TAT-14 at any time point (Fig 5.1B). The most active peptide, 
TAT-14, was taken forward for further experiments. 
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The interaction between two molecules of different sizes can be measured in 
vitro by fluorescence polarization. To verify that TAT-14 and 14mer can bind 
to Keap1, they were added to a solution containing Keap1, and a fluorescent 
14mer (F-14). Measuring the fluorescence polarization revealed that both 
peptides were able to displace F-14, showing that they are capable of binding 
Keap1 (Fig 5.2). Ki was calculated for both peptides, which revealed that TAT-
14 bound Keap1 more strongly than the 14mer (Ki = 3.628 and 12.24 nM 
respectively).  
Fig 5.1 TAT-14 is the most active disruptor of the Nrf2/Keap1 interaction. (A) 75 μM TAT-
10, TAT-14, and TAT-16 were incubated with THP-1 cells for 3 or 6h. (B) THP-1 cells were 
incubated with 75 μM TAT-16 for up to 24h. PBS was used as a vehicle control. HO-1 mRNA 
was measured by RT-qPCR. Mean ±SEM, n=3 (A) or n=1 (B); ***p<0.001; One way ANOVA 
with a Tukey’s multiple comparison test. 
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5.3.2 TAT-14 activates the Nrf2 pathway 
Fig 5.1 and 5.2 suggest that TAT-14 induces HO-1 by binding Keap1. In order 
to verify that this is a specific mechanism, a control peptide was created. The 
control peptide, TAT-sc, consists of the TAT cell penetration sequence linked 
to a scrambled arrangement of the 14mer peptide and therefore this peptide 
should enter the cell, but not bind Keap1. The ability of the peptides to 
disrupt the Nrf2/Keap1 interaction in THP-1 cells can be shown by measuring 
Nrf2 protein expression because the Nrf2/Keap1 interaction is required to 
prevent accumulation of Nrf2. THP-1 cells were incubated with 75μM TAT-14 
or TAT-sc for 1, 3 or 6h. Cell lysates were prepared and probed for Nrf2 
Fig 5.2 14mer and TAT-14 both bind Keap1. Varying concentrations of the (A) 14mer or (B) 
TAT-14 was added to a complex of Keap1 and F-14. Fluorescence polarization was recorded 
as a measure of Keap1 binding. Ki was calculated using non-linear regression (C). Results 
show n=3.  
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expression by Western immunoblotting. TAT-14 induced Nrf2 by 1h, which 
peaked at 3h and returned to basal levels by 6h (Fig 5.3). In contrast TAT-sc 
did not induce Nrf2 protein. This suggests that the induction of Nrf2 is due to 
the specific sequence of the 14mer, rather than a non-specific stress 
response caused by the addition of a cell penetrating peptide.  
 
 
 
 
 
 
 
 
Due to the fact that Nrf2 protein peaked at 3h, and the time delay between 
the peaks in Nrf2 protein and HO-1 mRNA can be as much as 9h (Park et al., 
2011b), a more thorough time course was conducted for HO-1 mRNA 
expression. TAT-sc was used as a control for Nrf2 independent HO-1 
expression. The 14mer without TAT was also added to show whether the 
peptide was able to penetrate the cell membrane alone. 
THP-1 cells were incubated with each peptide for 2, 4, 6, or 8h and HO-1 
mRNA was measured by qRT-PCR. TAT-14 powerfully induced HO-1 mRNA 
expression (Fig. 5.4) with a rapid 5-fold induction at 2h (p<0.001) and peaked 
at 6h with a 23.9-fold induction (P<0.001). HO-1 levels decreased again at 8h 
(11.7-fold; p=0.01). Although TAT-sc caused a small induction at 6h, it was 
not significant (2.9 fold; p>0.05), and was 8 fold less effective than TAT-14 
Fig 5.3 TAT-14 induces Nrf2 protein expression. THP-1 cells were incubated with 75 μM 
TAT-14 or TAT-sc for 1, 3, or 6h. Nrf2 expression in cell lysates was measured by Western 
immunoblotting. β-actin was used as a loading control. Data shown is representative of 
three independent experiments; replicates are shown in Appendix II. 
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(p<0.001). This indicates that the induction of HO-1 by TAT-14 is sequence 
specific. The 14mer did not induce HO-1 at all at any time point, revealing 
that the TAT sequence is necessary for activity. 
 
 
 
 
 
To test whether the increased HO-1 mRNA translated into protein, THP-1 
cells were incubated with either TAT-14 or TAT-sc. Cell lysates were prepared 
and probed for HO-1 protein expression by Western immunoblotting. 
Incubation with TAT-14 caused an increase in HO-1 protein expression at 9h, 
which peaked at 12h (Fig 5.5). HO-1 protein returned to basal levels by 16h. 
TAT-sc did not induce HO-1 protein at any time point tested. 
 
 
 
 
Fig 5.4 TAT-14 induced HO-1 mRNA expression peaks at 6h. THP-1 cells were incubated 
with 75 μM of the indicated peptide for up to 8h. PBS was used as a vehicle control. HO-1 
mRNA expression was measured by RT-qPCR. Mean ±SEM, n=3; *p<0.05, **p<0.01, 
***p<0.001; One way ANOVA with Tukey’s multiple comparison test. 
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TAT-14 is effective at 75μM, but compounds effective at lower 
concentrations are advantageous because they are cheaper to use, and are 
less likely to cause side effects. Therefore, TAT-14 was tested at a range of 
concentrations. THP-1 cells were incubated for 6h with 7.5-75μM TAT-14. 
HO-1 expression was measured by qRT-PCR.   
75μM TAT-14 was disproportionately more powerful than the lower 
concentrations (Fig 5.6). With a 32.5-fold induction over control (p<0.05), it is 
4.4 fold more powerful than 37.5 μM despite only having double the number 
of peptide molecules, although the difference between the two is not 
statistically significant (p>0.05). The lowest concentration of TAT-14 that 
induced HO-1 is 18.75 μM, which gave a 2.3-fold induction over control cells 
(not significant; p>0.05).   
Due to its effectiveness at 75μM, TAT-14 was used at this concentration for 
the remainder of the project. 
 
Fig 5.5 TAT-14 induces HO-1 protein expression. THP-1 cells were incubated with TAT-14 
or TAT-sc for 9, 12, or 16h. HO-1 expression in cell lysates was measured by Western 
immunoblotting. β-actin was used as a loading control. Data shown is representative of 
three independent experiments; replicates are shown in Appendix II. 
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HO-1 is one of many Nrf2 driven genes. Other Nrf2-driven genes NQO1 and 
ferritin are also well documented to be responsible for cytoprotective effects 
(Kleszczynski et al., 2013; Liang et al., 2013; Versellotti et al., 2014). The 
effects of TAT-14 and TAT-sc on NQO1 and Ferritin H mRNA expression were 
tested by incubating THP-1 cells with 75μM of each peptide for up to 8h.  
Following TAT-sc incubation neither gene was significantly induced, whereas 
after incubation with TAT-14 both NQO1 and Ferritin H mRNA levels were 
significantly increased over control with a 5.5-fold (P<0.01) and 3.2-fold 
(p<0.001) induction respectively (Fig 5.7). These results show that TAT-14 
activates multiple Nrf2-driven genes.  
Fig 5.6 TAT-14 activates HO-1 mRNA in a concentration dependent manner. THP-1 cells 
were incubated with varying concentrations of TAT-14 for 6h. HO-1 expression was 
measured by RT-qPCR. Mean±SEM, n=3; *p<0.05; One way ANOVA with Tukey’s multiple 
comparison test. 
188 
 
 
 
 
 
 
 
 
Fig 5.7 TAT-14 induces NQO1 and Ferritin mRNA. THP-1 cells were incubated with 75μM of 
the indicated peptide for 8h. RNA was extracted and RT-qPCR was used to measure (A) 
NQO1 expression, or (B) Ferritin expression. Mean ±SEM, n=3; **p<0.01, ***p<0.001; One 
way ANOVA with Tukey’s multiple comparison test. 
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5.3.3: Anti-inflammatory effects of TAT-14 in THP-1 cells 
Activation of Nrf2 results in suppression of inflammation, making the 
Nrf2/Keap1 interaction a potential drug target.. However, the effects of 
activating Nrf2 using an inhibitor of the Nrf2/Keap1 interaction to dampen 
the inflammatory response are unknown. Therefore, THP-1 cells were 
stimulated with 75μM TAT-14 or TAT-sc for 4h before addition of 10μg/mL 
LPS for 4h. Supernatants were prepared and soluble TNF levels were 
measured by ELISA. Fig 5.8 demonstrates that LPS induced TNF production 
(524 pg/mL TNF), which was significantly inhibited by the presence of TAT-14 
(339 pg/mL TNF, p=0.0438; t-test). Interestingly, TAT-sc slightly increased TNF 
expression, although this was not statistically significant, suggesting that 
although it does not activate the Nrf2 pathway, there is a chance that it is not 
biochemically inert. 
 
 
 
 
Fig 5.8 TAT-14 inhibits LPS induced soluble TNF protein expression. THP-1 cells were 
incubated with TAT-14 or TAT-sc for 4h prior to 50ng/mL LPS for 4h. Supernatants were 
prepared, and TNF expression was measured by ELISA. Mean ±SEM, n=3; *p<0.05; 
student’s t-test. 
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In order to test whether TAT-14 inhibits LPS induced TNF at the mRNA level, 
THP-1 cells were incubated for 4h prior to addition of LPS for 4h. TNF mRNA 
expression was measured by qRT-PCR. Fig 5.9a shows that TNF mRNA is 
decreased by approximately 66% when LPS is added in the presence of TAT-
14 compared to LPS alone (Fig 5.9A; p=0.05). LPS-induced TNF in monocytes 
is driven by NF-κB (Yao et al., 1997). Therefore, the effect of TAT-14 on LPS-
induced IL-1β mRNA was also tested. THP-1 cells were incubated with 75 μM 
TAT-14 or TAT-sc for 4h before addition of LPS for 4h. IL-1β mRNA was 
measured by qRT-PCR. TAT-14 inhibited LPS induced IL-1β mRNA by 39% (not 
significant; Fig 5.9B).  
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Fig 5.9 TAT-14 inhibits TNF mRNA expression. THP-1 cells were incubated with 75 μM TAT-
14 or TAT-sc for 4h before addition of 10 μg/mL LPS. (A) TNF mRNA expression and (B) IL-
1β expression were measured by RT-qPCR. Mean ±SEM, n=3; **p<0.01; One Way ANOVA 
with Tukey’s multiple comparison test. 
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5.4 Discussion 
Nrf2 activity is primarily regulated by the Nrf2/Keap1 interaction. Disruption 
leads to expression of Nrf2, and upregulation of cytoprotective genes (Itoh et 
al., 1999). However, the Keap1 interaction is redox sensitive, and the vast 
majority of Nrf2 activators do so through modification of Keap1 cysteine 
residues by electrophiles and oxidative stress. These are non-specific reactive 
molecules that can cause off-target effects (Levonen et al., 2014). 
Competitive inhibition of the Nrf2 binding site on Keap1 may increase 
specificity for Nrf2 activation. This study identified TAT-14 as the most 
biologically active of three cell-penetrating Neh2 mimetic peptides. TAT-14 
was shown to directly bind the Kelch domain of Keap1 in vitro, and induce 
Nrf2 protein expression in THP-1 monocytes. TAT-14 induced ARE-driven 
genes, HO-1, NQO-1, and ferritin H. In addition, TAT-14 downregulates LPS-
induced TNF expression in THP-1 monocytes. This study shows for the first 
time that a competitive inhibitor of Keap1 activates Nrf2 in monocytes, and 
has anti-inflammatory properties. This suggests that TAT-14 is a useful tool in 
studying Nrf2 activation, and that Keap1 inhibition might be a viable strategy 
in combating inflammatory diseases. 
Inhibiting the Nrf2/Keap1 interaction was attempted by producing peptide 
sequences homologous to the Keap1 binding sequence in the Neh2 domain 
of Nrf2. Testing the three peptides TAT-10, TAT-14, and TAT-16 in THP-1 cells 
revealed that TAT-14 was the most effective activator of HO-1. TAT-10 was 
the least effective – it is possible that it does not bind as well to Keap1, and 
this is confirmed by Lo et al (2006) who purified the Nrf2/Keap1 complex by 
chitin pull-down assay, and then added the 10mer, 14mer, and 16mer 
peptides to show that they displace Nrf2 from the complex (measured by 
Western blotting). This in vitro assay showed that the 10mer is the least 
active peptide, showing inhibition of Nrf2/Keap1 after addition of 1μg of the 
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peptide to the sample, where both the 14mer and 16mer show similar 
activity with 100ng. The effect of the 10mer is probably exaggerated in this 
experiment because it is the smallest peptide, meaning that there are more 
molecules per gram.  TAT-16 was less effective than expected. The 16mer is 
the strongest binding peptide in vitro, but in THP-1 cells it is unable to 
produce the same effect. TAT-16 is very different from TAT-14. It contains an 
extra AFFAQ on the N-terminus, and misses PIQ on the C-terminus of the 
Keap1-binding sequence. It is possible that there is interference between the 
TAT and 16mer caused by the N-terminal amino acids or lack of the PIQ 
sequence, which could affect either cell penetration or Keap1 binding. TAT-
14 is the only peptide that shows strong effects in both THP-1 cells and in 
vitro binding assays. Due to the high bioactivity of TAT-14, neither TAT-10 nor 
TAT-16 was investigated further. 
Induction of HO-1 does not indicate that TAT-14 is a competitive inhibitor of 
Nrf2. Therefore, fluorescence polarization was used to show that TAT-14 
binds to the kelch domain of Keap1. This was measured by using TAT-14 or 
the 14mer to displace a FITC-conjugated 14mer from the Kelch domain in 
vitro. TAT-14 bound Keap1 strongly, with a Ki of 3.628 nM. Interestingly this 
is stronger than the 14mer. This is not undesirable – an improvement on the 
binding affinity of the native sequence is a good thing, but from a drug design 
perspective it is important to understand why it occurs. It is possible that the 
TAT sequence stabilises the ETGE β-turn structure required for Keap1 
binding.  
Under basal conditions, Nrf2 is constitutively produced and degraded (Zhang 
and Hannink, 2003). The Nrf2/Keap1 interaction is necessary for degradation 
of Nrf2. Therefore, when the Nrf2/Keap1 interaction is inhibited, the amount 
of cellular Nrf2 increases. TAT-14 increases cellular Nrf2, whereas TAT-sc 
does not. Coupled with the FP data, this suggests that TAT-14 is disrupting 
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the Keap1/Nrf2 interaction. Importantly, TAT-sc did not produce the same 
effects, showing that TAT-14 activity is sequence specific. There are two 
mechanisms by which the Nrf2/Keap1 interaction can be inhibited. The first 
is disruption of the DLG/Kelch interaction, which inhibits Keap1-induced 
degradation of Nrf2 (Katoh et al., 2005; Baird et al., 2013). The other is 
disruption of the ETGE/Kelch interaction, which is the high affinity binding 
sequence of Nrf2 (Tong et al., 2006b). TAT-14 almost certainly acts through 
inhibiting the ETGE motif because the Keap1 protein used in the FP assay 
contains no dimerization site, and the F-14 peptide only contains an ETGE 
motif.  Therefore, the displacement of F-14 caused by TAT-14 in the 
fluorescence polarization assay is an inhibition of the strong-binding ETGE 
motif. There is no evidence to suggest that it doesn’t use the same 
mechanism to displace Nrf2 in THP-1 cells. 
Induction of HO-1, Ferritin and NQO1 mRNA indicates that the increased 
cellular Nrf2 is functional. All three genes are Nrf2-driven, suggesting that 
Nrf2 transcription partners are either already present in the nucleus, or that 
their presence is Nrf2-dependent. TAT-14 is an effective inducer of HO-1 
expression in THP-1 cells; less effective per molecule than curcumin, but 
more effective than alpha-lipoic acid and epigallocatechin (Ogborne et al., 
2005; Rushworth et al., 2006; Ogborne et al., 2008). At low concentrations, 
however, TAT-14 was ineffective. There could be a number of reasons for 
this. In cellular assays Keap1 is accessible only by bypassing cell membranes. 
Even with a cell penetration sequence TAT-14 may not enter cells as 
efficiently as small molecules. Furthermore, in cellular assays the Keap1 
concentration is unknown. Cells also have thousands of molecules that can 
potentially interfere with binding efficiency, and it is already well-known that 
short peptides are rapidly degraded by proteases (Pernot et al., 2011). The 
ratio of TAT-14 to Keap1 molecules could be quite low once these factors 
have been taken into account. Another factor that could lower the efficiency 
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of TAT-14 is its mode of action. One of the key features of signalling 
pathways, especially those that involve degradation products and ROS, is 
signal amplification. TAT-14 should not activate Nrf2 via signalling pathways, 
and therefore there will be no amplification of the signal upstream of this. 
One molecule of TAT-14 binds one molecule of Keap1. However, Nrf2 binds 
Keap1 in a 1:2 ratio, meaning that for every two molecules of TAT-14 only 
one molecule of Nrf2 is activated.  It is possible that, to some extent, lack of 
reactivity is the price to pay for target specificity. 
Nrf2 knockout mice are susceptible to inflammatory diseases such as sepsis 
(Thimmulappa et al., 2006; Kong et al., 2010), which has led to research into 
small molecules that may activate Nrf2 and inhibit inflammation. Although 
there has been some measure of success with small molecules (Kalayarasan 
et al., 2009;  Kim et al., 2013; Zhao et al., 2013b; Ramyaa et al., 2014), none 
of these are specific activators of Nrf2. In this study the effect of TAT-14 on 
inflammatory mediators was investigated in THP-1 cells. The results showed 
that TAT-14 inhibits TNF mRNA production by 66%. This does have an effect 
on protein production; soluble TNF protein was inhibited by 35%. It is 
possible that the discrepancy between mRNA and protein production is due 
to the fact that the ELISA does not measure membrane-bound TNF. IL-1β was 
also inhibited at the mRNA level, although the effect was not statistically 
significant. These data suggest that Nrf2 plays a large role in dampening the 
immune response upstream of gene transcription, and therefore support the 
hypothesis that the Nrf2/Keap1 interaction is a good drug target.  
This study shows that competitive inhibition of the Nrf2/Keap1 interaction 
using TAT-14 is a viable strategy in inhibiting production of inflammatory 
mediators. Non-competitive mechanisms of inhibiting the Nrf2/Keap1 
interaction tend to have a common problem. This is that Nrf2 is a stress 
sensor which acts as part of a negative feedback system in which cellular 
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stress pathways activate Nrf2, causing a subsequent decrease in stress. Many 
of the well-characterised small molecules that activate Nrf2 do so by 
activating cell signalling pathways, or increasing ROS production (Rushworth 
et al., 2006; McNally et al., 2007; Lee and Lee, 2011), which are common 
activators of many cell signalling pathways. This is highlighted by the fact that 
the Nrf2 activator bardoxolone methyl has just been pulled from clinical trials 
for type-2 diabetes and stage 4 chronic kidney disease because patients given 
the drug were found to be more susceptible to serious cardiovascular side-
effects, including heart failure compared to those given a placebo (de Zeeuw 
et al., 2013). Whether this is caused by Nrf2 is unknown because 
bardoxolone methyl is not a specific activator of the Nrf2 pathway (Gao et 
al., 2013), and many have argued that the adverse effects could have been 
predicted (Thomas, 2012; Rossing, 2013; Zhang, 2013). TAT-14 is designed to 
bind Keap1 specifically in order to keep non-specific interactions to a 
minimum. Therefore, any negative side effects should be a direct result of 
Nrf2 activation. This means that further work involving TAT-14 will either 
validate Nrf2 as a drug target and maybe even TAT-14 as a viable drug, or it 
will be a valuable tool that can provide insight into any disadvantages of 
activating Nrf2.  
One limitation with this study is that, short of running experiments on every 
protein in the human genome, it is almost impossible to prove that TAT-14 is 
a specific activator of Nrf2. Measures have been taken to ensure its 
specificity as much as possible. It is homologous to the Keap1-binding region 
of Nrf2, it has been shown to bind Keap1, and the scrambled peptide does 
not exhibit similar activity. However, this study does not account for the fact 
that there are other proteins, including IKKβ and Bcl-2, which use the same 
binding pocket of Keap1 as Nrf2. The effect of TAT-14 on these mediators is 
unknown, and is the minimal amount of future work required to verify its 
specificity. It is likely that because TAT-14 contains the exact binding 
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sequence of Nrf2, any other mediators that are affected by it will also be 
affected by any other drug that inhibits the Nrf2/Keap1 interaction by the 
same mechanism. This does not apply to the TAT sequence. TAT is assumed 
throughout this study to have little biological activity beyond cell 
penetration. There is no evidence to suggest that it should have adverse 
effects, but the FP assay revealed that TAT-14 binds Keap1 more strongly 
than the 14mer alone suggesting that it is not entirely inert.  
Although THP-1 cells are a good model cell line for inflammation, TAT-14 
needs to be validated in primary human monocytes in order to confirm that 
its effects are physiologically relevant (Rushworth et al., 2005; Rushworth et 
al., 2008). Testing it in other tissue types would also be advantageous 
because Nrf2 is a key regulator implicated in protecting against a wide range 
of diseases including neurodegenerative diseases (Ryu et al., 2013), and 
cancer (Bishayee et al., 2011). Whether TAT-14 has potential to be used in 
animal research is unknown. One study has shown that TAT conjugated 
peptides similar to the ones used in this study improve brain injury in mice 
after being directly injected into the affected tissue, but more thorough work 
could be done on different delivery methods and bodily distribution (Zhao et 
al., 2011). The final limitation is that TAT-14 may only be useful in cells with 
fully functional Keap1. Cell lines with Keap1 mutations include NCI-H1184 
and NCI-H1648 lung cancer cells (Padmanabhan et al., 2006), which contain 
mutations in the Kelch domain that reduces Nrf2 binding. TAT-14 may not be 
able to activate Nrf2 in these cells because the same mechanisms that 
prevent sequestration of Nrf2 should also apply to TAT-14, although this has 
not been determined experimentally. In addition other cell lines, including 
A549 cells and NCI-H460 cells, have silenced Keap1 expression (Wang et al., 
2008b). A Keap1 targeting peptide would likely be ineffective in these cells.  
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The current work shows that TAT-14 activates the Nrf2 pathway, binds 
Keap1, and inhibits LPS-induced inflammatory mediators in THP-1 cells. 
Future work can expand on this research in two broad directions. The first is 
finding a more drug-like molecule to target the Nrf2/Keap1 interaction. The 
second is to use TAT-14 to further characterise the effects of targeting the 
Nrf2/Keap1 interaction.   
The long term goal of inhibiting the Nrf2/Keap1 interaction is to produce 
therapeutics to increase cytoprotection and decrease toxic insult. Diseases in 
which these are major factors include inflammatory and neurodegenerative 
diseases (Hsieh and Yang, 2013; Marques et al., 2014; Wu et al., 2014). 
Classically, there have been criticisms of peptides as drugs. Aside from being 
expensive to make peptides have poor oral uptake and have issues entering 
tissues in vivo (especially crossing the blood-brain barrier). Small peptides are 
also prone to degradation. In cell culture studies this isn’t huge problem, but 
in vivo the drug has to reach its target tissue. This poses a particular problem 
with oral delivery of a drug because it must bypass the digestive tract 
without degradation (Gupta et al., 2013). 
Small molecules may overcome some or all of these issues, but finding a 
small molecule inhibitor of the Nrf2/Keap1 interaction is a difficult task. The 
main approaches have been to modify Nrf2 mimetic peptides to find 
improved binding sequences, or to screen libraries of compounds by FP 
assay. The former approach was undertaken by Hancock and co-workers 
(2012), who formed a fusion peptide from the 7-amino acid long Keap1 
binding sequences of Nrf2 (DEETGEF) and sequestosome-1 (DPSTGEL). The 
resulting peptide (DPETGEL) showed stronger binding than either of the 
native peptides by FP assay. Interestingly the core ETGE sequence could not 
be improved upon, suggesting that any small molecules that could be made 
should at least be large enough to mimic this sequence. The same group 
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went on to show that activity could be improved further by modifying n-
terminal conjugates to become more lipophilic (Hancock et al., 2013).  
Although these studies offer important insights into the chemistry of the 
Nrf2-Keap1 interaction, progress towards a small molecule inhibitor using 
this method has not progressed quickly. Screening libraries of compounds is 
another method, which has shown more promise. In a recent screen of 
337,116 compounds a single molecule has been considered to be a promising 
lead (Wang et al., 2012a) with Keap1 binding activity and predicted non-
reactivity. An independent study of a similar scale found several compounds 
that bind Keap1, but only one showed biological activity (Zhuang et al., 
2014). Although these are important discoveries, such a low hit-rate is 
worrying considering the amount of work that still needs to be done before 
the molecule can be considered anywhere near ready for therapeutic use. 
Despite the focus on small molecules, there is still hope for a peptide based 
solution. Despite the criticisms of peptides, these arguments are made 
almost redundant by the fact that there are over 100 peptide drugs licensed 
for medical use for the treatment of a wide range of medical conditions 
including type 2 diabetes and hypertension (Craik et al., 2013). Keap1 
targeting peptides have been shown to reduce damage to the blood-brain 
barrier after traumatic brain injury in mice (Zhao et al., 2011). The peptides in 
the study were TAT-14 with an extra proline residue between the TAT and 
14mer, and TAT-10 with a calpain cleavage sequence between the TAT and 
10mer. The calpain cleavage site was added to take advantage of the 
ubiquitously expressed cleavage protein, calpain, and was intended to 
remove the TAT from the 10mer to prevent any interference with its ability 
to bind Keap1. Interestingly TAT-14 with proline did not show any biological 
effects but TAT-CAL-10 induced ARE driven gene expression and protected 
against tissue damage from traumatic brain injury. Although the work is 
promising for the use of peptides as drugs, it also highlights two weaknesses 
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with the approach. Firstly, altering the peptide sequence to achieve cell 
penetration is both necessary and has the potential to block activity of the 
peptide. This is highlighted by the differences in the results between the 
present study and the work by Zhao and co-workers. The 10mer has 
biological activity in the mouse study, but not in this study. This is probably 
because in this study TAT is still attached at the point of Keap1 binding. 
Secondly, the peptides were injected directly into the brain in order to 
bypass the blood brain barrier. This is not a practical method of drug delivery. 
However, these problems are not insurmountable. Optimisation of peptide 
sequences and cell penetration motifs have not been extensively studied 
with Keap1 inhibitors in cells or animal models. In addition, drug delivery 
research into using nanoparticles as drug delivery mechanisms is ongoing, 
and may solve problems with bioavailability in the future (Chatterjee et al., 
2014). 
In addition to potential therapeutic advantages, TAT-14 can be used as a tool 
to study specific activation of the Nrf2 pathway. This study has directly led to 
the commercial production of TAT-14 by several biotechnology companies 
including Tocris (catalog number: 4811), and Merck Millipore (catalog 
number: 492042). TAT-14 can be used to extend this project in several ways. 
Most importantly, it can be used to simulate the effects of a future drug 
targeting the Nrf2/Keap1 interaction. Diseases where one such drug could be 
of therapeutic benefit, side effects, and mechanisms of action can all be 
predicted with TAT-14. There are also immediate questions about Nrf2 
signalling in inflammation that TAT-14 can help answer. Testing the effect of 
TAT-14 on other Keap1 substrates will help to verify the specificity of Keap1 
as a drug target. It is possible that the effect on some of these mediators will 
be marginal because their binding affinity for Keap1 is orders of magnitude 
lower than Nrf2 (Hancock et al., 2013). Once this is established further 
experiments can be done to elucidate the source of the anti-inflammatory 
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activity of TAT-14. There are several proposed mechanisms by which Nrf2 
could dampen the inflammatory response. The first is via its target genes, 
which have been implicated in protection against various inflammatory 
diseases (Yeligar et al., 2010; Shyur et al., 2011). This can be considered 
unlikely in the case of TAT-14 because the kinetics of ARE gene induction and 
anti-inflammatory activity don’t match. The second is by affecting Keap1 
binding partners, which include IKKβ and NF-κB itself (Lee et al., 2009a; Kim 
et al., 2010; Yu et al., 2011). The third is by cross talk between Nrf2 and NF-
κB signalling, potentially involving competition with the transcriptional co-
factor CBP (Liu et al., 2008; Ziady et al., 2012). Studying upstream activators 
of TNF should be the focus of this future study. Confirming a role for NF-κB, 
and finding out which part of the pathway the inhibition occurs at could help 
to understand how Nrf2 confers anti-inflammatory activity. Using co-
immunoprecipitation to test the effects of TAT-14 on the binding between 
IKKβ or NF-κB and Keap1 would be a good initial experiment to confirm 
whether these interactions play a role in the activity of TAT-14. 
Another interesting project would be to research the effects of long-term 
treatment with a Keap1 inhibitor. The effects of TAT-14 are transient, but 
either repeated stimulations or expressing it in a plasmid could provide 
sustained activation. Finally, Nrf2 is a promising target for lots of diseases. 
This project has focused on inflammatory effects, and a similar peptide has 
shown benefits in traumatic brain injury (Zhao et al., 2011). However, 
neurodegenerative diseases, cancer, and diabetes (Lastres-Becker et al., 
2012; Kavitha et al., 2013; Xu et al., 2014a) all show roles for Nrf2, and TAT-
14 could be used to verify the Nrf2/Keap1 interaction as a drug target in 
these diseases. 
In conclusion, TAT-14 is a peptide which specifically activates Nrf2, causing 
powerful induction of ARE-containing genes. It is anti-inflammatory in THP-1 
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monocytes, suggesting that developing the Nrf2/Keap1 interaction is a good 
drug target worthy of further research. TAT-14 itself may have potential as 
an anti-inflammatory drug, and could be used heavily in the future 
development of Keap1 inhibitors. Furthermore, TAT-14 is commercially 
available for use as a tool to study the Nrf2 pathway before more drug-like 
molecules are developed.  
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Chapter 6: The effects of Nrf2 over-expression on 
chemoresistance in malignant melanoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements: 
Dr Vicky Sherwood provided the HEMa-LP melanocytes and the melanoma cell lines 
(originally a gift from Antoni Ribas, UCLA).   
Gabriela Cabral, a project student, performed the experiments in Figs 6.3A and B, 
6.4A and B, 6.5A and B, 6.8A, 6.9A, and 6.10A. 
204 
 
6.1 Introduction 
Malignant melanoma is a form of skin cancer that affects melanocytes, which 
are cells that produce the pigment melanin. Although melanocytes are most 
commonly found in the stratum basale of the skin, they are also located in 
other areas of the body such as the bones, inner ear and eyes (Wakamatsu et 
al., 2008; Zhang et al., 2012b; Ye et al., 2013). Over 13, 000 people were 
diagnosed with malignant melanoma in 2011 in the UK. In comparison to 
other skin cancers it is rare (over 100,000 people were diagnosed with non-
melanoma skin cancer in 2011), but far more deadly; out of 2794 deaths 
caused by skin cancer in the UK in 2011, 2209 (79%) were melanoma patients 
(CRUK., 2014c). 
Early diagnosis of melanoma almost always results in successful recovery 
from the disease. The usual treatment is surgery, which has an extremely 
high success rate. 20-year survival is about 90% for stage I melanomas and 
80% for stage II melanomas (Lee et al., 2013d). Unfortunately, melanoma has 
a tendency to aggressively metastasise and once this has occurred, surgery is 
often no longer an option. Melanoma is highly resistant to chemotherapy 
and radiotherapy, and patients that have unresectable stage IV (Table 6.1) 
melanoma have approximately 5-10% survival rate for 5 years after 
diagnosis, and even those whose melanomas are operable still only have 
about a 15-30% 5-year survival rate (Wevers et al., 2013). 
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A common problem with cancer treatment is that mechanisms which normal 
cells use to protect themselves from damage are hijacked by cancer cells, 
providing resistance to chemotherapy and radiotherapy. This is almost 
certainly the case in melanoma cells, which contain high concentrations of 
melanin. Melanin is a blanket term to describe a group of tyrosine-derived 
pigment compounds in a variety of organisms that are responsible for skin 
colour, freckles, and play a role in eye colour (Stamatas et al., 2004; 
Wakamatsu et al., 2008). Although the function of melanin is under 
investigation, a primary function is likely to protect against UV damage. 
Table 6.1. Stages of melanoma and treatment options (NHS, 2012; ACS, 2013).  
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Melanin is noted for its ability to absorb UV light, and a high density of 
melanin has been linked with protection against UV-induced DNA damage. In 
agreement with this line of thought, people with dark skin are less 
susceptible to melanoma than those with fair skin (Meredith and Riesz, 2003; 
Tadokoro et al., 2003). The chances of African Americans getting melanoma 
in their lifetime is 0.09% compared to 1.93% for the American population as 
a whole (Altekruse et al., 2010). 
Melanoma cells, therefore, are believed to be highly resistant to 
radiotherapy. There has also been little success with chemotherapy. 
Dacarbazine is the standard treatment, but even the most optimistic studies 
show that it has a poor overall response rate at around 10-12% (Patel et al., 
2011; Bedikian et al., 2014). While it may have a small effect, its median 
response duration is measured in months, and it does not cure the disease 
(Velho, 2012). Targeted therapies have had better response rates, but are 
still underwhelming. About 65-70% of melanomas contain a mutation in 
BRAF, with the most common being V600E (older studies report this as 
V599E) (Davies et al., 2002; Kumar et al., 2003). BRAF is involved in inducing 
cell proliferation via MAP kinase pathways. The V600E mutation commonly 
found in melanoma patients activates BRAF in these cells. BRAF inhibitors 
have shown favourable improvements over dacarbazine treatment. 
Unfortunately, BRAF inhibitors are no use to patients without mutated BRAF, 
and the cancer grows resistant after about 8-9 months of treatment in most 
patients, who then relapse (Villanueva et al., 2010; Chapman et al., 2011; Sun 
et al., 2014).  
Currently, the most promising form of therapy against melanoma is 
immunotherapy. Ipilimumab inhibits a regulator of cytotoxic T-cell activity, 
allowing them to target tumours. Trials show a significant improvement in 
patients treated with ipilimumab, but also had high rates of severe adverse 
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effects that were linked to some patient deaths. Most side effects are related 
to immune system activation (Hodi et al., 2010; Robert et al., 2011; Ribas, 
2012). A new drug, pembrolizumab, is another immunotherapeutic agent 
targeted against an immunosuppressive receptor, programmed death 
receptor 1 (PD-1) to perform a similar function. It has recently been used in 
phase I clinical trials and was found to exhibit a overall response rate of 20-
26%. No patient deaths were linked to the drug, and side effects were mild 
(Robert et al., 2014). 
One possible method of melanoma treatment is to increase susceptibility of 
melanoma cells to chemotherapeutics. The transcription factor Nrf2 is often 
credited for protecting cells against various types of damage. It has been 
implicated in protecting cells from DNA damage and has been identified to 
play an important role in chemoprevention (Khor et al., 2008; Kim et al., 
2012b; Rodriguez et al., 2013; Singh et al., 2013a; Yang et al., 2014c). Like 
melanin, the mechanisms associated with Nrf2 that protect normal cells from 
damage also protect cancerous cells from chemo and radiotherapy. Silencing 
Nrf2 activity in vitro and in vivo has been shown to increase the effectiveness 
of chemotherapeutic drugs in several cancer cell types including lung, breast 
and pancreatic cancer cells (Wang et al., 2008b; Singh et al., 2010b; Arlt et 
al., 2013). 
Skin cells are thought to express high concentrations of protective enzymes 
in order to deal with increased exposure to UV light and other toxins that are 
likely to be encountered by the body’s exterior. Therefore, it is very possible 
that Nrf2 plays a strong role in the resistance of melanoma to chemotherapy. 
This study investigated Nrf2 expression in melanoma cells and whether 
silencing Nrf2 can enhance the effectiveness of chemotherapy. 
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6.2 Aims 
Hypothesis: Melanoma cells express higher levels of Nrf2 than melanocytes. 
Cell lines with high levels of Nrf2 expression are more resistant to toxicity 
caused by chemotherapeutic drugs. Nrf2 siRNA sensitises melanoma cells to 
the toxic effects of chemoptherapeutic drugs. 
 
Aims: 
1. To analyse 11 melanoma cell lines for expression of Nrf2 and 
downstream target genes compared to melanocytes. 
 
2. To investigate any correlation between Nrf2 expression and 
chemoresistance. 
 
3. To study the effects of silencing Nrf2 on chemotherapeutic drug 
induced toxicity in melanoma cells. 
 
4. To investigate potential mechanisms of Nrf2-depedent 
chemoresistance.  
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6.3 Results 
6.3.1 Expression of Nrf2 pathway members in melanoma cell lines 
Overexpression of Nrf2 has been noted in a number of cancers, including 
lung cancer, breast cancer and endometrial cancer (Jiang et al., 2010; Chen et 
al., 2012; Zhan et al., 2012). In this study Nrf2 protein expression was 
investigated in 11 human melanoma cell lines and human melanocytes by 
Western blot analysis. All 11 melanoma cell lines contained more Nrf2 
protein than melanocytes (Fig 6.1A). Analysing densitometry of the 
melanoma samples revealed that Colo829 contained the least Nrf2 protein. 
Nrf2 expression in other melanoma cells was expressed in relation to 
Colo829 cells to show the differences between the cell lines. M202, 
UACC1273, A2058, and M263 cells contained higher amounts of Nrf2 protein 
than the other melanoma cell lines (6.2, 6.3, 8.5 (p<0.01), and 5.9-fold more 
than Colo829 cells respectively) (Fig 6.1B). Nrf2 mRNA expression was also 
examined by RT-qPCR. M202, UACC1273, and M238 cells had higher Nrf2 
mRNA expression than other cell lines (Fig 6.1C), but the differences were 
not large, and there was no significant difference between any samples. 
A375 cells had markedly low Nrf2 expression at both mRNA and protein level.  
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Nrf2 activity is inhibited by its binding partner, Keap1. Therefore, 
transcriptional activity of Nrf2-regulated genes was examined. HO-1 and 
NQO1 were chosen because they have been linked with chemoresistance. 
M202 cells expressed higher levels of both HO-1 and NQO1 mRNA compared 
to other melanoma cell lines. Other cell lines with high expression of HO-1 
mRNA are SK-MEL-5 and SK-MEL-28 (Fig 6.2A), which had modest Nrf2 
expression. In contrast, UACC1273 and A2058 cells had high NQO1 mRNA 
expression (Fig 6.2B), which correlates with the high Nrf2 protein observed in 
these cells. M263 cells and M308 cells did not have particularly high 
expression of either gene relative to the other melanoma cell lines.  
 
Fig 6.1. Nrf2 expression in melanoma cell lines. (A) Protein extracts of 1x106 cells were 
prepared for each cell line. 50 µg protein was loaded onto a polyacrylamide gel, and Nrf2 
expression was measured by Western blot analysis. Image shown is representative of 3 
independent experiments. (B) Densitometry was measured for each of the three replicate 
experiments and normalised to the lowest expressing cell line, Colo829 cells. (C) 1x106 cells 
of each cell line were isolated and RNA was extracted. Nrf2 mRNA expression was 
measured by RT-qPCR. Mean ± SEM, n=3; *p<0.05, **p<0.01, ***p<0.001; one way ANOVA 
with Tukey’s multiple comparison test. 
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Fig 6.2. NQO1 and HO-1 expression in melanoma cell lines. 1x106 cells were collected for 
each cell line and RNA was extracted. Samples were analysed by RT-qPCR for (A) NQO1 and 
(B) HO-1 mRNA expression. (C) Protein extracts of 1x106 cells were prepared for each cell 
line, and 50 µg protein was loaded onto a polyacrylamide gel. HO-1 expression was 
measured by Western blot analysis. Image shown is representative of 3 independent 
experiments. (D) Densitometry was measured for each of the three replicate experiments 
and expressed as fold expression relative to melanocytes. Mean ± SEM, n=3; **p<0.01, 
***p<0.001; one way ANOVA with Tukey’s multiple comparison test. 
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6.3.2 Effect of chemotherapeutic drugs on cytotoxicity in melanoma cells 
The following cell lines were selected for further study based on the 
expression data (Table 6.2): M202, UACC 1273 and SK-MEL-5 cells were 
selected for their high expression of Nrf2 and its downstream targets. M238 
and A375 were selected because they had low expression of these same 
genes. Each cell line was examined for its resistance against three anti-cancer 
drugs: dacarbazine, doxorubicin and cisplatin. IC50 values are summarised in 
Table 6.4. 
 
 
 
 
 
 
 
 
Dacarbazine is a drug commonly prescribed to melanoma patients, although 
it has poor efficacy in the clinic (Patel et al., 2011; Bedikian et al., 2014). To 
date, resistance to dacarbazine has not been linked to Nrf2 activity. The 
effects of dacarbazine on cytotoxicity in these 5 cell lines was measured by 
MTS assay. M202 cells and UACC 1273 cells were highly resistant to 
dacarbazine, and even the highest concentration used (100 µM) did not 
significantly affect cell viability (Fig 6.3A and D). In contrast, cell viability of 
SK-MEL-5 and A375 cells was inhibited by 39% (p<0.05) and 46% (p<0.001) 
respectively after incubation with 100 µM dacarbazine (Fig 6.3B and C). Only 
M238 cells were affected by more than 50% by any concentration of 
Table 6.2. Summary of Nrf2 pathway expression in selected melanoma cell lines. 
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dacarbazine. Cell viability was decreased by 36% after incubation with 
100μM dacarbazine (p<0.001; Fig 6.3E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.3. Seeding density of cell lines in 96-well plates. Cells were seeded in 100 μL RPMI 
in 96-well plates. These seeding densities allow optimum growth over 72h. 
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Fig 6.3. The effects of dacarbazine on cytotoxicity of melanoma cells. Cells were seeded in 
96-well plates and incubated overnight at 37oC. Dacarbazine or DMSO was added to the 
cells in triplicate at 8 concentrations in 10-fold increments ranging from 10 pM to 100 µM. 
48h after incubation cytotoxicity was measured by MTS assay and expressed as a 
percentage compared to vehicle control cells. Mean ± SEM, n=3; Mean ± SEM, n=3; 
*p<0.05, **p<0.01, ***p<0.001; one way ANOVA with Tukey’s multiple comparison test. 
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The results with dacarbazine support the clinical evidence, which shows that 
dacarbazine is not a very effective drug. Doxorubicin may be a more effective 
drug than dacarbazine, but is not used to treat skin cancer presumably 
because its rapid clearance from the circulatory system and toxicity to non-
cancerous cells mean that the skin an unsuitable target for the drug (Zheng 
et al., 2010). However, doxorubicin is still involved in melanoma research, as 
drug delivery methods are researched (Pegoraro et al., 2013). 
Doxorubicin strongly inhibited cell viability in all melanoma cell lines. The 
most resistant cell lines were M202, in which doxorubicin had an IC50 of 1.1 
µM, and UACC 1273, in which doxorubicin had an IC50 of 1.0 μM (Fig 6.4A and 
D; Table 6.4). In contrast the most susceptible cell lines, A375 and M238 
doxorubicin had an IC50 of 0.2 µM (Fig 6.4 B and E), which is almost a 
magnitude lower than in UACC 1273 cells. SK-Mel-5 cells (IC50: 0.3 µM) were 
more resistant than A375 and M238 cells. Interestingly, at the highest 
concentrations of doxorubicin, SK-MEL-5 cells were less susceptible to 
doxorubicin. 10 µM doxorubicin caused at least an 80% inhibition of cell 
viability in every cell line except SK-MEL-5, which was a 65% reduction 
(P<0.001).  
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Fig 6.4. The effects of doxorubicin on cytotoxicity in melanoma cells. Cells were seeded in 
96-well tissue culture plates and incubated overnight at 37oC. Doxorubicin or DMSO was 
added to the cells in triplicate at 8 concentrations in 10-fold increments ranging from 10 
pM to 100 µM. 48h after incubation cell viability was measured by MTS assay and 
expressed as a percentage compared to vehicle control cells. Mean ± SEM, n=3; *p<0.05, 
**p<0.01, ***p<0.001; one way ANOVA with Tukey’s multiple comparison test. 
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Clinical trials have indicated that cisplatin alone has a response rate of 15-
20%, in melanoma, although as high as 50% has been reported. Cisplatin is 
often used in clinical trials as part of combination therapies with dacarbazine 
(Chapman et al., 1999; Luke and Schwartz, 2013). The effects of cisplatin on 
cell viability was investigated and compared with the effects of the other 
drugs. Cisplatin had the least effect in M202 cells, where it had an IC50 of 39.7 
µM (Fig 6.5A). In contrast, the most susceptible cell lines were A375 cells (IC50 
= 2.3 µM; Fig 6.5B) and M238 cells (IC50 = 7.1 µM; Fig 6.5E). Cisplatin had an 
IC50 of 11.9 µM in UACC 1273 cells (Fig 6.5D), and 12.8 µM in SK-MEL-5 cells 
(Fig 6.5C). Interestingly, although cisplatin had a low IC50 in M238 cells, cell 
viability was only blocked by 68% using the highest concentration of cisplatin 
(p<0.001). 
Interestingly, M202, UACC 1273, and SK-MEL-5 cells are more resistant than 
A375 and M238 cells to all three drugs. These three cell lines are those with 
the highest Nrf2 pathway expression. 
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Fig 6.5. The effects of cisplatin on cytotoxicity in melanoma cells. Cells were seeded in 96-
well tissue culture plates and incubated overnight at 37oC. Cisplatin or DMSO was added to 
the cells in triplicate at 8 concentrations in 10-fold increments ranging from 10 pM to 100 
µM. 48h after incubation cell viability was measured by MTS assay and expressed as a 
percentage compared to vehicle control cells. Mean ± SEM, n=3; . Mean ± SEM, n=3; 
*p<0.05, ***p<0.001; one way ANOVA with Tukey’s multiple comparison test. 
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Table 6.4. IC50 of drugs in melanoma cells. Cytotoxicity data from Fig 6.3, 6.4, and 6.5 
were analysed by non-linear regression, and IC50 values were calculated. 
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6.3.3 The role of Nrf2 in chemoresistance in melanoma cells. 
Although there is a correlation between Nrf2 expression and 
chemoresistance in the selected cell lines, this alone does not mean that Nrf2 
is responsible, nor does it give any indication of how powerful an effect Nrf2 
would have if it was responsible. Therefore, the three cell lines containing 
high amounts of Nrf2 (M202, UACC 1273, and SK-MEL-5) were taken forward 
for further experiments. 
First, siRNA knockdown was verified in the melanoma cell lines. Nrf2 siRNA 
and a negative control (Neg) siRNA were transfected into the three cell lines, 
and Nrf2 mRNA expression was measured after 48 and 72h by RT-qPCR.  All 
cell lines were very resistant to siRNA knockdown and Nrf2 expression could 
not be knocked down in UACC 1273 cells at all (data not shown). 200 nM 
siRNA caused a 57% knockdown of Nrf2 siRNA after 48h in M202 cells 
(p<0.01; Fig 6.6A), which remained reduced by 40% after 72h. In SK-MEL-5 
cells, a higher concentration of Nrf2 siRNA was required to ensure that the 
Nrf2 siRNA remained low at 72h. 250 nM siRNA ensured a knockdown of Nrf2 
mRNA by 57% at 48h (P<0.05), which remained knocked down by 55% at 72h 
(p<0.05; Fig 6.6B). 
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High Nrf2 expression does not guarantee its transcriptional activation. Nrf2 is 
regulated at the protein level by Keap1. Furthermore, a correlation between 
Nrf2 and HO-1 is not necessarily indicative of Nrf2 activity, because HO-1 has 
other transcription factors that regulate its activity independently of Nrf2. 
Therefore, both M202 cells and SK-MEL-5 cells were transfected with siRNA 
as previously described and HO-1 mRNA expression was measured after 48h 
by RT-qPCR. M202 cells showed a 47% (p<0.05) inhibition of HO-1 mRNA (Fig 
6.7A), and SK-MEL-5 cells showed a 39% (p<0.05) inhibition of HO-1 mRNA 
Fig 6.6. Nrf2 expression in melanoma cell lines. (A) 1x106 M202 cells were transfected with 
200ng or (B) 1x106 SK-MEL-5 cells were transfected with 250 ng of Nrf2 or negative control 
(Neg) siRNA by electroporation. Electroporated cells with no siRNA (e-) were used as a 
transfection control. Transfected cells were seeded in 6-well plates and incubated at 37oC 
for 48 or 72h. Total RNA was extracted and Nrf2 mRNA expression was measured by RT-
qPCR and normalised to GAPDH. Mean ± SEM, n=3; *p<0.05, **p<0.01; one way ANOVA 
with Tukey’s multiple comparison test. 
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(Fig 6.7B). Considering the low rates of Nrf2 knockdown achieved, this data 
suggests that Nrf2 is a major factor in the regulation of HO-1 in these cell 
lines, and confirms that Nrf2 is transcriptionally active in addition to being 
over-expressed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.7. Nrf2 is transcriptionally active in M202 and SK-MEL-5 cells. (A) 1x106 M202 cells 
were transfected with 200ng or (B) 1x106 SK-MEL-5 cells were transfected with 250ng of 
Nrf2 or negative control (Neg) siRNA by electroporation. Electroporated cells with no siRNA 
(e-) was used as a transfection control. Transfected cells were seeded in 6-well plates and 
incubated at 37oC for 48 or 72h. Total RNA was extracted and HO-1 expression was 
measured by RT-qPCR and normalised to GAPDH. Mean ± SEM, n=3; *p<0.05; one way 
ANOVA with Tukey’s multiple comparison test. 
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These results suggest that Nrf2 in M202 and SK-MEL-5 cells is 
transcriptionally active, inducing target genes, which means that it may 
contribute to chemoresistance by upregulation of cytoprotective genes. 
Therefore, the effect of Nrf2 siRNA on chemoresistance was tested. M202 
cells and SK-MEL-5 cells were transfected with Nrf2 or control siRNA as 
described above, and seeded in 96-well plates for 24h followed by 
dacarbazine for 48 h and cytotoxicity measured by MTS assay. There was 
little difference between cytotoxicity in cells that contain control siRNA or 
Nrf2 siRNA in either cell line, although in M202 cells cytotoxicity was slightly 
higher in cells containing Nrf2 siRNA (Fig 6.8A). In SK-MEL-5 cells cell viability 
was almost identical regardless of the siRNA used (Fig 6.8B). Two-way 
ANOVA analysis showed that Nrf2 siRNA was not a significant factor in the 
differences in cell viability in M202 or SK-MEL-5 cells. IC50 values could not be 
calculated for either cell line because cell viability was not inhibited by more 
than 50%.  Despite the minor differences in M202 cells, cytotoxicity was not 
significantly increased by Nrf2 siRNA, which suggests that Nrf2 is not involved 
in chemoresistance to dacarbazine. 
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Fig 6.8. The effects of Nrf2 siRNA on dacarbazine-induced toxicity. 1x106 (A) M202 cells or 
(B) SK-MEL-5 cells were transfected with Nrf2 siRNA or negative control siRNA as previously 
described. Cells were seeded in 96-well tissue culture plates and incubated overnight at 
37oC. Dacarbazine or DMSO was added to the cells in triplicate at 8 concentrations in 10-
fold increments ranging from 10 pM to 100 µM. 48h after incubation cell viability was 
measured by MTS assay and expressed as a percentage compared to vehicle control cells. 
Mean ± SEM, n=3; datasets were statistically analysed by two-way ANOVA 
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The role of Nrf2 in protecting melanoma cells from doxorubicin was then 
examined in M202 cells and SK-MEL-5 cells.  In M202 cells there was little 
difference in cytotoxicity at concentrations of doxorubicin lower than 0.1 
µM. At 0.1 µM and 1 µM cell viability was inhibited by 16% and 74% 
respectively in cells transfected with Nrf2 siRNA, whereas in cells containing 
negative control siRNA this was just 7% and 58% (Fig 6.9A). IC50 values for 
doxorubicin were calculated to be 0.72 μM in negative control cells, but 0.32 
μM in Nrf2 siRNA cells, a reduction of 56% (Fig 6.9C). However, two-way 
ANOVA analysis of the data revealed that the differences observed in cells 
containing Nrf2 siRNA were not significant. In SK-MEL-5 cells a similar pattern 
occurred, but the effect was not as strong. IC50s were calculated as 0.3 µM in 
negative control cells and 0.16 μM in cells containing Nrf2 siRNA. This is a 
smaller reduction than in M202 cells, but still stands at 41% (Fig 6.9C). As 
with M202 cells, two-way ANOVA analysis revealed that these differences 
were not statistically significant.  
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Fig 6.9. The effects of Nrf2 siRNA on doxorubicin-induced toxicity. 1x106 (A) M202 cells or 
(B) SK-MEL-5 cells were transfected with Nrf2 siRNA or negative control siRNA as previously 
described. Cells were seeded in 96-well tissue culture plates and incubated overnight at 
37oC. Doxorubicin or H2O was added to the cells in triplicate at 8 concentrations in 10-fold 
increments ranging from 10 pM to 100 µM. 48h after incubation cell viability was measured 
by MTS assay and expressed as a percentage compared to vehicle control cells. (C) IC50 
values were calculated by non-linear regression. Mean ± SEM, n=3; datasets were 
statistically analysed by two-way ANOVA. 
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Due to the range of efficacy that cisplatin had, and its clinical relevance over 
the other active drug, doxorubicin, a tighter concentration range was used to 
examine the effect of Nrf2 siRNA on cisplatin-induced toxicity. This was to 
increase the sensitivity of the assay, and obtain more accurate IC50 values for 
cisplatin. In both M202 cells, cisplatin was more effective in causing cytotoxic 
effects in cells transfected with Nrf2 siRNA than in cells transfected with 
negative control siRNA. Two-way ANOVA analysis showed that the reduced 
resistance to cisplatin in M202 cells was significant (p<0.01). Nrf2 siRNA 
lowered the IC50 of cisplatin in M202 cells by 46%, bringing the IC50 of 
cisplatin down from 26.2 µM to 14.2 µM (Fig 6.10A and C). In SK-MEL-5 cells 
Nrf2 siRNA did not significantly affect cisplatin-induced toxicity. The IC50 of 
cisplatin was 40.8 µM in control cells and 27.9 µM in cells containing Nrf2 
siRNA (Fig 6.10B and C). 
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Fig 6.10. The effects of Nrf2 siRNA on cisplatin-induced toxicity. 1x106 (A) M202 cells or 
(B) SK-MEL-5 cells were transfected with Nrf2 siRNA or negative control siRNA as previously 
described. Cells were seeded in 96-well tissue culture plates and incubated overnight at 
37oC. Cisplatin or PBS was added to the cells in triplicate at 8 concentrations in 10-fold 
increments ranging from 0.1 μM to 100 µM. 48h after incubation cell viability was 
measured by MTS assay and expressed as a percentage compared to vehicle control cells. 
(C) IC50 values were calculated by non-linear regression. Mean ± SEM, n=3; datasets were 
statistically analysed by two-way ANOVA. 
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6.3.4 Cisplatin upregulates ROS and the Nrf2 pathway in M202 cells. 
This data suggests that Nrf2 plays a role in protecting M202 cells from 
cisplatin chemotherapy. However, the mechanisms behind this role of Nrf2 
are unknown. One possibility is that cisplatin induces Nrf2 expression via ROS 
induction. Therefore, H2DCFDA was used as a probe to measure ROS 
production in M202 cells in response to cisplatin stimulation. 50 μM cisplatin 
induced ROS by 3.2-fold over control cells (p<0.001), and at 100 μM ROS was 
increased by 4.1-fold (Fig 6.11; p<0.001).  
 
 
 
 
ROS are known to signal upstream of Nrf2 (Numazawa et al., 2003). It is 
possible that although Nrf2 is overexpressed in M202 cells, it can also be 
induced by cisplatin. In addition to basal levels of Nrf2, upregulation of Nrf2 
Fig 6.11. Cisplatin induces ROS in M202 cells. M202 cells were seeded in a black 96-well 
plate. Cells were allowed to grow to 80% confluency over 48h. Media was removed and 
replaced with H2DCFDA in PBS for 40 min. H2DCFDA was removed and replaced with media 
for 20 minutes. Fluorescence was read at 485/520 nm.  The indicated concentration of 
cisplatin was added to the cells for 4h. Fluorescence was measured at 485/520 nm. Mean ± 
SEM, n=3; ***p<0.001; one way ANOVA with Tukey’s multiple comparison test. 
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could also occur, which would contribute to chemoresistance observed in 
M202 cells. Therefore, M202 cells were incubated with 5 μM cisplatin for up 
to 8h. Samples stimulated by cisplatin had elevated Nrf2 after 6h, and Nrf2 
expression remained high at 8h (Fig 6.12A). To test whether HO-1 expression 
was also increased, M202 cells were stimulated with cisplatin by the same 
method for up to 24h. HO-1 expression was measured by Western blot. The 
results showed that HO-1 was elevated at 24h (Fig 6.12B). These results 
support the idea that cisplatin activity is combated by Nrf2 activity that is 
both present at high concentrations basally, but also induced by the drug 
itself. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.12. Cisplatin induces Nrf2 and HO-1 in M202 cells. M202 cells were seeded in 6 well 
plates at a density of 0.5 x 106 per ml and allowed to grow to 80% confluency. 5 μM 
cisplatin was added for the indicated time period. Cell lysates were prepared and samples 
were analysed by western blot for (A) Nrf2 or (B) HO-1. β-actin was used as a loading 
control. Data shown is representative of three independent experiments; replicates are 
shown in Appendix II. 
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6.4 Discussion 
Malignant melanoma is the most deadly form of skin cancer, largely because 
it is resistant to non-surgical forms of therapy. Nrf2 has been linked with 
chemoresistance in several cancers including lung, breast and endometrial 
cancer (Jiang et al., 2010; Chen et al., 2012; Zhan et al., 2012). In this study 
Nrf2 expression, activity, and its effect on chemoresistance was investigated 
in a selection of 11 melanoma cell lines. Nrf2 was found to be expressed 
highly in all cell lines compared to melanocytes. The Nrf2 target gene HO-1 
was found to be over-expressed in three cell lines at mRNA and protein level. 
5 cell lines with varying levels of Nrf2 expression were selected for toxicity 
experiments using anti-cancer drugs. Chemoresistance to dacarbazine, 
doxorubicin and cisplatin correlated with Nrf2 expression. Doxorubicin was 
the most effective drug in all 5 cell lines, whereas dacarbazine was barely 
effective at all. Nrf2 siRNA increased the susceptibility of M202 cells to 
cisplatin, suggesting that Nrf2 plays a role in chemoresistance in melanoma. 
However, Nrf2 siRNA did not significantly affect melanoma cells treated with 
doxorubicin or the standard treatment, dacarbazine.  The mechanisms by 
which Nrf2 might protect against cisplatin are unknown. This study showed 
that cisplatin induces ROS production in M202 cells and it also upregulates 
Nrf2 and HO-1 protein expression, although more work is required to put 
these experiments into context.  
Nrf2 was found to be highly expressed in all melanoma cell lines, as 
measured by Western blot. Interestingly, none of the cell lines had lower 
Nrf2 expression than the melanocytes, which would be an expected result if 
Nrf2 depletion was a significant cause in the onset of melanoma. No loading 
control for the Western blots was provided because its expression cannot be 
assumed to be constant between different cell lines. However, cell numbers 
and total protein loaded onto the gel was controlled for, and the results were 
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repeatable by densitometry, indicating that the data obtained is reliable. In 
addition the data correlated well with NQO1 mRNA expression, which was 
measured by PCR. HO-1 expression did not correlate well, although this may 
be because of other factors in its regulation. SK-MEL-28 cells, for example, 
were rejected for further work because, although they had high HO-1 
expression, they have a known mutation in the HO-1 promoter that enhances 
its expression (Okamoto et al., 2006).  
The cells that were selected for further research were chosen mainly for their 
Nrf2 expression, but also for their ability to induce NQO1 (UACC 1273), HO-1 
(SK-MEL-5), or both (M202). A375 and M238 cells were selected because 
they both had low expression of Nrf2 and its target genes. 
Dacarbazine is the current standard chemotherapeutic treatment for 
metastatic melanoma. It had poor efficacy in the melanoma cell lines, 
although was least effective in those that expressed Nrf2. Despite this, Nrf2 
siRNA had no effect on dacarbazine-induced cytotoxicity, which suggests that 
if an Nrf2 inhibitor does have a role to play in the treatment of melanoma it 
is not as a supplement to dacarbazine. It is possible that selection bias could 
be a reason for these findings. If these cell lines were derivatives of those 
taken from melanoma patients, it is possible that the patients have already 
received a failed dacarbazine treatment regime. Furthermore, the fact that 
the treatment regime has failed may be the very reason the cells were 
gathered in the first place. In all probability, however, it is more likely that 
the resistance to dacarbazine observed in this study is an accurate 
representation of the current state of melanoma treatment. All clinical 
evidence points to the fact that dacarbazine is a poor drug. Patients who are 
treated with dacarbazine have a median survival of about 9 months, and the 
objective response rate is reported to be 10-12% (Patel et al., 2011; Bedikian 
et al., 2014).   
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Doxorubicin was a much more effective drug than dacarbazine in these 
assays. IC50 values were below 1 μM in all cell lines. The cell lines showed the 
same pattern, with those expressing high amounts of Nrf2 being more 
resistant than those that do not. Nrf2 siRNA transfected cells were not 
significantly more susceptible to doxorubicin than negative control siRNA. 
This suggests that Nrf2 does not play a role in protecting the cells against 
doxorubicin. However, it may be prudent to repeat the experiment using a 
tighter concentration range of doxorubicin between 0.1-1 μM because there 
is a slight variation between Nrf2 siRNA and negative control siRNA at these 
concentrations. Unlike dacarbazine, doxorubicin is not currently used to treat 
melanoma, which brings into question the clinical significance of this portion 
of the study. The reasons for the limited use of doxorubicin are that it has 
serious toxic effects on non-cancerous tissue, and poor delivery to target 
tissue due to clearance from the circulatory system (Zheng et al., 2010). 
However, a lot of research is currently being done on drug delivery 
mechanisms which have been shown to improve the effectiveness of 
doxorubicin in melanoma in vivo, while decreasing non-specific toxicity 
(Zheng et al., 2010; Pegoraro et al., 2013; Wang et al., 2014e. If these 
advancements overcome the weaknesses of doxorubicin, evidence in this 
study and others suggests that it is a more promising drug than dacarbazine 
in terms of effectiveness against melanoma cells. Combining drug delivery 
research with mechanisms to increase the effect of doxorubicin may be a 
realistic option for the future of chemotherapy against melanoma. 
The IC50 of cisplatin, like doxorubicin and dacarbazine, was lower in cells 
containing less Nrf2. Nrf2 siRNA had lowered the IC50 by 46% in M202 cells, 
showing that Nrf2 plays a role in protecting the cells from cisplatin. Cisplatin 
was more effective than dacarbazine, but less so than doxorubicin. Despite 
this, cisplatin is a more clinically relevant drug than doxorubicin. It can be 
used in combination therapy with dacarbazine or temozolamide (Chapman et 
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al., 1999; Alrwas et al., 2014), although clinical trials have not shown any 
benefit over dacarbazine treatment alone. Despite this, clinical trials 
involving cisplatin are still occurring (Lian et al., 2013; Alrwas et al., 2014), 
and increasing susceptibility of melanoma cells to cisplatin may be a valid 
strategy for the future treatment. In vivo studies in other cancers support 
this method of chemotherapy (Ji et al., 2013b; Jiang et al., 2013), and this 
study suggests that inhibiting Nrf2 activity may be one way of achieving it in 
melanoma. 
Cisplatin is believed to work by several methods. The classical mechanism is 
by crosslinking DNA, and the others include production of ROS and activation 
of inflammatory mediators (Casares et al., 2012; Enoiu et al., 2012). The 
mechanism by which Nrf2 protects against cisplatin induced toxicity is 
unknown but, as a broad protective transcription factor it could conceivably 
block any of the known mechanisms.  
Nrf2 is known to be induced by, and protect against ROS (Numazawa et al., 
2003; Kombairaju et al,. 2014). The data in this study that shows an induction 
of the Nrf2 pathway and ROS in M202 cells correlates with the idea that this 
is the primary mechanism. In addition recent research on Nrf2 and 
melanoma suggests that Nrf2 siRNA increases cisplatin-induced ROS, 
although a causal relationship between ROS inhibition and increased 
susceptibility to cisplatin was not shown (Miura et al., 2013). 
As detailed in previous chapters, Nrf2 plays an important role in protecting 
against inflammation. A study in mice has linked Nrf2 and HO-1 to cisplatin 
resistance by inhibiting induced inflammatory mediators (So et al., 2008) 
Nrf2 has also been shown to increase DNA repair in response to UV damage 
in skin cells (Rodriguez et al., 2013), and can upregulate the base excision 
repair enzyme, OGG1 (8-oxoguanine DNA glycosylase) (Singh et al., 2013a). 
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Furthermore, well-established blockers of apoptosis are also connected with 
the Nrf2 pathway. One of these is Bcl-2, which is a target of Nrf2 
transcription (Niture and Jaiswal, 2012).  
In addition to blocking mechanisms of action by cisplatin, Nrf2 also 
upregulates multidrug resistance transporters; cisplatin may be neutralised 
by these before its downstream mechanisms begin (Vollrath et al., 2006; 
Aleksunes et al., 2008). 
A major issue with Nrf2 as a cancer target is the lack of compounds that 
inhibit its activity, and the few that do are non-specific. Both brusatol and 
trigonelline have been shown to increase susceptibility of cells to 
chemoresistance through Nrf2 inhibition (Boettler et al., 2011; Ren et al., 
2011; Arlt et al., 2013). Perhaps the most important future work is to 
elucidate the mechanisms by which Nrf2 is over-expressed, because this will 
largely determine the kinds of drugs that would work. For example, brusatol 
is thought to work by increasing Nrf2 ubiquitination, but this mechanism of 
Nrf2 inhibition may not work in cells where Keap1 does not bind Nrf2 in the 
first place. 
Current research suggests that Nrf2 can become over-expressed by 
numerous mechanisms. These mechanisms are still under investigation, but 
they include mutations of Nrf2 and Keap1, and silencing Keap1, disrupting 
Nrf2 degradation and resulting in elevated Nrf2 expression.   
Although our laboratory has previously shown that Nrf2 can be regulated at 
the mRNA level, this study shows little difference in Nrf2 mRNA expression 
between the melanoma cell lines (Rushworth et al., 2008). Although Nrf2 
mRNA regulation cannot be ruled out as a hypothetical possibility, there is 
currently no evidence to suggest that it plays a role in the over-expression of 
Nrf2 in cancer. Nrf2 has been shown to be mutated, however. Mutations of 
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the DLG and ETGE motif of Nrf2 have been found in around 10% of lung 
cancer patients, resulting in its increased expression (Shibata et al., 2008).   
There has been much work on the role of Keap1 in cancers, and it has been 
found that Keap1 can be silenced or mutated, both of which result in a 
decrease in Nrf2 degradation.  Mutations in the IVR/kelch domain of Keap1 
have been identified in a number of cancers including adenocarcinoma, 
ovarian, and endometrial cancers (Padmanabhan et al., 2006; 
Konstantinopoilos et al., 2011; Wong et al., 2011). In addition, a recent paper 
identified a Keap1 mutation in melanoma cells (Miura et al., 2013). Silencing 
of Keap1 has been shown to occur by microRNA and by hypermethylation of 
its promoter. The latter has been observed in lung cancer cells and prostate 
cancer cells (Wang et al., 2008b; Zhang et al., 2010; Eades et al., 2011).   
Sequestosome 1 is a scaffold protein involved in inducing degradation of 
ubiquitinated proteins. It contains an STGE motif that binds to Keap1 in the 
same binding pocket as Nrf2’s ETGE sequence. Overexpression of 
sequestosome 1 is believed to result in overexpression of Nrf2 by competing 
for Keap1, and inducing Keap1 degradation. Evidence for this has been 
provided by silencing of sequestosome 1, which caused increased Keap1 
expression and a reduction of Nrf2 activity. There is not yet evidence that 
sequestosome 1 plays a role in Nrf2 upregulation in cancer (Copple et al., 
2010). 
The numerous mechanisms by which Nrf2 can be over-expressed limit the 
number of possibilities for effective drug targets. Ignoring difficulty and 
monetary factors, the most obvious solution is to simply block Nrf2/ARE 
binding. However, Nrf2/MAF binding or Nrf2 mRNA production are also 
potentially targets for drug design.   
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There were several limitations in this study. The use of cell lines provided a 
broad range of data, but require confirmation in patient samples. 
Furthermore, cancers are known to adapt to chemotherapy, becoming 
resistant to treatment over time, and the treatment regimen of the patients 
these cells were derived from is unknown (Duru et al., 2014; Sun et al., 2014). 
This is especially relevant with dacarbazine, which was the least effective of 
the three drugs and the most used in the treatment of melanoma.  
Future work investigating the role of Nrf2 in melanoma could go in several 
directions. Firstly, the work in this study can be extended and verified. There 
are other drugs used in melanoma chemotherapy, such as temozolomide 
which Nrf2 may have an effect on. The effect of the Nrf2 pathway on 
immunotherapy is also unknown. Further investigation into the role of Nrf2 
target genes is also important. There is not currently an Nrf2 inhibitor, but if 
specific target genes can be identified as drug targets, inhibiting them may 
have the same effect. The work can be verified by extending the study into 
human tissue to examine Nrf2 expression, and mutations in the Nrf2 
pathway. Animal studies may also be useful, although they would be a better 
option if a specific Nrf2 inhibitor was widely available. Tangential, but still 
relevant to this project would be the development of such an inhibitor.  
In conclusion, Nrf2 has been found to be over-expressed by varying degrees 
in 11 melanoma cell lines. Cell lines with more Nrf2 are more chemoresistant 
to dacarbazine, doxorubicin, and cisplatin than those with less Nrf2. Knocking 
down Nrf2 using siRNA increases susceptibility of M202 cells to cisplatin, but 
not dacarbazine or doxorubicin. Therefore, this study suggests that Nrf2 plays 
a role in the high resistance to chemotherapy observed in malignant 
melanoma treatment. These conclusions support the need for research into 
inhibition of the Nrf2 pathway as a potential therapeutic target.   
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Chapter 7: General Discussion 
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Nrf2 is an important subject of medical research. The protective effects of 
Nrf2 are extremely well documented. Nrf2 knockout mice are more 
susceptible to oxidative damage (Kurzatkowski et al., 2013), diabetic 
retinopathy (Xu et al., 2014b), tumourigenesis, inflammation (Cheung et al., 
2014), and bacterial infection (Reddy et al., 2009). The functions of Nrf2 are 
simultaneously diverse and monotonous. On one hand Nrf2 induces 
transcription of a wide variety of genes, regulating a wide variety of 
processes. On the other hand almost all of these processes, even those that 
are harmful to the organism, are cytoprotective (Joshi and Johnson, 2012; 
Gupte et al., 2013; Turpaev, 2013; Xiang et al., 2014). In addition to being 
protective, the way in which it is regulated makes it ideal for targeting. It is 
primarily regulated by its interaction with Keap1, and is highly inducible. 
Therefore, Nrf2 activators are of interest for their therapeutic potential. 
Cancer is an exception to the benefits of Nrf2. In cancer, aberrant activation 
of Nrf2 can lead to protection of cancer cells from chemo- and radiotherapy 
(Itoh et al., 1999; Shibata et al., 2008a; Singh et al., 2010b).  
This study investigated the protective role of Nrf2, mechanisms of targeting it 
in the diet and inflammation, and the consequences of its overexpression in 
cancer. Diallyl polysulfides are examined in THP-1 monocytes to examine HO-
1 induction, and it was found that long-chain diallyl polysulfides are more 
effective than short chain polysulfides. DAPS was identified and characterised 
as a novel activator of the Nrf2 pathway. However, it failed to prevent H2O2-
induced cytotoxicity or LPS-induced TNF expression. This suggests that 
powerful Nrf2 activation is not sufficient to provide Nrf2-mediated 
protection, perhaps due to lack of target specificity. TAT-14 is a 14 amino 
acid long peptide that mimics the ETGE Keap1-binding sequence of Nrf2 
conjoined to a TAT cell penetration sequence. It was shown to bind Keap1 
using a fluorescence polarization assay, and activate the Nrf2 pathway in 
THP-1 monocytes. Unlike DAPS, it did inhibit LPS-induced TNF and IL-1β 
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expression. This suggests that targeting the Nrf2/Keap1 interaction by 
competitive inhibition is a preferable mechanism of activation. To aid these 
studies into the protective role of Nrf2, two luciferase assays were developed 
to identify inducers of Nrf2 and inhibitors of the inflammatory mediator, NF-
κB. Finally, this study examined Nrf2 expression in melanoma, and found that 
Nrf2 and its target genes can be overexpressed in melanoma cell lines. 5 cell 
lines were carried forward, and it was found that cells that overexpress Nrf2 
were more resistant to chemotherapeutic drugs than those with low Nrf2 
expression. Furthermore, Nrf2 siRNA rendered M202 cells susceptible to 
cisplatin, and had a similar effect in SK-MEL-5 cells. These results suggest that 
an Nrf2 inhibitor may be useful to use in combination with chemotherapy. 
The role of Nrf2 in inhibiting inflammation is well documented (Ma et al., 
2006; Osburn et al., 2008; Rushworth et al., 2008; Kong et al., 2010). There 
have been plenty of studies investigating the effects of natural products on 
Nrf2 activation in inflammation, and in vitro studies have been promising. 
Quercetin, sulforaphane and curcumin are all Nrf2 activators that have been 
used to inhibit inflammation in vivo and in vitro (Carmona-Ramírez et al., 
2013; Soetikno et al., 2013; Wu et al., 2013; Zhao et al., 2013b; Ramyaa et al., 
2014).  However, there is little evidence for the anti-inflammatory capability 
of these compounds when they are used in clinical trials. Quercetin has 
shown mild effects on blood pressure, but did not affect inflammatory 
mediators in two studies (Pfeuffer et al., 2013; Zahedi et al., 2013). In clinical 
trials the role of curcumin remains unclear, and is better noted for studies 
into cardiovascular conditions. In one study, 500mg/day curcumin over seven 
days was shown to decrease serum cholesterol levels and increase plasma 
antioxidant capacity. However, 6g/day curcumin did not have a strong 
protective effect (Pungcharoenkul and Thongnopnua, 2011). Another study 
in elderly patients showed no change in cholesterol levels after 6 months of 
curcumin supplementation (Baum et al., 2007).   
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 Currently, the most promising is the organosulfur compound sulforaphane, 
which has been linked with positive antioxidant effects in humans, and may 
protect human gastric mucosa against helicobacter pylori infection. In the 
latter case, a mouse model was used to show that this may be due to anti-
oxidative and anti-inflammatory mechanisms which are dependent on Nrf2 
(Yanaka et al., 2009; Kensler et al., 2012). 
There are other promising compounds however, that warrant further 
research. These are the organosulfur compounds found in garlic. Allicin is the 
precursor of diallyl polysulfides, and has been used in human studies. It has 
been shown to reduce inflammatory mediators involved in excercise-induced 
muscle damage, including IL-6, in athletes (Su et al., 2008). It has also been 
shown to reduce the size of mouth ulcers (Jiang et al., 2012). Diallyl 
polysulfides are thought to be the bioactive components of crushed garlic, 
and may exert their activity via Nrf2 activation (Chen et al., 2004). Diallyl 
polysulfides are fairly stereotypical Nrf2-activating natural products. They are 
reported to inhibit oxidative stress (Kuo et al., 2013; Zeng et al., 2013), but 
also signal though ROS production (Gong et al., 2004; Chandra-Kuntal et al., 
2013). Animal studies suggest that consumption of these molecules through 
the diet may be highly beneficial to long term health (Kalayarasan et al., 
2008; Kalayarasan et al., 2009). 
This study showed that with the lengthening of the polysulfide chain, diallyl 
polysulfides activate the Nrf2 pathway more effectively, but this does not 
translate to increased protection against ROS induced cytotoxicity or LPS-
induced TNF. This does not mean that DAPS has no positive effects 
whatsoever – untested effects that have been associated with diallyl 
polysulfides include protection against cardiac dysfunction (Huang et al., 
2013b), lung disease (Sapkota et al., 2014), and inhibition of angiogenesis 
(Thejass and Kuttan, 2007). The fact that diallyl polysulfides have been 
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associated with these effects indicates that they are molecules worth 
pursuing, but this research suggests that the correlation between chain 
length and Nrf2 activation does not predict any correlation between chain 
length and cytoprotection. Research should continue to compare polysulfides 
to find which ones have the most beneficial effects. There is probably an 
optimal chain length that activates protective pathways while not causing 
too much damage. Furthermore, longer diallyl polysulfides may have a 
greater anti-bacterial or anti-cancer effect, which is likely to work via pro-
apoptotic pathways rather than cytoprotective pathways (Ma et al., 2014).   
Garlic contains many compounds in addition to diallyl polysulfides (Lawson et 
al., 1993), so while it is important to find the active ingredients, dietary 
studies are more reliable if they use garlic or garlic oils instead of the 
individual constituents. Testing this in vivo can ensure that the experiment is 
representative of the diet. Some of the constituents of garlic may have 
additive effects, or may interfere with the health benefits. Another factor 
that this methodology takes into account is that oral delivery is possible, so 
bioavailability can be measured. 
One way of taking high amounts of specific molecules is dietary supplements. 
These have their own problems. In principle they may be a good idea, and 
would be a more practical way of getting specific nutrients. They solve the 
problem that food contains other molecules, and allow for optimisation of 
individual components to maximise health benefits. The problem with them 
is that current laws determining their regulation are poor. The problems 
customers face can include mislabelling of products, contaminants, and 
incorrect health claims which are often based upon shoddy evidence or 
miscommunication between researchers and laypeople (Petroczi et al., 
2011).  
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Although there have been mixed results for Nrf2 activators in nutritional 
research, Nrf2 itself has consistently been shown to have value as a 
protective mediator. Therefore, there has been much interest in targeting it 
therapeutically. Factors that matter in drug design are slightly different to 
nutritional research. Drugs are designed to do specific jobs during diseases to 
alleviate symptoms and combat the source of the disease. Unlike compounds 
consumed through the diet, drugs are desired to have a strong acute effect, 
and are delivered as purified molecules at known concentrations. The most 
important difference between medicine and the diet, therefore, is targeting.  
Nrf2 is a good target because of both its regulation and function. It has a very 
clear primary regulator in Keap1, and the Nrf2/Keap1 interaction has been 
very well characterised, even if the mechanisms of exactly how Nrf2 is 
regulated by the interaction are still under investigation (Tong et al., 2006; 
Baird et al., 2013). There are two notable examples of drugs that target the 
Nrf2/Keap1 interaction. One is dimethyl fumarate, and the other is 
bardoxolone methyl. Dimethyl fumarate is thought to have neuroprotective 
effects via Nrf2 activation. It was approved this year by the Food and Drug 
Administration in the USA for treatment of multiple sclerosis after successful 
clinical trials (Linker et al., 2011; Ruggieri et al., 2014). In contrast, when 
bardoxolone methyl was used in clinical trials for stage 4 chronic kidney 
disease, the trial was stopped due to patient deaths (de Zeeuw et al., 2013), 
despite early work showing beneficial effects (Tran et al., 2008). The adverse 
events were cardiovascular in nature, and may be due to increased fluid 
retention and increased blood pressure (Chin et al., 2014). The problem with 
bardoxolone methyl is that it is not a specific activator of the Nrf2 pathway, 
and is therefore liable to have unpredictable side effects (Gao et al., 2013). It 
has even been argued that although the specific effects may have been 
unpredictable, the fact that bardoxalone methyl induces ROS and cellular 
stress indicates that harmful side effects were extremely likely (Thomas, 
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2012; Rossing, 2013; Zhang, 2013). It is important to note that there is no 
reason to believe that dimethyl fumarate is a specific Nrf2 activator, either 
(Chen et al., 2013; Zhao et al., 2014). These trials show that Nrf2 is clearly a 
good drug target, but there is a tendency for Nrf2 activators to activate non-
specific pathways, and the side effects can be lethal.  
An alternative approach is to design competitive inhibitors of the Nrf2/Keap1 
interaction. By mimicking the features of the Keap1-binding sequence of 
Nrf2, it should reduce off-target effects barring any that Nrf2 would have 
itself. Targeting Nrf2 by inhibiting its interaction with Keap1 can be carried 
out with reasonable specificity, and low toxicity (Hancock et al., 2012; Tian et 
al., 2012). This study tested a cell-penetrating peptide mimicking the Keap1-
binding sequence of the Neh2 domain in THP-1 monocytes. The data shows 
that the peptide induces Nrf2 expression and subsequent transcription of 
known Nrf2 target genes. It also inhibited LPS-induced TNF production. The 
most important insight that can be gained from this research is that targeting 
the Nrf2/Keap1 interaction works in cell culture, and lowers expression of an 
inflammatory mediator. TAT-14 can be used as a tool for future research to 
simulate the effects of a more drug-like molecule. Another aspect of future 
work is to enhance drug delivery mechanisms, which may enhance the 
effectiveness of a peptide-drug. It will not solve the problem of poor 
metabolic stability of peptides, however, so a small molecule inhibitor is still 
a preferable option. It should be noted, however, that although it is often 
thought that peptides make poor drugs, they do reach the market, and a 
similar Nrf2-targeting peptide has been shown to protect against brain 
damage in vivo (Zhao et al., 2011; Craik et al., 2013). 
Since this work started there has been a lot of progress in the search for a 
small molecule inhibitor of the Nrf2/Keap1 interaction. The peptide sequence 
of Keap1 binding proteins has been tested, and a hybrid sequence combining 
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elements of the Nrf2 and SQSM1 binding domains has been shown to 
improve binding efficiency over both native sequences in vitro (Hancock et 
al., 2012). The best success, however, has been from large scale screening 
studies. So far three small molecules have been identified that can displace 
the native Nrf2 sequence in a fluorescence polarization assay and induce 
ARE-dependent gene expression in cell culture models. Two of these came 
from screening libraries of 300, 000 compounds and the other from a library 
of 250, 000 compounds (Wang et al., 2012a; Jiang et al., 2014; Zhuang et al., 
2014). There has been no clinical success for these molecules, and beneficial 
effects have not been shown.   
This study has shown that an effect of blocking the Nrf2/Keap1 interaction 
with TAT-14 is to inhibit pro-inflammatory cytokine production. A long term 
prospect is the possibility of using TAT-14 or a similarly constructed peptide 
as a drug to use in inflammatory diseases. Nrf2 deficiency causes lupus-like 
symptoms and increases susceptibility to sepsis in mice, so a murine model 
of sepsis may be a good starting point for such a project (Ma et al., 2006; 
Kong et al., 2010). 
However, this barely scratches the surface of the numerous benefits 
targeting Nrf2 may have. Future work can be done with TAT-14 to investigate 
these effects. This work can study the protective role of Nrf2 in other 
diseases, such as airway diseases or cardiovascular diseases. There is also the 
issue of other Keap1 binding proteins. Inhibiting the Nrf2/Keap1 interaction 
may have effects on IKKβ, Bcl-2, or SQSM1 signalling, and this warrants 
further experimentation (Copple et al., 2010; Tian et al., 2012). Arguably the 
most pressing concern is the bardoxolone methyl clinical trial (de Zeeuw et 
al., 2013). It is assumed that the adverse side effects were due to its non-
specificity, and although this is very likely, it is not certain. TAT-14 should 
have none of these side effects, and could be used alongside bardoxolone 
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methyl in studies in vitro and in vivo to investigate likely causes of the side 
effects, and whether Nrf2 activation is likely to be involved. If Nrf2 activation 
is the cause of the side effects, TAT-14 will mimic the effects of bardoxolone 
methyl and it is extremely important to find this out before further clinical 
trials take place.  
The current state of the field is quite promising. Small molecules are being 
found, and attempts to validate Nrf2 as a drug target using peptides have 
been successful. To continue, targeting Nrf2 activation for medicinal 
purposes should focus on direct inhibitors and move away from molecules 
that induce Nrf2 expression by reacting with cysteine residues on Keap1 in 
order to maximise the effectiveness and safety of the drug. 
There is an exception to the protective roles of Nrf2, and this is during 
cancer. In a healthy individual Nrf2 protects against the onset of cancer by 
detoxifying carcinogens. During cancer its protective utility is hijacked, and 
used to protect cancer cells from damage. This can cause radio- and 
chemoresistance. This study investigated the role of Nrf2 in malignant 
melanoma, and showed that all 11 cell lines tested contained more Nrf2 than 
melanocytes. Some of these cell lines also showed high levels of transcription 
of HO-1 or NQO1. Others did not. 3 cell lines with high Nrf2 expression and 
HO-1/NQO1 expression were carried forwards, as were 2 cell lines which had 
comparatively low expression. The cells highly expressing Nrf2 were more 
resistant than those that don’t to dacarbazine, cisplatin, and doxorubicin. 
Nrf2 was silenced in two of the cell lines that have high Nrf2 expression, 
M202 and SK-MEL-5 cells. Nrf2 siRNA sensitised M202 cells to cisplatin, and 
had similar effects in SK-MEL-5 cells that didn’t reach statistical significance. 
These results suggest that Nrf2 protects melanoma cells against 
chemotherapy, but it does not protect against the standard treatment 
dacarbazine, or doxorubicin. 
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There are a number of mechanisms by which Nrf2 may be contributing to 
chemoresistance against cisplatin, and future work could focus on 
establishing what these are (Fig 7.1).  
 
 
 
 
 
 
There is some indirect evidence that Nrf2 may inhibit cisplatin by facilitating 
its cellular export. Nrf2 is known to induce multidrug-associated resistance 
proteins, and their role in inhibiting the effects of cisplatin is controversial. 
For example, one study shows that MRP2 protects against cisplatin-induced 
kidney damage in mice, and inhibits build-up of platinum (Wen et al., 2014). 
Fig 7.1. Cisplatin-induced apoptosis.  Cisplatin induces apoptosis by crosslinking DNA 
directly, or by inducing oxidative stress. Nrf2 could potentially inhibit cisplatin-induced 
apoptosis at many places along the pathway, but current knowledge of Nrf2 activity 
suggests that the most likely mechanisms are by A) inhibiting cisplatin cellular 
accumulation, B) inhibition cisplatin-induced oxidative stress, or C) inhibiting cisplatin-
induced DNA damage. 
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In direct contrast, another study has shown that MRP2-/- mice did not have 
any effect on cisplatin activity and that in human cancer patients there was 
no correlation between MRP2 polymorphisms and cisplatin toxicity (Sprowl 
et al., 2012). Cisplatin exerts its toxic effects by two key methods. The first is 
by crosslinking DNA directly, and the second is by producing ROS, which can 
cause both DNA and general cellular damage. Enough damage causes 
apoptosis. Unfortunately, Nrf2 inhibits apoptosis, and there are several 
mechanisms by which the Nrf2 pathway may protect cancer cells from 
cisplatin-induced apoptosis. Nrf2 is a known antioxidant, and there is some 
evidence suggesting that Nrf2-induced target genes, such as HO-1, block 
cisplatin-induced ROS (Kim et al.,2008; Kim et al., 2009). Nrf2 is also known 
to upregulate some DNA repair enzymes, such as OGG1 (Singh et al., 2013a) 
and anti-apoptotic mediators, such as Bcl-xL and Bcl-2 (Niture and Jaiswal, 
2012; Niture and Jaiswal, 2013).   
Inhibition of Nrf2 likely does not have an effect on its own, but the evidence 
provided in this study and others suggests that Nrf2 inhibition may be a valid 
strategy to enhance chemotherapy. Combination treatments are fairly 
common (Daponte et al., 2013; Robert et al., 2013; Lazaryan et al., 2014; 
Suzuki et al., 2014), and could be considered a long term target for the use of 
a drug targeting Nrf2. 
If Nrf2 inhibition is ever to be used in chemotherapy the most important 
project that needs to be done is to find inhibitors of the Nrf2 pathway. 
Melanoma is not the only cancer to be protected by the Nrf2 pathway, 
suggesting that Nrf2 inhibition could be a way of increasing the effectiveness 
of chemotherapy in many cancers. There are no Nrf2 inhibitors currently 
available, and the little research into them has used molecules that are not 
specific. Hypothetically, there are several possible sites of Nrf2 inhibition that 
could make good drug targets.  
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The first possibility is to block Nrf2 production. Little is known about 
regulation of Nrf2 production, but there are interesting leads, which could 
merit further investigation. The Nrf2 promoter contains a sequence that can 
form a G-quadruplex, and it is possible that regulation of this structure could 
affect Nrf2 mRNA production (Waller et al., 2014). MicroRNAs have been 
shown to regulate Nrf2 translation (Singh et al., 2013b; Yang et al., 2014d), so 
it may be possible to either mimic the effects of these sequences or to alter 
the regulation of the microRNAs to inhibit Nrf2 production. 
Brusatol is thought to inhibit Nrf2 by increasing its ubiquitination and 
degradation (Ren et al., 2011). This is currently the only method of inhibiting 
Nrf2 using a small molecule that has been experimentally verified. It is also 
an extremely difficult mechanism to design a drug for because the 
interaction that increases Nrf2 ubiquitination is unknown. Some cancers 
overexpress Nrf2 due to silenced Keap1, which can be caused by 
hypermethylation of its promoter (Guo et al., 2012). Demethylation of DNA is 
difficult to target specifically, but Chen et al (2014) have successfully 
reactivated epigenetically silenced ICAM-1 using a targeted mechanism in 
HEK293 cells. A similar approach to Keap1 may help reduce aberrant Nrf2 
expression.  
There are several ways to inhibit Nrf2 nuclear activity. Currently Nrf2 nuclear 
import is probably not a viable option because not enough is known about 
the regulation of its nuclear localisation sequences (Theodore et al., 2008). 
However, there are two key interactions required for Nrf2-dependent gene 
transcription. These are the Nrf2/Maf interaction (Li et al., 2008), and the 
Nrf2/ARE interaction. Of these the Nrf2/Maf interaction is probably more 
viable because blocking the ARE may also block other sites, such as the TRE, 
and MARE. The Neh3, Neh4, and Neh5 domains in Nrf2 are also known to be 
required for transcriptional activation (Katoh et al., 2001; Nioi et al., 2005; 
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Apopa et al., 2008). Currently they are not well enough understood to be 
considered potential drug targets. 
There are a lot of possibilities for Nrf2 inhibitors, and a lot of research is still 
required to make them a reality. The benefits to Nrf2 inhibition in cancer are 
becoming increasingly evident, and further research into potential inhibitors 
would be welcome. 
In conclusion, this study has identified DAPS as a novel dietary activator of 
Nrf2, and has used TAT-14 to validate the use of Keap1 inhibitors to inhibit 
inflammatory cytokine production. This research also failed to link a powerful 
activation of the Nrf2 pathway by DAPS with a cytoprotective effect, 
highlighting the superiority of non-reactive activators of the Nrf2 pathway. 
TAT-14 can be used as a tool to investigate the effects of Nrf2 activation 
before a small molecule activator is fully characterised. In addition, the 
protective effects of Nrf2 are hijacked by malignant melanoma, and protect 
melanoma cells from chemotherapeutic drugs, such as cisplatin and 
doxorubicin. This, combined with research in other cancers, suggests that 
Nrf2 inhibitors may be effective when used in conjunction with 
chemotherapy. Targeting Nrf2 in cancer requires a better understanding of 
its regulation if an effective drug is to be found. 
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Appendix I: Buffer contents 
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Cell culture 
 
Freezing medium 
Per vial: 
900 μL sterile foetal bovine serum 
100 μL sterile DMSO 
 
Western immunoblotting (Novex) 
 
1x running buffer (800 mL) 
40ml NuPage 20x MOPS SDS running buffer  
760ml deionised H2O 
 
1x transfer buffer 
680mL deionised H2O 
80mL methanol 
40mL 20X Transfer Buffer 
1 ml NuPAGE Antioxidant 
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Western immunoblotting (Bio-rad) 
 
SDS PAGE gels 
The following components provide enough for two SDS PAGE Gels 
 
Bottom gel stock 
90.75 g Tris Base 
Top up to 500 mL with deionised H2O 
pH to 8.8 
10ml 20% SDS 
 
Upper gel stock 
12.11 g Tris Base 
Top up to 200 mL deionised H2O 
pH to 6.8 
4 mL 20% SDS 
 
10% APS 
23 mg APS crystals 
230 μL deionised H2O 
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Resolving gel 
 Gel Concentration 
7.5% 10% 12% 
Bottom gel stock 3.7 mL 3.7 mL 3.7 mL 
30% acrylamide  3.7 mL 5 mL 6.5 mL 
Deionised H2O 7.4 mL 6 mL 4.5 mL 
10% APS 130 µL 130 µL 130 µL 
TEMED 13μL 13μL 13μL 
 
 
Stacking gel 
600μL upper gel stock 
1 mL 30% acrylamide 
4.25 mL ddH2O 
75 μL 10% APS 
7.5 μL TEMED 
 
5x running buffer (1 L) 
30 g Tris Base 
140 g Glycine 
5 g SDS 
Top up to 1 L with deionised H2O 
 
10x transfer buffer (1 L) 
24.26g Tris Base  
112.6g Glycine  
1g SDS  
Make up to 1L with deionised H2O 
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1x transfer buffer (1L) 
100ml 10x Transfer Buffer  
700ml H2O  
200ml Methanol 
 
 
Immunoblotting 
 
20x TBST (1 L) 
48.4g Tris Base 
160g NaCl 
62ml 5M HCl 
20ml Tween-20 
pH to7.6  
Top up to 1 L in deionised H2O 
 
ELISA 
 
Coating buffer – 0.2M sodium phosphate 
11.8 g Na2HPO4 
16.1 g NaH2PO4  
Make up to 1.0 L with deionised H2O 
pH to 6.5. 
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PBS 
16.0 g NaCl  
2.32 g Na2HPO4 
0.4 g KH2PO4 
0.4 g KCL  
Make up to 2 L with deionised H2O   
pH to 7.0 
 
Wash buffer 
2.0 L PBS 
100 μL Tween-20 
 
Assay diluent 
 
90% PBS 
10% foetal bovine serum 
pH 7.0. 
 
Fluorescence polarization assay 
 
Sodium phosphate buffer 
1.5 mL 100 mM Sodium Phosphate 
150 µL Tween-20 
13.35 mL water 
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Interaction solution 
11.1 µL F-14 (5 μM stock) 
17.9 µL Keap1(18.57 μM stock) 
9971 µL sodium phosphate buffer 
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Appendix II: Western blot replicates 
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Fig 4.2 
 
 
 
 
 
 
 
 
 
Fig 4.4 
 
 
 
 
 
 
 
Fig 4.2. Garlic oils induce Nrf2 accumulation in THP-1 cells. THP-1 cells were incubated 
with 10 μg/mL Naturex, Stringer or PS Mix for the indicated time point. DMSO was used as 
a vehicle control. Whole cell lysates were prepared and Nrf2 expression measured by 
western blot analysis. β-actin expression is shown as a loading control. Results are 
representative of three independent experiments. 
Fig 4.4. Garlic oils Induce HO-1 protein expression in THP-1 cells. THP-1 cells were 
incubated with 10 μg/mL Naturex, Stringer or PS Mix for the indicated time point. DMSO 
was used as a vehicle control. Whole cell lysates were collected and HO-1 expression was 
measured by Western blot. β-actin expression is shown as a loading control.  
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Fig 4.6C 
 
 
 
 
 
 
 
Fig 4.10B 
 
 
 
 
 
 
 
 
 
Fig 4.6C. DATTS and DAPS-induced HO-1 expression in THP-1 cells.   Cells were incubated 
with 20μM DATTS or DAPS for the indicated time points. 24h DMSO was used as a vehicle 
control. Whole cell lysates were prepared and HO-1 expression measured by Western blot 
Analysis.  
Fig 4.10B. Nrf2 siRNA suppresses DAPS-induced HO-1 expression. THP-1 cells were 
transfected with 200nM Nrf2 siRNA or negative control siRNA. An electroporated sample 
with no siRNA was used as a control. After 24h, cells were incubated with 20 μM DAPS for 
24h. DMSO was used as a vehicle control. Cell lysates were collected and HO-1 expression 
was measured by Western blot. β-actin expression is shown as a loading control.  
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Fig 4.11 
 
 
 
 
 
 
 
Fig 4.12B 
 
 
 
 
 
 
Fig 4.11. DATTS and DAPS induce Nrf2 protein expression in THP-1 cells.   THP-1 cells were 
incubated with 20 μM DATTS or DAPS for the indicated time period. DMSO was used as a 
vehicle control. Cell lysates were collected and Nrf2 expression was measured by western 
blot. β-actin expression is shown as a loading control.  
Fig 4.12B. p38MAP kinase regulates DATTS and DAPS-induced Nrf2 expression. THP-1 
cells were incubated with 10 μM SB203580 for 30min prior to incubation with DAPS for 4h. 
Cell lysates were probed for Nrf2 expression by western blot. β-actin expression is shown 
as a loading control. 
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Fig 4.13A 
 
 
 
 
 
Fig 4.13B 
 
 
 
 
 
Fig 5.3 
 
 
 
 
 
Fig 4.13A. DAPS induces HO-1 via ROS production. THP-1 cells were incubated with 1mM 
NAC for 30min prior to addition of 20 μM DAPS for 24h. DMSO was used as a vehicle 
control. Cell lysates were probed for HO-1 expression by western blot.  β-actin is shown as 
a loading control.  
 
Fig 4.13B. DAPS induces Nrf2 via ROS production. THP-1 cells were incubated with 1mM 
NAC for 30min prior to incubation with DAPS for 4h. Cell lysates were probed for Nrf2 
expression by Western blot. β-actin is shown as a loading control.  
 
Fig 5.3 TAT-14 induces Nrf2 protein expression. THP-1 cells were incubated with 75 μM 
TAT-14 or TAT-sc for 1, 3, or 6h. Nrf2 expression in cell lysates was measured by Western 
immunoblotting. β-actin was used as a loading control.  
345 
 
Fig 5.5 
 
 
 
Fig 6.12A 
 
 
 
 
 
 
 
 
Fig 5.5 TAT-14 induces HO-1 protein expression. THP-1 cells were incubated with TAT-14 
or TAT-sc for 9, 12, or 16h. HO-1 expression in cell lysates was measured by Western 
immunoblotting. β-actin was used as a loading control. 
Fig 6.12A. Cisplatin induces Nrf2 in M202 cells. M202 cells were seeded in 6 well plates at 
a density of 0.5 x 106 per ml and allowed to grow to 80% confluency. 5 μM cisplatin was 
added for the indicated time period. Cell lysates were prepared and samples were analysed 
by western blot for Nrf2 expression. β-actin was used as a loading control.  
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Fig 6.12B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.12B. Cisplatin induces HO-1 in M202 cells. M202 cells were seeded in 6 well plates at 
a density of 0.5 x 106 per ml and allowed to grow to 80% confluency. 5 μM cisplatin was 
added for the indicated time period. Cell lysates were prepared and samples were analysed 
by western blot for HO-1 expression. β-actin was used as a loading control.  
